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Summary 
Antimicrobial resistance is one of the major problems faced by the medical industry today. The 
ability of bacteria to rapidly acquire resistance against antibiotics and the over prescription and 
inappropriate use of antibiotics further exacerbate this crisis. Few new antimicrobials are, 
however, making it through the drug discovery pipeline. The search and development of novel 
and effective antimicrobials is therefore of the utmost importance. 
Lantibiotics are ribosomally synthesized cationic antimicrobial peptides with extensive post-
translational modifications. They are active against a wide range of Gram-positive bacteria, 
including antibiotic-resistant strains. They are characterized by the presence of lanthionine and 
methyllanthionine rings and have been suggested as alternatives or for use in conjunction with 
antibiotics against resistant pathogens. Staphylococcus aureus is the most common bacteria 
isolated from skin and soft tissue infections (SSTIs). Strains of S. aureus have emerged with 
resistance against antibiotics with the most common being methicillin-resistant S. aureus 
(MRSA). Several lantibiotics are active against MRSA in vivo and have even shown superior 
activity to traditional antibiotics. Lantibiotics therefore show much promise for the treatment 
of SSTIs caused by resistant- and non-resistant S. aureus. 
In this study the bacterially diverse soil of the Fynbos in the Western Cape was screened for 
novel antimicrobials. Two antimicrobial producing Bacillus strains were isolated, Bacillus 
clausii AD1 and Bacillus amyloliquefaciens AD2. Both of these strains produce lantibiotics 
with B. clausii AD1 producing a known lantibiotic, clausin. B. amyloliquefaciens AD2 
produces a novel two-component lantibiotic which was designated amyloliquecidin. The 
lantibiotic operon of amyloliquecidin was sequenced and annotated. All the genes required for 
successful production of amyloliquecidin are present in the operon. Amyloliquecidin was 
characterized in vitro and along with clausin is active against clinical strains of S. aureus 
(including MRSA), Enterococcus spp., Listeria spp. and beta-haemolytic streptococci. 
Amyloliquecidin has remarkable stability at physiological pH compared to nisin and clausin. 
A comparative in vivo murine infection model was used to evaluate the effectiveness of 
amyloliquecidin, nisin, clausin and Bactroban (commercial S. aureus topical treatment) in 
treating wound infections caused by S. aureus. All the lantibiotics proved to be just as effective 
as the Bactroban treatment. Furthermore, the tested lantibiotics did not have a negative 
influence on the wound closure rates of infected and non-infected wounds. Bactroban had a 
negative effect on wound healing compared to the lantibiotics. 
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To our knowledge amyloliquecidin is the third two-component lantibiotic isolated from 
Bacillus. This study represents the first to test the effectiveness of amyloliquecidin in vivo and 
is one of a handful to test lantibiotics as topical treatments. 
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Opsomming 
 Antimikrobiese weerstandbiedende bakterieë is op die oomblik een van die grootste probleme 
in die mediese veld. Die antibiotika krisis word vererg deur die vermoë van bakterieë om vinnig 
weerstand op te bou teen antibiotika, asook die alledaagse misbruik van antibiotika. Daar is 
ook ŉ tekort in die hoeveelheid antibiotika wat na die finale fases van ontwikkeling gaan. Om 
die oorhand teen antibiotika-weerstandige bakterieë te kry is dit van uiterste belang dat meer 
effektiewe antibiotika ontdek word. 
Lantibiotika is kationiese antimikrobiese peptiede wat deur die ribosoom gesintetiseer word en 
bevat ŉ verskeidenheid van modifikasies wat na translasie ingebou word. Hulle word 
gekarakteriseer deur lanthionien en metiellanthionien ringe. Lantibiotika is aktief teen ŉ 
verskeidenheid Gram-positiewe bakterieë en kan in kombinasie met antibiotika, of as 
alternatief gebruik word. Staphylococcus aureus is die mees algemene bakterium wat 
geassosieer word met vel en sagte weefsel infeksies (VSWIs). Staphylococcus aureus met 
weerstand teen antibiotika is ook al geïsoleer, die mees algemene weerstandige ras is 
methisillien-weerstandige S. aureus (MWSA). Lantibiotika is wel aktief teen MWSA in vitro 
en in vivo, met van hulle wat tot beter aktiwiteit as die voorgeskrewe antibiotika het. 
Lantibiotika kan dus gebruik word as behandeling vir VSWIs wat veroorsaak word deur 
weerstandige S. aureus, asook teen nie-weerstandige rasse. 
In hierdie studie was die bakteriese diverse grond van die Fynbos in die Wes-kaap ondersoek 
vir bakterieë wat antimikrobiese middels produseer. Twee Bacillus rasse, Bacillus clausii AD1 
en Bacillus amyloliquefaciens AD2, wat antimikrobiese middels produseer, is geïsoleer. 
Bacillus clausii AD1 produseer ŉ bekende lantibiotikum, naamlik clausin. Bacillus 
amyloliquefaciens AD2 produseer ŉ nuwe twee-komponent lantibiotikum, amyloliquecidin. 
Die lantibiotikum operon wat verantwoordelik is vir die produksie van amyloliquecidin is 
geïdentifiseer en geannoteer. Die operon bevat al die gene benodig vir die biosintese van 
amyloliquecidin. Amyloliquecidin is in vitro gekarakteriseer en het aktiwiteit teen ŉ 
verskeidenheid Gram-positiewe bakterieë. Amyloliquecidin en clausin is aktief teen S. aureus 
(insluitend MWSA), Enterococcus spp., Listeria spp. en beta-hemolitiese streptococci wat 
vanaf infeksies geïsoleer is. Amyloliquecidin is baie stabiel by filologiese pH en aansienlik 
meer stabiel as nisin en clausin. Die effektiwiteit van nisin, clausin en amyloliquecidin in die 
behandeling van muis vel infeksies veroorsaak deur S. aureus was vergelyk met die 
kommersiële behandeling Bactroban. Al drie lantibiotika het die verspreiding van S. aureus 
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met die selfde effektiwiteit as Bactroban belemmer. Geen van die lantibiotika het ŉ negatiewe 
effek op wond genesing nie. Bactroban, inteendeel, belemmer wond genesing. 
So ver ons weet is amyloliquecidin die derde twee-komponent lantibiotikum wat uit Bacillus 
geïsoleer is. Die studie is ook die eerste om die effektiwiteit van amyloliquecidin in vivo te 
rapporteer, asook ook een van die min studies wat kyk na lantibiotika as behandeling vir 
topikale infeksies. 
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Preface 
This dissertation is represented as a compilation of 5 chapters. Each chapter is introduced 
separately and is written according to the style of the American Society for Microbiology.  
Chapter 1: General Introduction 
Chapter 2: Biosynthesis, Mode of Action and Clinical Applications of Lantibiotics 
Chapter 3: In vitro Characterization of a Novel Two-Component Lantibiotic from Bacillus 
amyloliquefaciens 
Chapter 4: Evaluation of the in vivo Efficacy of Lantibiotics in the Treatment of S. aureus-
Induced Skin Infections in Mice 
Chapter 5: General Discussion and Conclusions 
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General Introduction 
The use of antibiotics to treat bacterial infections is probably the most important contribution 
to medical sciences in modern times. Hundreds of antibiotics have been described that target 
cell wall development, DNA- and protein-synthesis (1). The increase in antibiotic resistance is 
steering science back into the “pre-antibiotic” era and can result in minor infections turning 
into life threatening diseases (2). Antibiotic resistance is exacerbated by over-prescription and 
misuse of antibiotics (3, 4). The appropriate use of antibiotics is therefore important in trying 
to control the spread of resistance. Bacteria become resistant to antibiotics by random mutation, 
expression of latent resistant genes, or the exchange of genetic material (e.g. horizontal gene 
transfer). Therefore, despite many attempts to control antibiotic resistance, it is inevitable that 
bacteria will mutate or adapt. The search and development for novel antimicrobials is thus 
crucial. It is possible to speed up the discovery of new antimicrobials by using high through-
put screening techniques, bioinformatics, structural-, chemical- and synthetic-biology (5, 6). 
The probability of finding novel antimicrobials can also be increased by screening unexploited 
environments with diverse bacterial populations. 
Lantibiotics are antimicrobial peptides that can be used in combination with antibiotics or as 
possible alternatives. Lantibiotics are ribosomally synthesized and post-translationally 
modified peptides. Their main characteristic is that they contain meso-lanthionine (Lan) and 
methyllanthionine (MeLan) residues (7, 8). Lanthionine and MeLan modifications are 
introduced with the help of modification enzymes that are required for, but not limited to, 
dehydration and cyclization reactions (7, 8). Lantibiotics are generally only active against 
Gram-positive bacteria. Several lantibiotics have shown promising activity in vitro and in vivo 
against antibiotic-resistant pathogens (9-12). A few lantibiotics are being developed for the 
treatment of infections caused by Gram-positive bacteria (Novacta Biosystems; Oragenics). 
Staphylococcus aureus is the major cause of skin and soft tissue infections (SSTIs). The species 
has developed resistance against antibiotics, with the most common example being methicillin-
resistant S. aureus (MRSA). The recommended treatment for SSTIs caused by S. aureus, 
Bactroban, is ineffective against MRSA (13, 14). Resistance of MRSA to one of the last resort 
treatments, vancomycin, have also started to emerge (15-19). Several lantibiotics are active 
against MRSA and vancomycin-resistant strains, making them possible alternatives for 
treatment of S. aureus SSTIs (9-12). Little has been published on the in vivo treatment of topical 
infections by lantibiotics. Lantibiotics are, however, effective in the treatment of S. aureus 
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infections when administered via subcutaneous, intraperitoneal, intranasal and intravenous 
routes (9-11, 20). Nisin spun into nanofibers, and applied topically, is also effective in the 
control of in vivo infections caused by S. aureus (21). From these results it is evident that 
lantibiotics have applications in the treatment of SSTIs. 
In this study, we set out to isolate and characterize novel antimicrobials from the highly diverse 
Fynbos soils of the Western Cape, South Africa. A novel two-component lantibiotic, 
amyloliquecidin, and the lantibiotic clausin were isolated from strains of Bacillus 
amyloliquefaciens AD2 and Bacillus clausii AD1, respectively. By making use of an in vivo 
imaging system, we evaluated the effectiveness of the lantibiotics and compared their activity 
with that of nisin and Bactroban in the treatment of S. aureus-induced skin infections in mice. 
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Introduction to Lantibiotics 
Lanthipeptides are ribosomally synthesized and post-translationally modified (PTMs) peptides 
(RiPPs), that contain meso-lanthionine (Lan) and methyllanthionine (MeLan) residues (1). 
Lanthionine and MeLan modifications are introduced by modification enzymes that are 
required for, but not limited to, dehydration and cyclization reactions (1, 2). Lanthipeptides are 
broadly classified into four classes based on their modification machinery. Class I peptides are 
modified by two enzymes namely LanB and LanC, whereas the other three classes have bi-
functional lanthionine synthetases.  
Dehydratase enzymes are responsible for the dehydration of Ser to dehydroalanine (Dha) and 
Thr to dehydrobutyrine (Dhb) (3, 4). Dha and Dhb undergo subsequent cyclization reactions, 
via a Michael addition of Cys residues to the dehydrated Dha/Dhb, resulting in Lan containing 
two Ala residues and MeLan containing an additional methyl group, respectively (3, 4). In class 
I, the dehydration and cyclization reactions are alternating, with reactions following one after 
another, and for class I and II dehydration generally proceeds in an N- to C-terminal direction 
(4–6). Additional PTMs can include formation of labionin residues, formed as a result of the 
initial enolate undergoing a second Michael addition with a second Dha, and oxidative 
decarboxylation of the lantibiotic C-terminus during aminovinylcysteine formation (7–9). The 
structural genes of lanthipeptides’ form part of a gene cluster containing all the biosynthetic 
machinery for their modification, export, leader cleavage and regulation (2).  
One group of lanthipeptides showing great potential are those with antimicrobial activity, 
namely lantibiotics. First reported in 1928, nisin is the best studied lantibiotic and is used as 
preservative in dairy products (10, 11). Since the discovery of nisin the production of 
lantibiotics by a variety of Gram-positive bacteria has been reported, and with sequenced 
genomes becoming more readily available, the identification of putative lantibiotics is 
increasing rapidly (2, 12). Lantibiotics have potent activity against related Gram-positive 
bacteria, many of which are clinical isolates of Staphylococcus spp., Enterococcus spp. and 
Clostridium spp. including some antibiotic-resistant strains (13, 14). The majority of 
lantibiotics bind to the cell wall precursor lipid II. They can form pores in the cell membrane 
and prevent cell wall biosynthesis (15). The prototypical lantibiotic nisin binds to the 
pyrophosphate moiety of lipid II via two of its N-terminal rings, resulting in the inhibition of 
further cell wall biosynthesis and facilitating formation of the pore complex (16–18). 
Formation of the pore complex results in cell membrane permeabilization and dissipation of 
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the proton motive force (16–18). Lantibiotics also have possible roles in the modulation of the 
innate immune system (19, 20). The lantibiotics gallidermin, Pep5 and nisin induce the release 
of multiple chemokines at levels similar to that of the human cationic antimicrobial peptide 
(cAMP) LL-37, with nisin seemingly able to activate multiple signalling pathways, including 
ERK/MAPK, PKC and PKA (19). At high concentrations nisin is also able to activate 
neutrophils, resulting in formation of neutrophil extracellular traps (NETs) (20). Neutrophil 
extracellular traps are known for trapping and killing bacteria (21). Formation of NETs is also 
induced by a known immune modulating bacterial cAMP, phenol-soluble modulin-γ (PSM- γ; 
from Staphylococcus epidermidis), although at lower concentrations than reported for nisin 
(22). It is hypothesized that the direct antimicrobial activity of lantibiotics, produced by 
commensal bacteria, may play a role in the protection of the host from possible pathogenic 
bacteria (23, 24). Cinnamycin and duramycin indirectly inhibit phospholipase A2 and 
ancovenin is a potential angiotensin I converting enzyme inhibitor, suggesting that they can 
also play a role in immune modulation (25–27).  
In silico analysis of sequenced genomes reveals the wide-spread occurrence of lantibiotics in 
several bacteria associated with humans. It is thus possible that they may play an important 
role in the host-microbe interaction, although very little research has been done on this subject.  
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Classification, Biosynthesis and Mode of Action of Lantibiotics 
Classification 
Several classification systems proposed for lantibiotics are based on differences in structure, 
function, amino acid sequences and biosynthetic machinery. For the purpose of this review, a 
combination of classification systems based on amino acid sequence similarity of the 
unmodified precursor peptides (w/o leader sequence) and biosynthetic machinery will be used, 
as first proposed by Cotter et al. (28).  
Classification according to modification machinery separates all lanthipeptides into four 
groups. Lantibiotics are divided into 13 subgroups (named after the prototypical lantibiotic in 
that group), based on unmodified precursor peptide amino acid sequences (w/o leader 
sequence). 
Class I 
Class I are linear lantibiotics modified by two distinct enzymes to produce precursor peptides. 
Serine is dehydrated to Dha and Thr is dehydrated to Dhb, which are then cyclized resulting in 
the Lan/MeLan structures, respectively (3, 4). Gene designations for enzymes involved in this 
process have been widely used and remain unchanged, e.g. lanB for dehydratase and lanC for 
cyclase (1). Khusainov et al. (29) have recently shown interaction between the nisin leader 
peptide and LanBC complex. By systematically replacing two to four amino acid regions in 
the leader sequence with Ala, they found that three regions, i.e. STDK (-22-19), FNLD (-18-
15) and PR (-2-1) contribute to the interaction of the leader with LanB and LanC, whereas only 
one region, LVSV (-14-11), contributes to the interaction with LanC (Fig. 1). In all modified 
leader sequences the interaction with LanC was severely affected, however, LanB is less 
affected by these changes, suggesting a less specific interaction of the dehydratase with specific 
leader regions. Changes in the FDLEI-motif of Pep5 also influence its biosynthesis, most likely 
due to disturbances in its interaction with LanB (30). However, the FDLEI-motif is not 
essential for biosynthesis, as reported for the FNLD-motif of nisin (30). These results strongly 
suggest that conserved regions in class I leader sequences are important for the proper initial 
interaction of class I synthetases and the precursor peptide.  
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Lubelski et al. (4) showed that the presence of lanthionine rings interferes with the dehydrating 
activity of LanB. The authors have also shown that LanC complex formation (with pre-nisin), 
and not its cyclase activity is important for proper biosynthesis kinetics of nisin. In the same 
study they also provided evidence for the alternating and directional activities of LanB and 
LanC and proposed a new working model for nisin PTM (Fig. 2). In the proposed model LanB 
and LanC, localized at the cytoplasmic membrane, interacts with a dedicated lantibiotic integral 
membrane ABC-transporter, LanT (31, 32). It is speculated that LanT pulls the precursor 
peptide through active sites of the LanBC complex using ATP in the process. This is due to the 
observations that LanC does not utilize ATP and LanB does not contain motifs that would be 
able to use ATP. Finally, the fully modified precursor peptide is transported across the 
membrane and the leader peptide is cleaved off by an extracellular serine protease, LanP (4). 
This model was proposed with the nisin biosynthetic machinery in mind. However, with few 
exceptions, modification enzymes of class I lantibiotics have homology and usually cluster 
closely together, suggesting that this model may be applicable to all class I lantibiotics (33).  
Class I is further subdivided into five subgroups based on unmodified precursor peptide amino 
acid sequence (w/o leader sequence), including, nisin-, epidermin-, streptin-, Pep5- and 
planosporicin-like lantibiotics. The lantibiotics in these subgroups contain similar N-terminal 
ring topology that is analogous to the nisin lipid II-binding motif, with the exception of the 
Pep5-like lantibiotics. 
Nisin-like lantibiotics 
Nisin-like lantibiotics include all natural nisin variants as well as salvaricin D, subtilin, ericin 
A and geobacillin I (Fig. 3). Nisin-like lantibiotics have a conserved N-terminal region and 
similar ring topology. Geobacillin I also has a similar ring topology to that of other nisin-like 
lantibiotics. However, differences include a single-amino acid linker between rings C and D 
Pep5               --------MKNNKNLFDLEIKKETSQ-NTDELEPQ 
Planosporicin      MGISSPALPQNTADLFQLDLEIGVEQ---SLASPA 
Streptin           --------MNNTIKDFDLDLKTNKKD----TATPY 
Nisin              ----------MSTKDFNLDLVSVSKK--DSGASPR 
Epidermin          -----MEAVKEKNDLFNLDVKVNAKESNDSGAEPR 
                              . . *:*::    ..       *  
FIG 1 Leader peptides of prototypical class I lantibiotics. Fully conserved-, strongly- and weakly-conserved residues 
are indicated by *, : and ., respectively. Bold letters indicates LanP cleavage sites. 
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and a reduction in the size of ring C (34). Ring E is a Lan, instead of a MeLan and it has two 
additional C-terminal overlapping rings (34). 
Nisin-like lantibiotics bind to the cell wall precursor lipid II with intramolecular hydrogen 
bonds forming a “pyrophosphate cage” (17). This complex results in inhibition of cell wall 
biosynthesis and facilitates insertion into the membrane. Insertion results in the leakage of 
cytoplasmic contents, followed by dissipation of the proton motive force (15, 16, 35, 36). The 
first two N-terminal MeLan rings play a crucial role in the binding of lipid II (37–39). Ring A 
of nisin is flexible towards amino acid substitutions. With addition of positive residues 
correlating with increased antimicrobial activity, and ring disruption resulting in substantial 
loss of activity (37, 38). The more conserved ring B, is less flexible with regards to amino acid 
substitutions, with larger amino acids occasionally interfering with the cyclization reaction, 
resulting in loss of activity (37, 38). Removal or disruption of ring C results in substantial loss 
of activity (15, 38). The nature of the side chains of ring C amino acids also play a role in its 
biological activity (15). Substitution of Met at position 17 with Lys does not abolish activity, 
but reduces pore forming capabilities in lipid II-doped liposomes (15). 
Antimicrobial activity is still observed in C-terminal truncated nisin, and non-pore forming 
lipid II-binding lantibiotics with similar A and B rings. Truncated nisin still binds lipid II, with 
FIG 2 Proposed model for nisin biosynthesis. Ribosomal synthesis of prenisin (A), followed by recognition by NisBTC complex 
(B). Nisin is subsequently pulled through the active sites of the NisBC complex by NisT (C-E). The alternating actions of NisB 
and NisC incorporates the Lan/MeLan rings. NisB first dehydrates Ser/Thr followed by cyclization by NisC (indicated by*; C 
and D, respectively). The pulling action of NisT allows for the consecutive dehydrations/ring formations (E). Finally modified 
nisin is exported out of the cell and the leader peptide is cleaved by NisP. Figure adapted from Lubelski et al. (4). 
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reduced antimicrobial activity and no pore formation, and acts as an antagonist to full length 
nisin (37, 38, 40). Nisin also displaces lipid II from its functional locations in Gram-positive 
bacteria, thereby interfering with cell wall biosynthesis (40, 41). The other antimicrobial action 
of nisin-like lantibiotics is to produce pores in the cell membrane. Once nisin has been anchored 
to lipid II, via the pyrophosphate cage, conformational changes result in the formation of stable 
pores consisting of eight nisin molecules and four lipid II molecules (17, 42). The three amino 
acid hinge region links the N-terminal A, B, C rings with the C-terminal D and E rings. The 
hinge provides conformational flexibility which facilitates pore formation (15, 43). 
Substitution of the three amino acids making up the hinge (positions 20-22) with small chiral 
amino acids results in increased activity (43, 44). Negative-, aromatic-residues and shortening 
of the hinge region, has a detrimental effect on activity and pore formation (15, 43, 44). 
Geobacillin I also forms pores despite only having one amino acid linker between rings C and 
D (36). Introduction of the Asn-Val-Ala linker, that increases activity in nisin, decreases 
geobacillin I activity and pore formation (36). Unlike nisin, substitution of the geobacillin I 
linker with Pro does not have such a detrimental effect on pore formation (36). These results 
suggest that geobacillin I has a different mechanism of pore formation compared to nisin. 
In addition to the antibacterial effect on vegetative cells, nisin and subtilin prevent spore 
outgrowth in Bacillus spp. and Clostridium spp. endospores (45-47). Nisin binds to lipid II of 
germinating spores and prevents spore outgrowth. However, truncated nisin (nisin 1-12 and 
 
 
 
NisinA           ITSISLCTPGCKTGALMG-CNMKTAT-CHCSIHVSK-- 
NisinF           ITSISLCTPGCKTGALMG-CNMKTAT-CNCSVHVSK-- 
NisinQ           ITSISLCTPGCKTGVLMG-CNLKTAT-CNCSVHVSK-- 
NisinU           ITSKSLCTPGCKTGILMT-CPLKTAT-CGCHFG----- 
NisinZ           ITSISLCTPGCKTGALMG-CNMKTAT-CNCSIHVSK-- 
Subtilin         WKSESLCTPGCVTGALQT-CFLQTLT-CNCKI--SK-- 
GeobacillinI     VTSKSLCTPGCITGVLM--CLTQNSCVS-CNSCIRC-- 
SalivaricinD     FTSHSLCTPGCITGVLMG-CHIQSIG-CNVHIHISK-- 
Entianin         WKSESVCTPGCVTGLLQT-CFLQTIT-CNCKI--SK-- 
EricinA          VLSKSLCTPGCITGPLQT-CYLCFPTFAKC-------- 
EricinS          WKSESVCTPGCVTGVLQT-CFLQTIT-CNCHI--SK-- 
PaenicidinA      VLSIVACSSGCGSGKTAASCVETCG-NRCFTNVGSLC- 
 
FIG 3 Nisin-like lantibiotics. Cys residues are shown in red. Bold letters in purple and green designate Thr and Ser 
that are dehydrated, respectively. Bold black letters indicate Ser that escape dehydration. Lines above letters indicate 
ring topology of nisin. Figure adapted from Rea et al. (49) and Dischinger et al. (50). 
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nisin1-22) is not able to prevent spore outgrowth, indicating that both modes of action are needed 
(37, 40). Additionally, nisin hinge mutants unable to form pores, still have antimicrobial 
activity against vegetative cells but do not prevent spore outgrowth (40). The Dha at position 
5 does not seem to be crucial in nisin to prevent spore outgrowth (37, 40). Contradictory results 
are reported for subtilin, which requires the Dha at position 5 for prevention of spore outgrowth 
(46, 48). Despite these differences, similarities in the amino acid sequence and similar ring 
topology leads to speculation that all nisin-like lantibiotics have similar biological activities 
with regards to vegetative cells and spore out growth.  
Epidermin-like lantibiotics 
Epidermin-like lantibiotics include, amongst others, mutacin 1140, epidermin, gallidermin and 
clausin. They have a conserved C-terminal region, which is important for the formation of an 
additional modification enzyme, LanD (Fig. 4) (51). LanD is responsible for the oxidative 
decarboxylation of a C-terminal Cys followed by cyclisation by LanC (with Dha/Dhb). This 
results in the formation of a C-terminal 2-aminovinyl-D-cysteine (AviCys; cyclisation with 
Dha) or 2-aminovinyl-methyl-D-cysteine (AviMeCys; cyclisation with Dhb) (9, 51, 52).  
Epidermin-like lantibiotics bind to lipid II, and have the nisin lipid II binding-motif, composed 
of rings A and B (16, 41, 53, 54). These peptides are much shorter than nisin-like lantibiotics 
and cannot form pores in cell membranes exceeding 40 Å (54). Interestingly, wild type 
gallidermin and gallidermin mutants (A12L) are more potent against L. lactis than nisin, even 
though they lack pore forming capabilities against L. lactis (54). This may be explained by the 
higher affinity gallidermin has for lipid I/II in vitro, which has also been observed for epidermin 
(16, 54). Pore formation is, however, observed in Micrococcus spp. and to some extent in 
Staphylococcus spp. possibly due to differences in cell membrane thickness and higher 
numbers of undecaprenol-linked molecules (54). However, the same A12L gallidermin mutant 
with increased L. lactis activity has significantly less activity against Staphylococcus spp. and 
Micrococcus spp. Pore formation is less prominent in Staphylococcus spp., however, 
gallidermin hinge mutants (A12L) still remains active, indicating that further interactions may 
be involved (54, 56). In a recent study by Chen et al. (55), changes in the size of ring A and its 
proximity to ring B had major influences on bioactivity of mutacin 1140. This is most likely 
due to interference with lipid II interaction. As with nisin-like lantibiotics, it seems that the 
A/B ring motif is crucial for lipid II-binding and bioactivity. Interestingly, introduction of a 
negatively charged amino acid in the hinge region (R13D) of mutacin 1140 only results in loss 
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of activity when combined with another mutation W4A (55). In contrast, introduction of 
negatively charged residues in the hinge region of nisin results in decreased activity (43, 44, 
57).  
Similar to truncated nisin, epidermin-like lantibiotics are able to sequester lipid II from its 
functional location. This may explain their antimicrobial activity in the absence of pore 
formation (16, 41, 58). This alternative mode of action is proposed to be conserved in 
lantibiotics with the nisin lipid II-binding motif (41). Bouhss et al. (53) also showed that clausin 
binds the pyrophosphate moiety in cell wall lipid intermediates, further illustrating the 
conserved lipid I/II binding characteristics between nisin- and epidermin-like lantibiotics. 
 
 
 
 
 
 
 
Streptin-like lantibiotics 
Streptin, produced by Streptococcus pyogenes, is the only lantibiotic described in this group 
(Fig. 5). Little experimental information is published on the structure and activity of streptin 
(59). Streptin 2 differs from streptin 1 by having three additional amino acids (TPY) on the N-
terminal (59). As concluded from data obtained with genome mining, streptin can also be 
produced by Bacillus sonorensis (gi: 657608345) and Clostridium beijerinckii (gi: 
652493081). The N-terminal ring structure of streptin is similar to that of nisin- and epidermin-
like lantibiotics, suggesting that it may also have similar lipid I/II binding properties. As with 
epidermin-like lantibiotics, streptin is short with only 23 amino acids and if it is capable of pore 
formation (depending on ring structure) it will most likely not rely on this for antimicrobial 
activity.  
 
 
Epidermin           IASKFICTPGCA--KTGSFNSYCC 
Gallidermin         IASKFLCTPGCA--KTGSFNSYCC 
StaphylococcinT     IASKFLCTPGCA--KTGSFNSYCC 
MutacinB-Ny266      FKSWSFCTPGCA--KTGSFNSYCC 
Mutacin1140         FKSWSLCTPGCA--RTGSFNSYCC 
Clausin             FTSVSFCTPGCG--ETGSFNSFCC 
MuntacinI           FSSLSLCSLGCTGVKNPSFNSYCC 
BsaA2               ITSHSLCTPGCA--KTGSFNSFCC 
 
FIG 4 Epidermin-like lantibiotics. Cys residues are shown in red. Bold letters in purple 
and green indicate Thr and Ser that are dehydrated, respectively. Bold black letters 
indicate Ser that escape dehydration. Lines above letters indicate ring topology of 
epidermin. Blue line indicates AviCys. Figure adapted from Rea et al. (49) and Dischinger 
et al. (50). 
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Pep5-like lantibiotics 
There are four characterized lantibiotics in this subgroup, i.e. Pep5, epicidin 280, epilancin 15X 
and epilancin K7 (Fig. 6). All four are produced by S. epidermidis. All the Pep5-like peptides 
have an additional modification, i.e. hydration-deamination of Dha/Dhb at position 1. After 
cleavage of the leader peptide the N-terminal Dha/Dhb at position 1 is exposed and becomes 
unstable. The unstable Dha (Epicidin 280, Epilancin 15X and Epilancin K7) and Dhb (Pep5) 
undergoes spontaneous hydration-deamination resulting in the formation of 2-oxopropionyl 
(Dha) and 2-oxobutyryl (Dhb) (60-64). Furthermore, the N-terminal 2-oxopropionyl undergoes 
further reduction to form 2-hydroxypropionyl. This reaction is most likely catalysed by the 
modification enzyme LanO (oxidoreductase), which is found in the operons of epicidin 280 
and epilancin 15X, and should also be represented in the operon of epilancin K7.  
Pep5-like lantibiotics form pores in sensitive organisms. However, they do not bind to lipid I/II 
like nisin-, epidermin- and streptin-(possibly) like lantibiotics, suggesting that they use a 
different recognition/docking mechanism (16, 61). Removal of the N-terminal cap of epilancin 
15X does not result in loss of activity, indicating that this modification is not essential for 
activity. The N-terminal cap may be more essential for stability and protection from cleavage 
(62). N-terminally truncated epilancin 15X, on the other hand, did display a decrease in activity 
against S. cornosus. This does indicate that there may be an additional non-lipid II docking 
molecule required for increased activity (62). Flexibility of Pep5-like lantibiotics seems to be 
important for proper bioactivity as mutations in the hinge region of Pep5 (K18P) were found 
to be very detrimental for bioactivity (63). Furthermore, the decreased activity observed for 
epicidin 280, compared to Pep5, may be a result of epicidin 280 being more rigid and not able 
to properly form pores (64).  
 
 
 
Streptin1     ---VGSRYLCTPGSCWKLVCFTTTVK 
Streptin2     TPYVGSRYLCTPGSCWKLVCFTTTVK 
 
FIG 5 Streptin-like lantibiotics. Cys residues are shown in red. Bold letters in 
purple and green indicate Thr and Ser that are dehydrated, respectively. Lines 
above letters indicate proposed ring topology of streptin. Red lines indicates 
alternative ring C for streptin with dashed lines possible bridging patterns (59). 
Figure adapted from Rea et al. (49) and Dischinger et al. (50). 
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Planosporicin-like lantibiotics 
In the updated classification proposed by Rea et al. (49), planosporicin produced by the 
uncommon actinomycete Planomonospora alba is the only lantibiotic in this group (Fig. 7) 
(65). However, the lantibiotic microbisporicin also produced by another actinomycete 
(Microbispora corallina) should be included in this group due to high sequence similarity with 
planosporicin and various genes in its gene cluster, as well as identical thioether bridges (66–
70). Microbisporicin does have additional modifications not found in planosporicin, including 
a chlorinated Trp, hydroxylated Pro and a C-terminal AviCys. These and other amino acid 
differences may explain the higher antimicrobial activity of microbisporicin (67). The extra 
modifications in microbisporicin are as a result of two modification enzymes, MibH 
(tryptophan halogenase) and MibO, which are responsible for the chlorination of Trp and 
hydroxylation of Pro, respectively (68). It should be noted that the gene clusters of 
planosporicin-like lantibiotics are not annotated according to the recent recommendations for 
RiPPs (1). Although there are similarities to the class II mersacidin, they do not have any of 
the conserved motifs found in this group (65–67). They do, however, have similar N-terminal 
ring topologies (nisin lipid II-binding motif) found in other class I lantibiotics (66, 67). The C-
terminal ring in microbisporicin is almost identical to that of epidermin-like lantibiotics (66, 
67). Castiglione et al. (65, 67) showed that microbisporicin and planosporicin are able to block 
peptidoglycan synthesis in a similar manner to that reported for mersacidin and actagardine. 
Microbisporicin and planosporicin cause accumulation of UDP-MurNAc-pentapeptide (UDP-
N-acetylmuramyl-pentapatide), similar to mersacidin and actagardine. Similar accumulation 
was not observed with nisin, which disrupts the membrane integrity, resulting in cessation of 
all macromolecular synthesis. It would be interesting to see if epidermin-like lantibiotics also 
result in this accumulation in a strain where they do not form pores. Due to the short nature of 
 
 
Pep5            TAGPAIRASVKQCQKTLKATRLFTVSCKGKNGCK----- 
Epilancin15x    S-ASIVKTTIKASKKLCRG---FTLTC----GCHFTGKK 
EpilancinK7     S-ASVLKTSIKVSKKYCKG---VTLTC----GCNITGGK 
Epicidin280     SLGPAIKATRQVCPKATRF---VTVSC-KKSDCQ----- 
 
FIG 6 Pep5-like lantibiotics. Cys residues are shown in red. Bold letters in purple and green indicate Thr and Ser that 
are dehydrated, respectively. Bold black letters indicate Thr/Ser that escape dehydration. Grey highlighted letters 
represents Ser/Thr that undergoes hydration-deamination. Lines above letters indicate ring topology of Pep5. Figure 
adapted from Rea et al. (49) and Dischinger et al. (50). 
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these peptides, reminiscent of epidermin-like lantibiotics, it is conceivable that they also only 
form pores under certain conditions. Microbisporicin has minimum inhibitory concentration 
(MIC) values that are superior to that of nisin for selected vancomycin-intermediate S. aureus 
(VISA), methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococci (VRE) 
(67). Further research is required to establish how microbisporicin and planosporicin target 
lipid II and if the nisin lipid II-binding motif has the same function in these lantibiotics. 
  
 
 
Planosporicin       ITSVSWCTPGCTSEGGGSGCSHCC 
Microbisporicin     VTSWSLCTPGCTSPGGGSNCSFCC 
 
FIG 7 Planosporicin-like lantibiotics. Cys residues are shown in red. Bold letters in purple 
and green indicate Thr and Ser that are dehydrated, respectively. Bold black letters 
indicate Thr that escape dehydration. Lines above letters indicate ring topology of 
planosporicin. Green highlighted Trp is chlorinated to chlorotryptophan. Red highlighted 
Pro is hydroxylated to dihydroxyproline. Figure adapted from Rea et al. (49) and 
Dischinger et al. (50). 
Stellenbosch University  https://scholar.sun.ac.za
  
21 
 
Class II 
Class II lantibiotics often have a more globular structure compared to class I. However, the 
main difference between class I and class II lantibiotics is the modification machinery they use 
for dehydration and cyclization. Class I uses LanB and LanC for dehydration and cyclization, 
respectively, whereas class II lantibiotics have one bi-functional synthetase LanM (1). LanM 
consists of an N-terminal dehydratase (no sequence homology to LanB) and a C-terminal 
LanC-like domain. Unlike LanB, LanM utilizes ATP to phosphorylate Ser/Thr to yield the 
respective dehydrated residues, followed by cyclization by the C-terminal LanC-like domain 
(2, 33, 71). Lee et al. (6) demonstrated using the LanM enzymes that modify lacticin 481 
(LctM) and haloduracin-β (HalM2), process them in an N- to C- terminal direction when the 
leader peptide is covalently attached. Furthermore, the dehydration and cyclization reactions 
occur on a similar time scale. Another observation is that the leader peptide is not strictly 
needed for LctM activity, but when the leader peptide is provided in trans enzyme activity 
significantly increases (5). It was, therefore, suggested that leader peptide binding does not 
result in a conformational change resulting in active enzyme, but rather stabilizes an active 
form of the enzyme shifting the equilibrium to more active enzyme (5). Dehydrations do not 
occur in a specified direction when the leader peptide is provided in trans (5). This suggests 
that attachment of the leader peptide to the core peptide allows for process directionality. As 
with the leader peptides of class I, class II leader peptides also contain conserved regions that 
are important for proper modification (Fig. 8) (2, 72, 73). However, in the case of lacticin 481, 
not all these regions are important for synthetase activity (73). The only single mutation that 
had a significant effect on activity was at position -7 (L-7K), which resulted in both decreased 
dehydration and cyclization (73). Similar results were also reported for mutacin II (L-7K) (72). 
Mutations of the lacticin 481 leader at positions I-4P, D-6P, L-7E/K and E-8A, resulted not 
only in decreased dehydration but also interfered with proper cyclization. Structural predictive 
tools calculate a helical motif for stretches of the leader peptide, and helical-breaking 
mutations, I-4G/P, L-5P, D-6G/P and E-8P, result in decreased dehydratase activity (73). 
Similar results are also found for the leader of nukacin ISK-1 (74). This suggests that LanM 
may bind to a secondary structure, and that disruption of this structure results in decreased 
synthetase efficiency. In addition to nukacin ISK-1 leader mutants (L-7P and E-8P) having 
reduced/diminished antimicrobial activity, they also have reduced helicity of the leader 
resulting from the presence of the helix-breaking residue Pro (74). These results further 
substantiate the possible binding of LanM to a secondary helical structure. The α-helical 
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structure is also found in class I lantibiotic leader peptides and, therefore, may be an important 
feature in the maturation of all lantibiotics (75). LanM is very promiscuous, with LctM able to 
process several class II lantibiotics with the lacticin 481 leader attached (73). Additionally, 
LctM can also process lacticin 481 with a mutacin II leader attached (73). 
Unlike class I lantibiotics, class II lantibiotics also have a bi-functional membrane protein, 
LanT that functions as a protease and a transporter (76, 77). Mutations in the leader of mutacin 
II (G-1A and G-2A) results in accumulation of dehydrated pre-mutacin, suggesting prevention 
of either cleavage, transport or both (72). In the lacticin 481 leader, the Gly-motif (G-2 and A-
1) is important for proteolysis. Furthermore, the protease domain of the bi-functional LctT 
recognizes the same putative secondary structure that LctM recognizes, upstream of the Gly-
motif (73, 76). The recognition by the protease domain of the LctT suggests that substrate 
recognition takes place in the protease- instead of the transport-domain (76). 
Class II is subdivided into eight subgroups based on the unmodified precursor peptide amino 
acid sequence. These include; lacticin 481-, mersacidin-, ltnA2-, cytolysin-, lactocin S-, 
cinnamycin-, sublancin- and bovicin HJ50-like lantibiotics.  
Lacticin 481-like lantibiotics 
This is a large group, made up of more than 19 characterized lantibiotics. Sequence alignment 
revealed that while some residues differ with high frequency there are several conserved 
residues throughout this group (Fig. 9) (28). All the lacticin 481-lantibiotics have Ser, Thr and 
Cys in similar positions, indicating that these are involved in ring formation (50, 78–82). There 
is also a conserved Glu in most lacticin 481 lantibiotics corresponding to position 13 of lacticin 
481 (Fig. 9). Mutation of the Glu13 (E13A) abolishes activity in lacticin 481 (83). Nukacin 
ISK-1 has an Asp at this site and changing this to Glu does not alter activity, however, other 
LactocinS         ----------------MKTEK--------KVL-DE---LSLHASAKMGARDVESSMNAD- 
BovicinHJ50       ----------------MMNAT------ENQIFVETVSDQEL--EMLIGG----------- 
Mersacidin        -MSQEAIIRSWKDPFSRENSTQNP---AGNPF-SELKEAQM--DKLVGAGDMEAA----- 
Lacticin3147      ----------------MKEKNMKKNDTIELQLGKYLEDDMI--ELAEGDESHGG------ 
Lacticin481       ----------------MKEQNSFN------LL-QEVTESEL--DLILGA----------- 
CytolysinCLL      ----------------MENLSVVP------SF-EELSVEEM--EAIQGS----------- 
CytolysinCLs      MLNKENQ----ENYYSNKLELVGP------SF-EELSLEEM--EAIQGS----------- 
Cinnamycin        ----------------MTAS----------ILQQSVVDADFRAALLENPAAFGASAAALPT 
Cinnamycin (cont.)PVEAQDQASLDFWTKDIAATEAFA       : .      : 
 
FIG 8 Leader peptides of prototypical class II lantibiotics. Strongly- and weakly-conserved residues are indicated by : and 
., respectively. Grey letters indicate site of leader cleavage. 
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changes at this position result in loss of activity (84). This Glu is also conserved in almost all 
mersacidin-like lantibiotics, and is important for activity (Fig. 10) (85). In nukacin ISK-1 the 
Gly at position 5, which is also conserved in lacticin 481-like lantibiotics, is not amendable to 
change, with only the G5W mutant resulting in activity (84).  
Mutants of mutacin II lacking thioether bridges have no or severely diminished activity (86). 
Similar results are also reported for lacticin 481 and nukacin ISK-1 also does not tolerate 
changes within its ring regions (84, 87). Collectively these results indicate that all three rings 
are important for antimicrobial activity. 
Nukacin ISK-1 and lacticin 481 bind to lipid II, and inhibit the transglycosylation step in 
peptidoglycan biosynthesis (83, 88, 89). This mode of action is similar to that reported for 
mersacidin- and planosporicin-like lantibiotics. A C14S ring mutant of nukacin ISK-1 (mutant 
 
 
Lacticin481              -KGGSGVIHTISHECNMNSWQFVFTCCS 
MutacinII                NRWWQGVVPTVSYECRMNSWQHVFTCC- 
MutacinK8                --MGKGAVGTISHECRYNSWAFLATCCS 
NukacinISK-1             -KKKSGVIPTVSHDCHMNSFQFVFTCCS 
NukacinKQU-131           -KKKSGVIPTVSHDCHMNSFQFMFTCCS 
StreptococcinA-FF22      --GKNGVFKTISHECHLNTWAFLATCCS 
StreptococcinA-M49       --GKNGVFKTISHECHLNTWAFLATCCS 
Macedocin                --GKNGVFKTISHECHLNTWAFLATCCS 
MacedocinA1              ---GHGV-NTISAECRWNSLQAIFSCC- 
ButyrivibriocinOB247     ---GDGVFRTISHECAMNTWMFIFTCCS 
ButyrivibriocinOR36      ---GDGVFRTISHECHMNTWMFIFTCCS 
ButyrivibriocinOR79      ---GNGVIKTISHECHMNTWQFIFTCCS 
Salivaricin9             ---GNGVVLTLTHECNLATWTKKLKCC- 
Salivaricin_A            -KRGSGWIATITDDCPNS----VFVCC- 
SalivaricinA1            -KKGSGWFATITDDCPNS----VFVCC- 
SalivaricinA2            -KRGTGWFATITDDCPNS----VFVCC- 
SalivaricinA3            -KKGPGWIATITDDCPNS----IFVCC- 
SalivaricinA4            -KRGPGWIATITDDCPNS----IFVCC- 
SalivaricinA5            -KRGPGWIATITDDCPNS----VFVCC- 
SalivaricinB             ---GGGVIQTISHECRMNSWQFLFTCCS 
SalivaricinG32           ---GNGVFKTISHECHLNTWAFLATCCS 
Variacin                 ---GSGVIPTISHECHMNSFQFVFTCCS 
Ruminococcin_A           ---GNGVLKTISHECNMNTWQFLFTCC- 
 
FIG 9 Lacticin 481-like lantibiotics. Cys residues are shown in red. Bold letters in purple and green indicate Thr 
and Ser that are dehydrated, respectively. Bold black letters indicate Thr/Ser that escape dehydration. Lines 
above letters indicate ring the topology of lacticin 481.  Where Thr/Ser are not bold or coloured the dehydration 
of Thr/Ser and structure of peptides are unknown. Grey highlighted Gly is conserved throughout group. Figure 
adapted from Rea et al. (49) and Dischinger et al. (50). 
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lacking ring A) has no interaction with lipid II, and a D13A mutant (same position as the 
conserved Glu in mersacidin) has less accumulation of UDP-MurNAc pentapeptide, indicating 
a role of ring A in lipid II binding (88). It would be interesting to see how lacticin 481 Glu13 
mutants interact with lipid II, and if there would be less accumulation of cell wall precursors. 
The absence of activity of mutacin II and lacticin 481 ring A mutants can, therefore, also be 
due to a lack of interaction with lipid II (86, 87). The conserved sequence of ring A (T-I/V-S/T-
x-E/D-C; x is undefined amino acids, superscript is minority residue changes) resembles the 
mersacidin-lipid II-binding motif (C-T-L/x-T/S-x-E-C), and is also important for lipid II binding 
and activity (88, 90). 
Mersacidin-like lantibiotics 
The mersacidin-like lantibiotics all have similar ring topology, and the putative mersacidin 
lipid II-binding motif is conserved throughout the group (Fig. 10). Mersacidin is, however, the 
only one in the group with a C-terminal AviMeCys (90, 91). Lipid II binding and subsequent 
blocking of peptidoglycan synthesis occurs for several mersacidin-like lantibiotics, including 
mersacidin, actagardine, lacticin 3147- and haloduracin-alpha (65, 90–94). Mersacidin is able 
to discriminate between lipid I and II, which suggests that the GlcNAc (N-acetyl-D-
glucosamine) of lipid II plays a role in recognition (90, 91). Similar to some class I lantibiotics, 
the pyrophosphate group is also implicated in lipid II binding (90).  
The structure-activity relationship of mersacidin has been extensively studied and shows that 
the peptide is not very amendable to change (85, 95). As expected, the highly conserved lipid 
II-binding motif (position 12-18) is not flexible with regards to amino acid substitutions, and 
only conservative amino acid changes are tolerated (85, 95). Actagardine A has a similar 
reluctance for substitution, with the B ring (lipid II-binding motif) being the least amendable 
and only conservative changes result in activity (96). The E11D mutant (Glu17 in mersacidin) 
is produced only at trace levels and is biologically inactive (96). The Gly at position 9 (relative 
to mersacidin) is also conserved throughout the group (and in lacticin 481-like lantibiotics), 
and several substitutions at this position are not well tolerated in mersacidin, actagardine and 
lacticin 3147-α (Fig. 10) (95–97). Mersacidin, actagardine and lacticin 3147-α have additional 
modifications. Mersacidin has an N-terminal AviMeCys and the accompanying LanD to 
catalyse the modification (90, 91, 98). Actagardine has an N-terminal sulfoxide group with 
formation catalysed by LanO (GarO) (99). Lacticin 3147α contains D-alanine residues which 
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arise from the hydrogenation of Dha (i.e. L-serine to D-alanine) by a dedicated modification 
enzyme LanJ (LtnJ) (100, 101). 
The alpha peptides of two-component lantibiotics also fall into this group. Two-component 
lantibiotics consist of two separate peptides (alpha and beta) that are inactive on their own and 
need to be combined for activity. As with mersacidin and actagardine, amino acid substitutions 
of the conserved Glu are not well tolerated. Ring A of the alpha peptides are more tolerant 
towards amino acid changes, compared to actagardine and mersacidin, and is not essential for 
activity (77, 95, 96, 102, 103). It has, therefore, been suggested that the A ring plays a possible 
role in protection from proteolytic cleavage, rather than activity (102). The conserved Gly at 
position 13 of lacticin 3147-α (conserved in alpha peptides) does not handle substitution well 
with mutants displaying reduced activity (97). Substitution of the conserved Glu (E22Q; Glu17 
in mersacidin) in the B ring of haloduracin-α containing the conserved lipid II-binding motif 
does not result in complete loss in activity (102). Follow up studies reported that the destruction 
of the B ring (corresponds to mersacidin C ring) only reduces the ability of haloduracin-α to 
inhibit lipid II polymerization (5-fold reduction), while an E22Q (corresponds to Glu17 in 
mersacidin) substitution abolished inhibition (up to 100 μM) (92, 104). These results are 
interesting, as haloduracin-α E22Q added to the beta peptide, still retained low levels of activity 
(92, 104). Disruption of the C ring (equivalent to haloduracin-α B-ring) in lichenicidin-α also 
does not abolish activity, but does result in a significant reduction (77). An E26A (corresponds 
to Glu17 in mersacidin) substitution abolishes activity (77). These results are in contrast to 
those reported for lacticin 3147-α, where destruction of the C ring (containing lipid II-binding 
motif) results in loss of activity (103). It should be mentioned that both lichenicidin and 
haloduracin were heterologously produced in Escherichia coli. In the case of lichenicidin, total 
extract (cell and supernatant) was used for activity assays, and for haloduracin, His-tagged 
purified peptide was obtained from cell extracts and processed in vitro with LanM. Lacticin 
3147 assays used cell-free supernatant (i.e. secreted peptide). Therefore, the lack of activity 
observed for the ring mutants may be due to peptide that is not exported, but accumulates in 
the cell. Small quantities of peptide with the correct mass were detected by colony mass 
spectrometry of lacticin 3147-α C19A and C25A mutants (103). This may also be the case in 
some experiments performed with other lantibiotics, where low excreted yields may obscure 
possible activity of un-secreted/low-secreted variants. 
Haloduracin-α with its leader attached, retains activity when combined with haloduracin-β, 
albeit significantly less than the wild type (92). The alpha peptide with the leader attached 
Stellenbosch University  https://scholar.sun.ac.za
  
26 
 
shows potent lipid II-binding (in vitro) activity. The leader peptide and the bacterial cell are 
both negatively charged, which could interfere with the lipid II interaction, and would explain 
the reduced antimicrobial activity. These results suggest that the N-terminal length does not 
influence lipid II binding. It would be interesting to evaluate if the same result is observed with 
other mersacidin- and lacticin 481-like lantibiotics. 
LtnA2-like lantibiotics 
This group only consists of the beta peptides of the two-component lantibiotics, which have 
little N-terminal homology, but a conserved C-terminal motif (C-P-T-T-K/A-C-T/S-x-x-C) (Fig. 
11). Geobacillin II, which is not part of a two-component lantibiotic system, can also be 
included in this group (34). The ring topologies of peptides in this group are highly similar, 
with identical C-terminal rings (50, 77, 105, 106). As with lacticin 3147-α, lacticin 3147β has 
 
 
Mersacidin                ---CTFTLPGGGGV-CTLTSEC--------IC--- 
Actagardine               ---------SSGWV-CTLTIEC--GTV---ICAC- 
PlantaricinC              ---KKTKKNSSGDI-CTLTSEC--DHLATWVC-C- 
RuminococcinB             ----GEPRVSDGSQFCTSTKEC-NWGTIMFVC-C- 
Michiganin                --------SSSGWL-CTLTIEC--GTI---ICACR 
Nai-802                   --------ASSGWV-CTLTIEC--GTV---ICACR 
Amylolysin                AEQRGISQGNDGKL-CTLTWEC--GLCPTHTCWC- 
 
 
Halloduracinα      GDVHAQ ------C--AWYNISCRLGNKGAYCTLTVECMPSCN- 
Amyloliquecidinα   ADVTPH ------C--AWYDISCKLGNKGAWCTLTVECQSSCN- 
Lichenicidinα      NDVNPE TITLSTC----AILSKPLGNNGYLCTVTKECMPSCN- 
PlantaricinWAα     GDPEAR ----K-CK--WWNISCDLGNNGHVCTLSHECQVSCN- 
EnterocinWα               -----KCPWWNLS--CHLGNDGKICTYSHECTAGCNA 
Lacticin3147Aα            ------CSTNTFSLSDYWGNNGAWCTLTHECMAWCK- 
SacAα                     ------CSTNTFSLSDYWGNKGNWCTATHECMSWCK- 
BhtA1                     ----IGTTVVNSTFSIVLGNKGYICTVTVECMRNCQ- 
SmbB                      ----IGTTVVNSTFSIVLGNKGYICTVTVECMRNCSK 
 
                 
 
FIG 10 Mersacidin-like lantibiotics. Cys residues are shown in red. Bold letters in purple and green designate Thr and Ser that are 
dehydrated, respectively. Bold black letters indicate Thr/Ser that escape dehydration. Lines above letters indicates the ring topology 
of mersacidin (blue line indicates AviMeCys) and haloduracin-α, respectively. Dashed line indicates a disulphide bridge with 
underlined Cys residues taking part in disulphide bridge formation. Grey highlighted residues are conserved throughout group. 
Yellow highlighted Ser are converted to D-Ala. Green highlighted letters indicate lanthionine sulfoxide bridge. Grey highlighted Thr 
is converted to 2-oxobutyryl. Red arrow indicates site of second proteolytic cleavage. Figure adapted from Rea et al. (49) and 
Dischinger et al. (50). 
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an additional modification, namely the reduction of Dha to D-Ala by the dedicated reductase 
LanJ (100, 101). The beta peptides of lichenicidin and lacticin 3147 are not amendable to 
disruption of any of their C-terminal Lan/MeLan rings, as disruption either results in low- or 
no-production variants (77, 103). Disruption of the C and D rings of haloduracin-β also results 
in significant loss of activity (102). However, no conclusions can be made for the disruption of 
ring B of haloduracin, as its disruption affects the formation of multiple other rings (102). Once 
again, the haloduracin-β variants were produced in E.coli and were processed in vitro by LanM, 
whereas lichenicidin and lacticin 3147 were produced and processed in their heterologous 
hosts, E. coli and L. lactis, respectively. The use of in vitro processing overcomes any 
limitations that may be faced by complex in vivo systems, such as no- or low production. 
Despite these differences, it is evident that the C-terminal Lan/MeLan rings of the beta peptides 
are required for proper synergistic activity with their corresponding alpha peptides. Similar to 
the alpha peptides, beta peptides have either a ring structure or a cap (e.g. oxobutyryl) at/near 
their N-terminal (77, 102, 103). The N-terminal cap may serve more of a protective role, as 
they are not essential for activity (77, 102, 103). The way in which the beta peptide recognizes 
the alpha peptide is unknown. However, experimental data shows that the alpha peptide must 
first bind to lipid II, followed by recruitment of the beta peptide which binds to the alpha 
peptide-lipid II complex, which results in pore formation (104, 107). The conserved nature of 
the C-terminal rings of the beta peptide does, however, suggest that the C-terminal may play a 
role in the recognition of the alpha peptide (103). It is also interesting to note that alpha and 
beta peptides seem to be promiscuous and are able to show synergistic activity when combined 
with different partners, as shown for combinations of lacticin 3147 and staphylococcin C55 
peptides (108). 
Some of the beta peptides undergo a secondary cleavage reaction to remove an additional six 
amino acid hexapeptide after the initial cleavage by LanT (77, 105, 109, 110). The protease 
involved in this reaction is not always identifiable in the gene cluster and may not be a 
dedicated protease. However, a serine protease, LicP, is involved in the cleavage of the 
hexapeptide from lichenicidin-β (77). LicP shows similarity to CylA, which is an extracellular 
protease responsible for N-terminal trimming of cytolysin peptides (77). Similarly, a putative 
extracellular protease was identified to be responsible for the cleavage of the hexapeptide from 
haloduracin-β (102). Geobacillin II could not be produced in vivo, it is thus not known whether 
a secondary cleavage reaction takes place (34). However, removal of at least two amino acids 
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after the GG-motif is required for activity and it has been proposed that the entire heptapeptide 
(YTEVSPQ) is removed after initial cleavage (34). 
Cytolysin-like lantibiotics 
This group consists of the two-component lantibiotics cytolysin and the newly isolated 
carnolysin (A1 and A2) and cerecidin (Fig. 12). Unlike the other two-component lantibiotics, 
the two peptides have substantial N-terminal homology to each other (111, 112). Recently, 
cerecidins (A1 and A7) were discovered in the genome of B. cereus As 1.1846, with homology 
to cytolysin Ls, carnolysin A2 and some LtnA2-like lantibiotics (113). Upon closer 
examination of the amino acid sequences the most similarity, with regard to cytolysin, is within 
the six amino acids cleaved off during the second cleavage (Fig. 12). Similar observations can 
be made for carnolysin and cerecidins. Cerecidins are not two-component lantibiotics and the 
two characterized peptides only differ by two amino acids, and have potent individual activity 
(113). The ring topologies of carnolysin and cytolysin are similar, both with only two 
Lan/MeLan rings (114–116). Cerecidins have a similar ring topology to cytolysin Ls and 
canrnolysin A2, with only two Lan rings and the DhxDhxXxxXxxCys (where Dhx = Dha/Dhb) 
motif at ring A (113). Cytolysin, carnolysin and most likely cerecidins contain the unusual 
stereoisomers LL-Lan and LL-MeLan in certain positions and the more common DL-Lan 
stereoisomer in others (114, 116). Furthermore, the LL- and DL-stereoisomers are in the same 
 
Lacticin3147β      TTPATPAISIL---SA------Y-ISTNT--CPTTKCTRAC----- 
Amyloliquecidinβ   ---TTPSSVPC---GV------F-VTAAF--CPSTKCTSSC----- 
Haloduracinβ       ------TTWPC---AT------VGVSVAL--CPTTKCTSQC----- 
Lichenicidinβ      TTPATTSSWTCITAGV------T-VSASL--CPTTKCTSRC----- 
PlantaricinWβ      ------SGIPC-TIGA------A-VAASIAVCPTTKCSKRCGKRKK 
EnterocinWβ        VT----TSIPC---TV------M-VSAAV--CPTLVCSNKC-GGRG 
StaphylococcinC55  ---GTPLALLG---GAATGVIGY-ISNQT--CPTTACTRAC----- 
BhtA2β             ------STPAC-AIGV-VG-----ITVAVT-GISTACTSRC--INK 
SmbAβ              ------STPAC-AIGV-VG-----ITVAVT-GISTACTSRC--INK 
Geobacillin_II     STIVCVSLRICNW------------S--LRFCPSFKVK--C---PM 
 
 
FIG 11 LtnA2-like lantibiotics. Cys residues are shown in red. Bold letters in purple and green indicate Thr and Ser that are dehydrated, 
respectively. Bold black letters indicate Thr/Ser that escape dehydration. Lines above letters indicate the ring topology of lacticin 3147β. 
Grey highlighted Thr are converted to 2- oxobutyryl. Yellow highlighted Ser are converted to D-Ala. Figure adapted from Rea et al. (49) 
and Dischinger et al. (50). 
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positions in carnolysin and cytolysin (114, 116). The LL-Lan/MeLan configuration is formed 
from the DhxDhxXxxXxxCys motif. This motif is also found in other lantibiotics, including 
haloduracin and lichenicidin, and is proposed to be responsible for the unusual LL-configuration 
(116). Using chiral GC/MS, it is observed that haloduracin-β has a 1:2 ratio of LL:DL-MeLan 
(116). This means that the LL-configuration is not so unusual. The formation of only two non-
overlapping rings in cytolysin Ls, carnolysin A2 and cerecidins make this group unique in 
lantibiotics (113, 114, 116). Carnolysin is even more unusual in that it contains D-Ala and D-
Abu, making it the first ribosomally synthesized peptide to contain D-Abu, and the first 
lantibiotic to contain LL-Lan/MeLan in combination with D-amino acids (114). The reductase, 
CrnJ, is responsible for the reduction of Dha and Dhb to D-Ala and D-Abu, respectively (114). 
Therefore making it more flexible than LtnJ (114). Cytolysin, in addition to antibacterial 
activity, also has lytic activity against erythrocytes and other eukaryotic cells, making it a 
virulence factor (116–118). The same lytic activity is not observed with mature carnolysin, and 
may be due to differences in amino acid sequence or to the additional PTMs found in carnolysin 
(114). Unlike the other two-component lantibiotics, both of the cytolysin peptides undergo a 
secondary proteolysis reaction to remove the hexapeptide (sequence for both Ls and LL are the 
same), this cleavage reaction (performed by CylA) is essential for activity (116). The same 
secondary cleavage is required for carnolysin to be active, with eight amino acids removed 
from carnolysin A1 (114). Carnolysin is not secreted in an active form and needs to be cleaved 
in vitro with GluC (both peptides) (114). There is a gene for a protease homologous to CylA 
(i.e. CrnP) in the carnolysin gene cluster. However, it is not known if the protease is active or 
if it is expressed under experimental conditions (114).  
The mode of action of these peptides is unknown and whether there is a docking molecule, 
such as lipid II, still needs to be established. In the absence of target cells (phosphatidylcholine: 
cholesterol lipid bilayers), CylLS and CylLL forms a complex, inhibiting CylLS from 
autoinducing the cytolysin operon (119). When CylLL binds to target cells (with a 6.5 fold 
higher affinity than CylLS) CylLS is released and able to autoinduce the operon (119). 
Cerecidins do not need an additional component for antimicrobial activity, and present the 
simplest architecture required for potent lantibiotic activity. Alanine scanning of cerecidin A7 
also revealed that the peptide does not tolerate Ala substitutions, with the exception of T13A, 
which resulted in increased activity (113). It would be interesting to see if cerecidins have the 
same haemolytic activity as cytolysin. These peptides may have evolved from the same 
ancestor and that cerecidins may have once been part of a two-component system. Another 
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possible introduction to this group, although not fully characterized, is a putative lantibiotic 
produced by Bifidobacterium longum DJO10A. This peptide is reported to have a broad 
antimicrobial spectrum, with activity against Gram-negative- and -positive bacteria (120, 121). 
Judging from the amino acid sequence, the N-terminal does not have any thioether rings. 
However, the C-terminal may have possible similarities in ring topology to carnolysin A1 and 
cytolysin LL. This is only speculation and further characterization of this peptide needs to be 
done to confirm structural and activity properties (120, 121). 
Lactocin S 
Lactocin S does not have significant homology to any of the other lantibiotics in class II, and 
belongs to its own subgroup (Fig. 13). It is the least modified lantibiotic and belongs to the few 
lantibiotics that contain D-amino acids (122, 123). Unlike lacticin 3147 and carnolysin, a LanJ 
has not yet been identified for the formation of D-alanine in lactocin S. The protein designated 
LasN (gi:1150481) has sequence similarity to CrnJ, suggesting its involvement in D-alanine 
formation (124, 125). Lactocin S has been synthesized using solid state synthesis and in doing 
so the stereochemistry of the ring structures was confirmed (126). The exact mode of action 
has not been elucidated, but it is known that activity is pH dependent (127).When Pediococcus 
acidilactici was grown in the presence of lactocin S at an initial pH of 6.8, growth commenced 
normally and declined steadily as the pH started to drop below 6. At pH values below 5.8 the 
turbidity of the culture started to decrease, suggesting cell lysis (127). When the initial pH was 
less than 5.5 no growth was detected (127). All experiments were corroborated with cell counts. 
 
 
CytolysinClyLl      GDVQAE--TTPVC--AVAATAAASSAACGWVGGGIFTGVTVVVSLKHC- 
CarnolysinA1        GDINGEFTTSPACVYSVMVVSKASSAKCA-AGASAVSGA--ILSAIRC- 
DJO10A              TDRNDD-GVAPASLSFAVSVLSVSFSACS------VTVVTRLASCGNCK1 
 
 
CytolysinClyLs      GDVQAE--TTPAC-----------------FTIGLGVGA--LFSAKFC- 
CarnolysinA2        GDVMPE--STPIC---------AGFATLM-SSIGLVKTI-----KGKC- 
CereicidinA1        SDVQPE--TTPLC-------------------VGVIIGL--TTSIKICK 
CerecidinA7         SDVQPE--TTPLC-------------------VGVIIGI--TASIKICK 
 
FIG 12 Cytolysin-like lantibiotics. Cys residues are shown in red. Bold letters in purple and green indicate Thr and Ser that are dehydrated, 
respectively. The bold black Thr escapes dehydration. Lines above letters indicate the ring topology of cytolysinCL and cytolysinCS, respectively. 
Yellow highlighted Ser and Thr are converted to D-Ala and D-Abu, respectively. 1Predicted structure, cleavage site and PTMs unknown. (113, 114). 
Figure adapted from Rea et al. (49) and Dischinger et al. (50) 
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These experiments suggest that at higher pH lactocin S is bacteriostatic and at lower pH, 
increasing the positive charge of the peptide and thus, the interaction with the bacterial 
membrane, results in bactericidal activity. The length of the peptide also suggests that it is 
possible for the peptide to form pores to result in membrane destabilization (54, 128). 
Cinnamycin-like lantibiotics 
The cinnamycin-like lantibiotics, that include cinnamycin, ancovenin, duramycin, duramycin 
B and C, are short globular lantibiotics with very high homology (Fig. 14). Cinnamycin rings 
are formed bi-directionally, such that the Cys involved in MeLan formation is located on the 
N-terminal side and the Cys involved in Lan formation is located at the C-terminal end (as with 
other lantibiotics) (129). This is also observed for the other lantibiotics in this group (129). 
Cinnamycin and duramycin peptides contain additional PTMs, namely a hydroxylated Asp 
(Asp15) and a lysinoalanine link between the C-terminal Lys and Dha (Dha6) (27). The 
biosynthetic enzymes involved in these modifications have been identified; LanX 
(hydroxylase) for the hydroxylation of Asp15, and the small protein, Cinorf7, is important for 
the formation of lysinoalanine in cinnamycin (129). The structures for all the cinnamycin-like 
peptides are known, revealing identical ring topology, with the exception of ancovenin, in that 
it lacks a lysinoalanine cross-link (27, 130, 131).  
Cinnamycin-like lantibiotics are not known for their antimicrobial activity, and are only active 
against a few bacterial strains. They interfere with membrane permeability, calcium uptake and 
protein transport (26, 132–136). Cinnamycin and duramycin bind ethanolamine phospholipids 
and phosphatidylethanolamine (PE), preferring smaller vesicles with a high membrane 
curvature (137–139). Bacterial cells with little or no PE prove to be resistant to these peptides 
(137). The lysinoalanine cross-link is important for activity, heterologously expressed 
cinnamycin, lacking lysinoalanine has no activity (129). Nuclear magnetic resonance of 
 
 
LactocinS     STPVLASVAVSMELLPTASVLYSDVAGCFKYSAKHHC 
 
FIG 13 Lactocin-like lantibiotics. Amino acid sequence of lactocin S. Cys residues are shown in red. Bold letters 
in purple and green indicate Thr and Ser that are dehydrated, respectively. The bold black Thr escapes 
dehydration. Yellow highlighted Ser are converted to D-Ala. Lines above letters indicates ring topology. Figure 
adapted from Rea et al. (49) and Dischinger et al. (50). 
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cinnamycin:LysoPE complexes also suggest interaction of lysinoalanine with the phosphate 
group of LysoPE (140). Phosphatidylethanolamine is a substrate for phospholipase A2, which 
is involved in inflammatory responses (e.g. vascular inflammation). Therefore, the 
sequestering of PE by cinnamycin and duramycin may result in immune modulation through 
the indirect inactivation of phospholipase A2 (139, 141, 142). Little is known of the 
antimicrobial activity of ancovenin and more focus has been placed on its role in the 
modulation of angiotensin I converting enzyme (ACE) (25, 130). 
Sublancin-like lantibiotics 
Sublancin 168, produced by B. subtilis168, was grouped as a lantibiotic due to the assumed 
presence of Dha and one MeLan bridge (143). However, it was recently shown that sublancin 
168 is not a lantibiotic, but rather an unusual S-linked glycopeptide (144). This is supported by 
the absence of the lantibiotic biosynthetic modification machinery in the B. subtilis168 
genome. There is some similarity between the leader peptide of sublancin and that found in 
other class II lantibiotics (same putative LanM/T recognition motifs), which may be required 
for recognition by the ABC-transporter SunT, which has some homology to PepT (143). The 
leader peptide was not required for the S-glycosyl transferase activity, which catalyses the 
attachment of glucose to Cys22 (required for bioactivity) (144). Based on these results 
sublancin-like lantibiotics should be removed from the updated classification system (49). 
 
 
 
Cinnamycin      CRQSCSFGPFTFVCDGNTK 
Duramycin       CKQSCSFGPFTFVCDGNTK 
DuramycinB      CRQSCSFGPLTFVCDGNTK 
DuramycinC      CANSCSYGPLTWSCDGNTK 
Ancovenin       CVQSCSFGPLTWSCDGNTK 
 
FIG 14 Cinnamycin-like lantibiotics. Cys residues are shown in red. Bold letters 
in purple and green indicate Thr and Ser that are dehydrated, respectively. Bold 
black Asp and Ser undergoes hydroxylation and escape dehydration, respectively. 
Lines above letters indicate the ring topology of cinnamycin. Dashed gold line and 
letters indicates lysinoalanine bridge and residues involved, respectively. Figure 
adapted from Rea et al. (49) and Dischinger et al. (50). 
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Bovicin HJ50-like lantibiotics 
In previous classification schemes bovicin HJ50 was grouped as a lacticin 481-like lantibiotic 
(49). However, it has recently been suggested that bovicin HJ50, along with several other 
similar lantibiotics, be placed in their own subgroup (145, 146). The basis for this, in addition 
to sequence homology and identical ring topology, is a disulphide bridge found in all these 
lantibiotics and is essential for their activity (Fig. 15) (145). The disulphide bridge forms the C 
ring of bovicin-like lantibiotics, whereas the corresponding ring in lacticin 481-like lantibiotics 
is formed by a thioether bridge. Characterized peptides in this new group include bovicin HJ50, 
suicin, perecin, cerecin and thuricin (145).  
Residues important for activity in bovicin HJ50 correspond to conserved amino acids in lacticin 
481-like lantibiotics, which is not surprising due to their high sequence similarities (145, 147). 
The N-terminal of bovicin HJ50 first interacts with the membrane, most likely through the lipid 
II-binding motif (T-L-T-K-D-C), followed by insertion of the C-terminal (147). In contrast to 
lacticin 481-like lantibiotics and similar to nisin-like lantibiotics, bovicin HJ50 can form pores 
and does not result in the accumulation of UDP-MurNAc pentapeptide (147). The pore-forming 
capability is proposed to be due to the presence of β-sheets and turns in the B- and C-ring 
regions when in the presence of a hydrophobic membrane environment (147). The disulphide 
bridge of the C ring does not contribute to the secondary structure of bovicin HJ50, but does 
contribute to the hydrophobicity of the peptide (145). Substitution of the C ring of bovicin 
HJ50 with that of other bovicin HJ50-like lantibiotics does not influence activity, taking into 
account that residues not involved in ring formation are not very conserved (145). Therefore, 
it is proposed that similar to the retention of the conserved lipid II-binding motif, the disulphide 
bond of ring C evolved in this subgroup for the retention of biological activity (145). 
 
 
BovicinHJ50     ADRGWIKTLTKDCPNVISSICAG-T-IITA--CKNCA 
Suicin          AGSGFVKTLTKDCPGFLSNVCVN-IGFISG--CKNC- 
Perecin         AGAGFIKTLTKDCPEVVSQVCGSFFGWVSA--CKNC- 
Cericin         AGPGWVETLTKDCPWNMPVACVT---ILGQRICKKCY 
Thuricin        AGPGWVETLTKDCPWNVPVACVT---IMGQRICKKCY 
 
FIG 15 Bovicin HJ50-like lantibiotics. Cys residues are shown in red. Bold letters in purple designate Thr that are 
dehydrated. Bold black letters indicates Ser/Thr that escape dehydration. Lines above letters indicate the ring topology of 
bovicin-HJ50. Dashed line indicates a disulphide bridge (145). 
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Class III and IV 
Class III and IV are not strictly lantibiotics as they generally do not have antimicrobial activity, 
but rather have other bioactivities. Therefore the modification enzymes and selected peptides 
will be briefly discussed. 
Class III and IV peptides are modified by bi-functional enzymes LanKC and LanL, 
respectively, and are responsible for the formation of lanthionines and labionines (LanKC) (1, 
148). These enzymes have lyase-, kinase- and cyclase-domains, which are responsible for the 
respective PTMs (1, 149, 150). The generation of dehydroamino acids occurs via independent 
phosphorylation and elimination steps catalysed by the central kinase- and N-terminal lyase-
domains, respectively (7, 149, 151–153). In LanKC, the cyclase domain is responsible for the 
respective cyclase reactions (formation of lanthionine and labionine), and in LanL the C-
terminal cyclase domain is responsible for cyclization resulting in Lan/MeLan rings (149, 153). 
Labionin results from a double Michael addition. Briefly, as with normal Lan-formation a Cys 
thiol is added to Dha and instead of protonation the subsequent enolate adds to a second Dha 
resulting in the labionin motif (7, 148). In contrast to class I and II modification enzymes, the 
direction of dehydration of LabKC (LanKC of labyrinthopeptins) proceeds in a C- to N-
terminal direction (150). Cyclization by AciKC and CurKC (LanKC of catenulipeptin and 
curvopeptin, respectively) also occurs in this direction (153, 154). CurKC has been extensively 
studied with regard to the directionality of all reactions (i.e. phosphorylation, elimination and 
cyclization) (154). The proposed biosynthetic route for curvopeptin is very interesting and 
complex. Ser1 is phosphorylated first followed by consecutive phosphorylation and 
elimination of Ser15 and Ser14 (resulting in Dha). The pSer1 undergoes elimination first 
(resulting in Dha), followed by C-terminal Lan formation. This is followed by the 
phosphorylation and elimination of Ser4 and Ser2, with the formation of the N-terminal Lan 
(i.e. Dha1) occurring last (154). Although biosynthesis occurs preferably in a C- to N-terminal 
direction alternative routes are also observed for CurKC, suggesting some flexibility in the 
processing order.  
Labyrinthopeptin-like lanthipeptides 
Labyrinthopeptins A1/A3 and A2 were the first lanthipeptides discovered that are modified by 
LanKC to form labionin (8). The three peptides have high sequence homology, with the only 
difference between A1 and A3 being an additional N-terminal Asp (Fig. 16). Longer 
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fermentation times of the producing strain revealed that the Asp is lost and A3 is converted to 
A1 (8). Although labyrinthopeptins do not have significant antimicrobial activity, A2 and A1 
have activity against neuropathic pain and antiviral activity, respectively (8, 155). 
Catenulipeptin has a similar ring topology to labyrinthopeptin, and also has no antimicrobial 
activity (153). The leader peptide is essential for proper modification, and in the case of 
labyrinthopeptin the conserved ILELQ is important for recognition and dehydration 
(cyclization was not evaluated) (156). The leader peptide in catenulipeptin is important for both 
dehydration and cyclization (153). The leader peptide has a helical structure, which represents 
an important secondary structure for lanthipeptide modification machinery (156).  
Although labyrinthopeptins are unique in that they only have labionin motifs, several 
labyrinthopeptin-like lanthipeptides do not contain this motif exclusively and have both Lan 
and Lab rings (151, 157, 158). Erythreapeptin can contain an N-terminal Lan and a C-terminal 
Lab. A similar mixture of Lan/Lab is also found for other labyrinthopeptin-like lanthipeptides 
(151, 157). However, it is not known whether Lan/Lab is present in one peptide, or if there is 
a mixture of peptides containing either Lan or Lab being produced (157). The ability of some 
LanKC enzymes to produce peptides with Lan and only trace amounts of Lab-containing 
peptides is interesting, with all of them harbouring the SerXXSerXnCys motif (assumed to be 
a precursor for Lan/Lab ring formation) at similar positions. The mechanism by which LanKC 
enzymes are able to select between Lan or Lab formation is unknown. It would be interesting 
to investigate if LabKC (LanKC of labyrinthopeptin) would be able to exclusively form Lab 
rings, in other Lan ring dominant labyrinthopeptin-like lanthipeptides. 
 
 
LabyrinthopeptinA1     --------SNASVWE-CC--STGSWVPFTCC- 
LabyrinthopeptinA2     --------SDWSLWE-CC--STGSL--FACC- 
Erythreapeptin         --------SNLSLLASCAN STVSLLT -CH- 
Avermipeptin           --------STVSLLS-CV--SAASV--LLCL- 
Griseopeptin           --------SQVSLLV-CEY-SSLS-VVL-CTP 
Curvopeptin            --------SSASLLL-CDKFSAFSTLL--CL- 
Catenulipeptin         --------SGLSVTG-CNGHSGISLL---CDL 
SapB                   ------TGSRASLLL-CGD-SSLS-ITT--CN 
SapT                   YTQGGCS-GLCTIVI-CAT-----VVI--CG- 
 
FIG 16 Labyrinthopeptin-like lantibiotics. Cys residues are indicated in red. Purple and green letters indicate 
dehydrated Thr and Ser, respectively. Bold and underlined letters indicate residues that take part in labionin formation 
(Ser/Thr must, therefore, be dehydrated). Letters underlined and not in bold indicate residues that can be involved in 
lanthionine or labionin formation. Bold black letters indicate Thr that escape dehydration. Lines above letters indicate 
the ring topology of labyrinthopeptinA1 (labionin rings) and dashed line indicates a disulphide bridge (151, 153, 157). 
Figure adapted from Dischinger et al. (50). 
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Venezuelin-like lanthipeptides 
Venezuelin is the only characterized peptide in this group and the only characterized peptide 
modified by LanL, making it the only peptide in class IV (149). Similar to class I and II LanC-
like domains, and unlike LanKC, LanL has a zinc binding site. The zinc ion is proposed to 
activate Cys in the precursor peptide for nucleophilic attack (149, 159). Each of the domains 
of VenL is responsible for their respective modifications, namely phosphorylation (central 
kinase domain), elimination (N-terminal lyase domain) and cyclization (C-terminal LanC-like 
cyclase domain) (149, 152). Furthermore, mutations in the lyase domain of VenL showed that 
some of the conserved domains of LanL and LanKC are functionally important, and that similar 
conserved regions found in LanM are not essential for dehydratase activity (152). 
Venezuelin has a globular structure, with four overlapping rings, reminiscent of cinnamycin-
like lantibiotics (Fig. 17) (149). Venezuelin was discovered using a bioinformatic approach 
(149). Production could not be detected by the host, Streptomyces venezuelae, or after cloning 
the gene cluster into a heterologous host. Therefore, it was reconstituted in vitro with E. coli as 
host, and using VenL to incorporate the various modifications (149). The gene cluster does not 
contain an obvious protease or protease cleavage site. An amino acid sequence (PFA) in the 
leader of venezuelin is similar to the AXA motif required for type I signal peptidases, and a 
similar motif is found in cinnamycin (AFA) (149, 160, 161). Several peptides were constructed 
with cleavage sites for commercial proteases in this position, and after modification and 
cleavage these constructs were tested for activity against several strains known to be sensitive 
to lantibiotics (149). As with class III lanthipeptides, no antimicrobial activity was observed 
for venezuelin (149). It should be noted that the cinnamycin-like lantibiotics are also not known 
for their antimicrobial activity. This suggests a possible structure-function relationship shared 
among venezuelin- and cinnamycin-like lanthipeptides (149). 
 
 
Venezuelin     TCECVGLLTLLNTVCIGISCA 
 
FIG 17 Venezuelin-like lantibiotics. Cys residues are shown in red. Bold purple 
and green letters indicates dehydrated Thr and Ser, respectively. Lines above 
letters indicates ring topology (149). 
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Conclusion 
Lantibiotics are a diverse group of post-translationally modified peptides, with differences in 
their biosynthesis, structure and biological activities. The current classification system attempts 
to encompass the diverse and complex nature of lantibiotics, and group them into designated 
classes and subclasses. Lantibiotics are first divided into two major groups based on the 
modification enzymes that install Lan/MeLan residues. However, classification into two 
groups based on modification machinery is not sufficient. By using the amino acid sequences 
of the unmodified core peptides, lantibiotics can be placed in respective subgroups. In most 
cases the lantibiotics in a particular subgroup also share similar structural properties (e.g. 
similar rig topology). This classification system can account for almost all characterized 
lantibiotics. Furthermore, it is also used to group and subgroup other lanthipeptides, namely 
those modified by bi-functional enzymes, LanL and LanKC. The main drawback of this 
classification system is that it does not account for biological activity. Although most 
lantibiotics are active against Gram-positive bacteria, some have alternative biological 
activities (e.g. labyrinthopeptin-like lantibiotics). Investigation into structure-function 
relationships may prove useful in further subdividing lantibiotics (and lanthipeptides in 
general) according to their biological activities. 
The identification of novel lantibiotics, with new and complex structures is aided by advances 
in in silico analysis of genomic data. With this increase in characterization of novel lantibiotics, 
the classification system will inevitably have to evolve to accommodate the increase in 
complexity and diversity. 
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Clinical Applications of Lantibiotics 
Nisin has been used as preservative in dairy products for over 40 years (162). However, due to 
the diversity and complex nature of lantibiotics (and lanthipeptides in general) they have also 
been explored for use in various medical applications. An increase in the number of sequenced 
genomes has also lead to an increase in in silico analyses of genomic data to find possible 
lantibiotic/lanthipeptide precursors (163). With the help of in vitro/in vivo engineering, these 
putative lantibiotics/lanthipeptides can be functionally expressed, further increasing the arsenal 
of candidates for medical application (148). Several medical applications have been proposed 
and some are in clinical trials (50, 109, 164). With the increase in discovery of novel lantibiotics 
this number will surely increase. 
Treatment of Infections 
Due to their antimicrobial properties, lantibiotics have found a place as potential alternatives 
or additions to antibiotics. However, there is already a substantial arsenal of antibiotics 
currently available for the treatment of a wide range of infections (165–170). Nonetheless, 
antibiotics are becoming ever more ineffective against once treatable infections (165–172). A 
pessimistic view may be that we are treating ourselves back into a “pre-antibiotic era”. The 
most recent world health organization (WHO) report on antimicrobial resistance revealed that, 
in most cases, more than 50% of E. coli, Klebsiella pneumonia and S. aureus isolates are 
resistant to specified antimicrobial drugs (170). Another report by the Centers for Disease 
Control and Prevention (CDC) indicated that in the United States more than 2 million people 
contract infections that are caused by microorganisms that are resistant to one or more of the 
prescribed antibiotics (166). In addition to morbidity and mortality experienced by patients, 
antibiotic resistance carries a significant economic burden resulting from increased societal- 
and medical-costs (166, 170, 171, 173). The over prescription, or prescription of ineffective 
antibiotics, is wide spread and contributes to the prevalence of resistance (167). Resistance can 
be seen as endogenous, arising inside the organism by mutation and selection, or exogenous, 
arising by horizontal gene transfer (HGT) (168). In a recent example of endogenous resistance, 
sub lethal concentrations of antibiotics resulted in resistance to multiple drugs (174). Resistance 
correlates with bactericidal antibiotics that induce formation of reactive oxygen species by 
bacteria that in turn causes mutations, in some cases resulting in resistance (174). Mutations 
that confer resistance, and are maintained in the population, can possibly then result in 
exogenous resistance via transfer of mutated genes to non-resistance strains by HGT (174). 
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Carbapenemase-resistance plasmids are transferred via HGT, not just between strains or 
species but across genera (175). This is an example of how wide-spread HGT is, and how the 
overuse of antibiotics may aid in the transfer of various antibiotic resistance elements to 
otherwise low-virulence organisms (175). In addition to resistance caused by direct 
antimicrobial use, the natural “resistome” of the environment also plays a role in the transfer 
of resistance elements to potential pathogens (172, 176). 
Although antibiotic resistance is on the increase, challenges faced by drug discovery programs 
(e.g. target selection and cost of research) have led to an antibiotic discovery void, with very 
few new antibiotic classes introduced over the past 25 years (168, 177). However, the search 
for new antibiotics has not come to a complete stand-still. With new technologies in high 
through-put screening techniques, bioinformatics, structural-, synthetic- and chemical biology, 
novel antibiotics are making it into the drug discovery pipeline (168, 177). The discovery of 
novel antibiotics is limited by several steps, including target selection, which is important if a 
novel antibiotic is to remain effective for a prolonged time period. Vancomycin is a good 
example of an antibiotic that has been used effectively for a prolonged time period (168). This 
is mainly due to its target, the lipid II MurNAc-pentapeptide end terminal motif D-Ala-D-Ala 
(178). Vancomycin resistance would, therefore, require the alteration of an end product, 
produced by multiple steps in the peptidoglycan pathway. In the case of VanA- and VanB-type 
glycopeptide resistance, operons containing several genes have to be imported and expressed, 
resulting in the end terminal D-Ala being replaced with D-lactate, conferring resistance to 
vancomycin (179–181). Even if a potential high-value target is found, such as lipid II, it should 
lack structural/functional homology to human targets so as to reduce toxicity. The antibiotic 
should also have desirable pharmacokinetic/pharmacodynamic properties. These are only some 
problems encountered in the drug discovery pipeline, which is also hampered by the high cost 
of research and development, compared to possible financial gains. 
Lantibiotics are attractive antimicrobials as they are active at low concentrations and mostly 
target lipid II, which is a high-value target. Additionally pore forming lantibiotics have a dual 
mode of action which can possibly reduce development of resistance. Furthermore, the 
availability of sequenced genomes, and use of bioinformatics make it possible to identify not 
only new lantibiotics, but also new classes of lanthipeptides, which may have novel and more 
effective modes of action (163). Development of more efficient in vitro/in vivo strategies for 
expressing these peptides also make large scale production a realistic possibility (148). 
Stellenbosch University  https://scholar.sun.ac.za
  
40 
 
Lantibiotics are, however, limited by their narrow spectrum of activity and are limited to Gram-
positive bacteria, and under some circumstances activity against Gram-negatives is reported.  
Lantibiotic activity against Staphylococcus aureus and other staphylococci 
Skin and soft tissue infections (SSTIs) are wide spread and are some of the most common 
infections. This is not surprising, as the skin is the largest organ in the body and comes in 
constant contact with the outside environment (182, 183). Skin and soft tissue infections caused 
by bacteria, can be defined as invasion of the dermis, epidermis and subcutaneous tissue by 
bacteria, which subsequently results in inflammation (183). The skin has its own unique 
microbiota, which maintains a symbiosis with the body, and usually does not cause infections 
or adverse inflammatory responses (184). However, host-microbe dysbiosis can occur and 
result in a disease state. Dysbiosis is mainly as a result of exogenous factors, such as infection 
and injury, but can also be caused by polymorphisms in host innate/adaptive immune system 
(184). 
Staphylococci are one of the main genera represented on the skin, either as commensals or 
pathogens, with S. aureus most commonly presenting as a pathogen (182, 184–186). The vast 
majority of SSTIs are caused by S. aureus and it is usually associated with boils, abscesses, 
carbuncles and localised wound sepsis (182, 183, 185). Pathogenic staphylococci have various 
virulence factors that make them very dangerous, including phenol soluble modulins (PSMs), 
produced by several pathogenic and commensal staphylococci. Phenol soluble modulins are 
small cationic antimicrobial peptides (cAMPs) that have direct antimicrobial- and 
proinflammatory-activities (187, 188). They can either play a role in immune defence or 
pathogenesis (22, 189, 190). Phenol soluble modulins produced by pathogenic S. aureus 
(PSMα peptides) lure neutrophils via chemotaxis and then induce lysis of the infiltrate 
neutrophils by a high dose of PSMs (22, 189, 190). Phenol soluble modulins and several other 
virulence factors, and the prevalence of S. aureus, make it a pathogen that can escalate from a 
minor to a major infection in a short time period (191, 192). 
It’s not surprising that S. aureus has developed resistance to antibiotics, with the most common 
being MRSA (170, 185). Methicillin resistance is due to a penicillin binding protein, known as 
PBP2a, which has low-affinity to β-lactams and is produced by the mecA gene (193). The mecA 
gene is found on a mobile genetic element known as the staphylococcal chromosomal cassette 
mec (SCCmec; i.e. resistance island), and encodes resistance to several other antibiotics in 
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addition to methicillin (193, 194). Cassette chromosome recombinases (ccr) are unique site 
specific recombinases that are found in SCCmec elements, and are used as one of the criteria 
to group SCCmec elements into types, along with the class of the mec gene complex (193). 
Currently there are eleven SCCmec types that are a combination of eight ccr gene- and six mec 
gene-complexes (194). J-regions are gene complexes which contain non-essential components, 
such as additional antibiotic resistant determinants, and are used to further group SCCmec into 
subtypes based on polymorphisms/variations in this region (193). There are SCCmec elements 
that do not contain the mecA gene but do contain other genes associated with SCCmec (193). 
Additionally, pseudo-SCC elements that do not have ccr genes have also been identified (193). 
A cytolytic PSM peptide, PSM-mec, has been linked to SCCmec elements. Transcription and 
translation of psm-mec may regulate the virulence properties of MRSA (195).  
According to the WHO report, MRSA proportions exceed 12% of S. aureus infections, and 
some regions report that between 60-70% of S. aureus strains are methicillin-resistant and that 
more than 90% are resistant to penicillin (170). The CDC reports on more than 80,000 severe 
MRSA infections per year in the United States, with more than 11,000 deaths, and is 
characterized as a serious threat (166). Infections caused by MRSA can be characterized as 
either being hospital acquired MRSA infections (nosocomial infection; HA-MRSA) or 
community acquired MRSA infections (CA-MRSA) (166, 196). There are genetic differences 
between HA- and CA-MRSA, in that they contain different SCCmec types (usually I-III and 
IV-VII, respectively). Infections caused by CA-MRSA are usually easier to treat due to less 
antibiotic resistance, however, they are more virulent due to increased toxin production (189, 
195–197). The more virulent CA-MRSA are more frequently being isolated from hospitals 
(197).  
A region in the SCCmec of HA-MRSA (SCCmec type II-III) strains called the F-region is 
linked to decreased virulence and colony spreading, and is not found in CA-MRSA (SCCmec 
type IV) (198, 199). This decrease in virulence is as a result of the transcription and translation 
products of psm-mec, which have a negative influence on the production of PSMα (causes 
neutrophil lysis) (198, 200). Contradictory results were obtained in another study that showed 
that PSM-mec has a positive effect on virulence (195). However, this discrepancy may be due 
to concentration differences of PSM-mec and PSMα produced by the different strains used, as 
well as differences in their genetic background (195, 200). 
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In addition to MRSA strains, strains with resistance to other antibiotics not associated with 
SCCmec have also been identified. This includes vancomycin-resistant S. aureus (VRSA), 
which can either have intermediate resistance (hVRSA) or high level resistance (VRSA). 
Resistance in hVRSA strains is due to adaptation due to prolonged exposure, whereas high 
level VRSA resistance is due to the acquisition of vancomycin resistance genetic elements, 
such as vanA (201, 202). Vancomycin-resistant enterococci and VRSA are usually co-isolated, 
and in vitro and in vivo HGT of vanA occurs between VRE and S. aureus, which is most likely 
the mechanism by which MRSA acquires vancomycin-resistance (202–206). Resistance to 
vancomycin is a serious threat, as vancomycin is usually the drug of choice for treatment of 
MRSA infections. 
Several lantibiotics are effective against antibiotic-resistant S. aureus in vitro and in vivo (13, 
104, 207, 208). Although lantibiotics have potential as treatment for SSTIs, there are limited 
published studies evaluating lantibiotics as topical treatments. Nisin incorporated into 
nanofibers is effective in the treatment and prevention of S. aureus in mice, using a topical 
infection model (209). The nisin nanofibers not only treat infection, but also significantly 
improves wound healing and closure. Nisin is also currently being used for the prevention of 
mastitis in cows and a treatment option is under development (162). Other lantibiotics, such as 
mutacin 1140 (Oragenics) and NVB333 (Novacta Biosystems), are currently either in 
development or preclinical trials for the treatment and prevention of Gram-positive infections.  
In addition to their application in the treatment of topical S. aureus infections, several 
lantibiotics have potential for use in other areas related to staphylococcal infections. 
Staphylococcus spp. can colonize medical devices such as catheters, cardiac devices and 
prosthetic implants, with formation of biofilms that further complicate treatment. Infections of 
these implants leads to increased morbidity and cost for patients (210, 211). Nisin and 
gallidermin incorporated into bone cement remains active against S. aureus and S. epidermidis 
in vitro (212, 213). Nisin-eluting cement also prevents infection by S. aureus when implanted 
subcutaneously in mice, as determined by bioluminescence (212). Additionally, no viable cells 
are isolated from implants after removal (212). Nisin in combination with RNAIII-inhibiting 
peptide (RIP) also prevents methicillin-resistant S. epidermidis colonization on grafts, when 
implanted into subcutaneous pockets on the back of rats (214). A nisin-RIP combination proved 
to be very effective in preventing colonization, with less than 10 CFU/cm2 remaining after 
seven days (214). Nisin, RIP and rifampin, individually, resulted in 7.8x103, 6.1x102, and 
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5.5x104 CFU/cm2, respectively (214). Teflon catheters coated with nisin and implanted 
intravenously in sheep maintains bactericidal properties for more than five hours after 
implantation, and polyvinyl chloride tracheotomy tubes coated with nisin has activity for 1-2 
hours after implantation in ponies (215). Gallidermin is effective in preventing biofilm 
formation by staphylococci in vitro and nisin incorporated into polymer films is effective in 
preventing S. epidermidis biofilm formation (216, 217).  
In murine infection models, microbisporicin has equivalent or superior activity when compared 
to reference treatments (e.g. penicillin, vancomycin and linezolid) in the treatment of MRSA 
and glycopeptide-intermediate S. aureus (67, 208). Interestingly, microbisporicin is more 
effective when administered intravenously compared to subcutaneous administration, 
suggesting better bioavailability when injected intravenously (67, 208). Lacticin 3147 is also 
able to control the systemic spread of S. aureus in mice, vancomycin still, however, more 
effective in reducing S. aureus spread (218). Mersacidin completely eradicates S. aureus in a 
murine rhinitis model, with no reports of mucosal lesions or morphological changes in the liver 
(219). Nisin is able to inhibit the growth of S. aureus in the respiratory tract of rats and does 
not have negative effects on the trachea, lungs and bronchi. (220). Mersacidin has superior 
activity against MRSA when compared to vancomycin in an in vivo infection model, where 
mice were injected intraperitoneally with lethal amounts of S. aureus (MRSA and methicillin 
sensitive S. aureus) and treated subcutaneously (221). In contrast to these results, nisin is 
ineffective in the treatment of S. aureus when mice are infected subcutaneously and in the 
peritoneal cavity (222, 223). However, in these studies infections were left longer before 
treatment, and a crude extract of nisin was used which may have resulted in insufficient amount 
of active peptide being available to prevent or treat infection (222, 223). It is also likely that 
there is an interaction between the peptide and host components when administered 
subcutaneously or directly into the peritoneal cavity. This is similar to microbisporicin, which 
showed better activity when injected intravenously (208). However, in the case of 
microbisporicin, some activity was still present when administered subcutaneously (208). 
Mersacidin also has reduced bioavailability when injected subcutaneously, which only 
improves after using the more water soluble potassium mersacidin (221).  
Problems such as production, solubility and enzyme degradation have held back lantibiotic use. 
However, nisin is produced commercially as a food additive and is effective in vitro and in 
vivo, illustrating that these hurdles can be overcome. It is highly likely that many of the lipid 
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II-binding lantibiotics would make good candidates for the treatment of multiple drug-resistant 
S. aureus. Based on their diversity, lantibiotics with desirable pharmacokinetic/dynamic 
properties are bound to be found. The continued advancement in synthetic biology and 
heterologous expression systems should also make large scale production more feasible. 
Lantibiotic activity against other Gram-positive bacteria 
Lantibiotics have activity against a wide range of Gram-positive bacteria, including several 
pathogens associated with human infections.  
Streptococci include several pathogenic strains and are divided into alpha- and beta-haemolytic 
streptococci. Alpha-haemolytic streptococci contain S. pneumonia, which is the cause of 
pneumococcal infections, including otitis media, sinusitis, pneumonia and meningitis. Several 
lantibiotics are active against S. pneumonia including actagardine, nisin and microbisporicin 
(208, 224, 225). Mice infected intraperitoneally with S. pneumonia, at concentrations sufficient 
to result in death, were treated with either nisin or vancomycin. Two intravenous treatments 
with nisin of 0.16 mg/kg each resulted in 100% survival, whereas the survival of mice treated 
with 1.25 mg/kg vancomycin was only 83% (224). After five minutes the nisin concentration 
in serum was 50 mg/l with a serum half-life of 0.9 hours and was not detectable after three 
hours. The low blood and tissue levels of nisin thus seem to be sufficient to prevent death of 
the mice (224). In another study carboxamides of actagardine were generated (225). The 
monocarboxamides were more active compared to the other variants in vitro and a more water 
soluble derivative was effective in a murine septicaemia model, with effective dose (ED50) 
values comparable to the reference antibiotics used (225). Compared to nisin, the actagardine 
derivative is eliminated faster with a serum half-life of 0.3 hours (224). The ED50 of 
microbisporicin is at least half that required for linezolid and penicillin G treatment of S. 
pneumonia, when compared in a murine lethal infection model (208). 
Beta-haemolytic streptococci are divided into groups A and B. Group A is found on the skin 
and inside the throat, and is responsible for most beta-haemolytic streptococcal infections. 
Common infections caused by group A beta-haemolytic streptococci (GAS; S. pyogenes) 
include impetigo, cellulitis, pharyngitis and scarlet fever. Several lantibiotics including 
microbisporicin, planosporicin, mersacidin, actagardine and lantibiotics produced by 
streptococci (e.g. salivaricin9 and streptin) are active against GAS (59, 65, 67, 221, 225, 226). 
A water soluble derivative of mersacidin has comparable activity to that of vancomycin, when 
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it is used for treatment of S. pyogenes in mice (221). The same water soluble actagardine 
derivative used against S. pneumonia is also effective in vivo against S. pyogenes (225). 
Planosporicin protects mice in a septicaemia model from S. pyogenes and has no toxicity up to 
100 mg/kg. However, compared to teicoplanin the ED50 of planosporicin is much higher at 3.75 
mg/kg compared to 0.18 mg/kg for teicoplanin (65). 
Enterococcal infections, especially those caused by VRE, are becoming an increasingly 
important problem (166). Vancomycin-resistant enterococci are characterized as a serious 
threat by the CDC and results in over 20,000 cases in the United States each year (166). Several 
lantibiotics, including lacticin 3147, nisin, mersacidin, epidermin, haloduracin and 
microbisporicin have promising in vitro activity against enterococci, with some active against 
VRE (13, 67, 104, 207, 227). Microbisporicin administered intravenously and subcutaneously, 
in mice, has the lowest ED50 against two VRE strains compared to linezolid (208). Although 
VRE is a threat the emergence of carbapenem-resistant enterococci (CRE) which are resistant 
to all treatments is even more serious (166). To date lantibiotics have not been specifically 
tested against CREs, which would make investigating lantibiotic activity against these strains 
imperative. 
Probionibacterium acnes is a member of the normal skin flora, mainly found in the sebaceous 
follicles, and under certain conditions can become an opportunistic pathogen. P. acnes is 
implicated in several disease states such as acne vulgaris, folliculitis, and sarcoidosis and can 
also cause postoperative infections (228). Most lantibiotics are active against P. acnes 
including mutacin B-Ny266, gallidermin, epidermin, microbisporicin, nisin and lacticin 3147 
(67, 227, 229, 230). 
Listeria monocytogenes is a foodborne pathogen and can cause sepsis, fetal loss and 
gastroenteritis (231, 232). Several lantibiotics are active against L. monocytogenes, and the 
extensive use of nisin in the food industry assists in the prevention of food spoilage caused by 
listeria. Nisin controls the spread of listeria in mice for three days after only one treatment 
(infected and treated intraperitoneally) (233). In addition, a nisin hinge variant, nisin V 
(M21V), is more effective than nisin A (233). 
Another important foodborne and nosocomial pathogen, involved in severe gastrointestinal 
tract (GIT) infections, is Clostridium difficile. Clostridium difficile associated diarrhoea 
(CDAD) is one of the major causes of hospital associated diarrhoea, with 250,000 infections 
per year in the United States alone, with at least $ 1 billion in excess medical costs (166). 
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Current treatment of CDAD includes oral administration of vancomycin and metronidazole, 
however, vancomycin treatment can lead to colonization of VRE in the GIT or even the spread 
of vancomycin resistance within a hospital environment. Nisin and lacticin 3147 are effective 
against C. difficile. Prevention of spore outgrowth by these and other lantibiotics, in 
Clostridium spp. and Bacillus spp. have also been demonstrated (14, 40, 47, 104, 234). 
Prevention of spore outgrowth can help in curbing the growth and spread of C. difficile which 
may contribute to the successful treatment of CDAD. Actagardine (NVB-302) is currently 
being developed for treatment of C. difficile and is undergoing phase I clinical trials. In an in 
vitro GIT model actagardine compares well with vancomycin in the treatment of C. difficile, 
with less deleterious effects on Bacteriodes fragilis (a GIT commensal) (235). Combination of 
actagardine and ramoplanin is especially effective against multiple C. difficile strains (236). 
Lacticin 3147 in a faecal fermentation model completely eliminates C. difficile within 30 min, 
with minimal effects on anaerobes, bacteroides and other Gram-negative bacteria. The 
enterococci, lactobacilli and bifidobacteria populations were, however, negatively affected 
(14). When lacticin 3147 is fed to pigs at similar concentrations it has no effect on the 
microbiota including lactobacilli and enterococci, with neither of the peptides detected in 
diagesta of pigs after 2 hours (237). This suggests that one or both of the peptides are either 
degraded during intestinal transit or already passed through to the stomach (237). 
Mycobacterium tuberculosis is the causative agent of the respiratory tract infection known as 
tuberculosis (TB). Worldwide 8.7 million people contracted and 1.3 million died of the disease 
in 2012 (170). Cases of multiple- and extensively-drug resistant M. tuberculosis place an 
immense burden on the efforts to control the spread of TB. The unique cell wall and slow 
growing nature of M. tuberculosis may make it difficult for lantibiotics (and other treatments) 
to exert antimicrobial activity. However, the ability of lantibiotics to bind to lipid II gives it an 
advantage over treatments such as rifampicin, which need to be transported across the plasma 
membrane. The lipid II structure of mycobacteria does differ from other bacteria, due to 
modifications on both MurNac and the peptide side chain (238). Despite these differences, 
nisin has activity against the non-pathogenic M. smegmatis and M. bovis, with intracellular 
ATP leakage and dissipation of the PMF (43, 239, 240). Nisin hinge mutants have improved 
activity against M. smegmatis (43). Nisin and lacticin 3147 are active against clinical 
mycobacteria isolates, with lacticin 3147 showing the best activity against M. tuberculosis 
(241). These lantibiotics have potential, however, an appropriate delivery system should be 
developed in order to reach M. tuberculosis, which reside in macrophages found in the distal 
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lung. Further research is required to establish the feasibility and use of lantibiotics as an anti-
mycobacteria treatment. 
Lantibiotic activity against Gram-negative bacteria 
Although lantibiotics are not known for their activity against Gram-negative bacteria, there are 
some exceptions. 
Helicobacter pylori causes a very difficult to treat GIT infection and is associated with several 
GIT disorders, including, peptic ulcer disease, chronic gastritis and gastric cancer (242). 
Treatment of H. pylori is difficult due to its location in the GIT and requires treatment with 
multiple drugs to be effective (242). Nisin has completed phase I clinical trials for the treatment 
of H. pylori, however, initiation of phase II trials have not been reported (243). 
Neisseria meningitides and Neisseria gonorrhoeae are the causative agents of meningococcal 
meningitis and gonorrhoea, respectively. Neisseria spp. are susceptible to lantibiotics such as 
mutacin B-Ny266, microbisporicin and nisin (67, 230). Neisseria meningitides and N. 
gonorrhoeae are especially sensitive to microbisporicin (0.5 and 0.25 μg/ml, respectively), 
compared to nisin (8 and 4 μg/ml, respectively) (67). 
Haemophilus influenza is an opportunistic pathogen and can cause bacteraemia, pneumonia- 
and bacterial-meningitis. Nisin, mutacin B-Ny266 and microbisporicin have in vitro activity 
against H. influenza. However, only microbisporicin (32 μg/ml) and mutacin B-Ny266 (13 
μg/ml) demonstrate moderate activity, while nisin is required at high concentrations (>66 
μg/ml) to be effective (67, 230).  
Campylobacter jejuni is a common cause of gastroenteritis and is identified as an important 
enteric pathogen, and is the leading cause of food borne-illness (244). Nisin and mutacin B-
Ny266 have in vitro activity against C. jejuni at relatively low concentrations (230).  
A lantibiotic from B. longum DJO10A has Gram-negative activity, including activity against 
Serratia marcescens, Proteus vulgaris and E. coli. However, this is observed using a crude 
lantibiotic preparation, and activity needs to be studied with purified peptide (120, 121). 
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Other therapeutic applications of lantibiotics 
Lantibiotics as immune modulators 
Several cAMPs play a crucial role in modulating the immune system during infection and 
injury, including, LL-37 and α- and β-defensins (245, 246). Most complex species have 
cAMPs, which interact with the innate immune system using several mechanisms. These 
peptides are generally short, gene encoded, overall positively charged, with a large proportion 
of hydrophobic residues, making them very similar to lantibiotics (245-247). 
Gram-positive bacteria, including staphylococci, are able to, or at least have the genetic 
potential to, produce lantibiotics. Several lantibiotic gene clusters can be identified in many 
pathogenic and commensal staphylococci (50, 248). It is hypothesized that lantibiotics 
produced by commensal bacteria may play a role in maintaining microbial balance, through 
direct antimicrobial activity (23, 24, 184). This has not yet been shown in vivo, however, a S. 
aureus strain with its lantibiotic gene cluster knocked-out does result in a growth-attenuated 
strain in a mouse abscess model (249). 
Nisin, gallidermin and Pep5 are able to induce the release of multiple chemokines at levels 
similar to that of LL-37 (19). Furthermore, nisin uses multiple signalling pathways including 
the ERK/MAPK, PKC and PLA pathways (19). Mice pre-treated with nisin followed by 
infection with Salmonella typhimurium and E. coli showed a significant reduction in bacterial 
counts compared to the control (19). Nisin does not have activity against these Gram-negative 
bacteria, suggesting that nisin is able to provide protection via an immunomodulatory 
mechanism. 
Phospholipase A2 plays an important role in inflammatory responses resulting from its role in 
the release of arachidonic acid. The oxidative metabolism of arachidonic acid results in 
eicosanoids, such as prostaglandins and leukotrienes, which are strong mediators of the 
immune system. Cinnamycin-like lantibiotics are able to indirectly inactivate phospholipase 
A2 by sequestering PE (substrate for phospholipase A2), thereby having potential to indirectly 
mediate inflammatory responses (139, 140-142). Another cinnamycin-like lantibiotic, 
ancovenin, is an inhibitor of ACE, which is important in regulating blood pressure by 
catalysing the conversion of angiotensin I to angiotensin II (25, 130). 
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These results suggest that lantibiotics are capable of interacting and modulating the immune 
systems, potentially using similar mechanisms employed by human and other cAMPs. 
Lantibiotics as ion channel regulators 
Duramycin has potential in the treatment of cystic fibrosis which is caused by abnormal 
chloride ion transport. Duramycin elevates intracellular calcium thereby activating an 
alternative chloride channel and increases chloride permeability in nasal epithelium of cystic 
fibrosis patients (250, 251). In a phase II clinical trial duramycin was shown to be safe and 
resulted in overall positive results on the pulmonary function of cystic fibrosis patients (252). 
Duramycin is also under development for the treatment of dry eye syndrome. 
Lantibiotics as treatment for neuropathic pain  
Labyrinthopeptin-like lantibiotics do not have antimicrobial activity, however, 
labyrinthopeptin A2 has been shown to be effective against neuropathic pain in mice (8). 
Tactile allodynia is measured in mice using a spared nerve injury model (8). Labyrinthopeptin 
A2 administered intravenously at concentrations ranging from 0.01 - 3.0 mg/kg results in 
significant attenuation of tactile allodynia (ED50 50ug/kg). Efficacy reaches 100% and remains 
stable over the six hours with loss of efficacy after 24 hours (8).  
Lantibiotics as contraceptives 
Nisin can completely immobilize sperm. The immobilization effect is time- and dose-
dependent with 50 μg/ml, 200 μg/ml and 300-400 μg/ml nisin required to immobilize rat, 
rabbit, human or monkey spermatozoa, respectively, in 20 seconds (253). Seminal fluid 
significantly affects nisin potency with up to 4x reduction in potency. Nisin (200 μg via 
intravaginal administration) was tested in vivo in rats for its contraceptive potential (253). None 
of the animals treated with nisin intravaginally before mating became pregnant, whereas all 
rats in the control group become pregnant. Nisin does not have any cytotoxic effects nor any 
effect on the oestrus cycle or fertility of rats (253). Nisin is also effective when used in rabbits 
as a contraceptive, with 1 mg nisin being sufficient and safe (254).  
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Conclusion 
The diversity of lantibiotics, in terms of structure and bioactivity, make them ideal candidates 
to be investigated for clinical use. The obvious use of lantibiotics as antimicrobials has been 
extensively studied, with research focusing on clinical and food preservation applications. 
Several problems plagued the large scale roll out of lantibiotics in the medical industry, which 
include production of insufficient quantities of lantibiotics, reduced solubility at higher 
concentrations/pH and protease degradation. However, several lantibiotics can be produced on 
a large scale, including nisin and lacticin 3147. Companies such as Novacta Biosysoltems and 
Oragenics are developing large scale fermentation and recovery processes for the lantibiotics 
they are pushing towards clinical use. Another company spearheading the development of 
lanthipeptides is LanthioPharma, that focus on the discovery and development of lanthipeptide 
based drugs for various clinical (other than antimicrobial) applications. By using 
lanthipeptides, LanthioPharma are developing novel peptides, and incorporating lanthionines 
into existing peptides (e.g. apelin), that are more stable and resistant to protease degradation. 
Lanthionine bridges in lantibiotics make them more stable than other linear peptides, and can 
provide protection against protease degradation. With such a diverse group of lantibiotics it is 
possible to find alternative naturally occurring lantibiotics that are more stable under required 
conditions. In addition to high natural diversity, the bio-engineering of lantibiotics and 
improvements in production processes, make it possible to tailor lantibiotics for specific needs. 
The solubility concerns that are raised for lantibiotics can be overcome by making derivatives 
that are more soluble, such as potassium mersacidin that is more water soluble but retains its 
antimicrobial activity. Incorporating lantibiotics, such as nisin, into nanofibers at high 
concentrations is also effective in delivery of nisin to sites of infection. By constraining 
lantibiotic release, using a delivery system, issues of low solubility can possibly be 
circumvented.  
Therefore, due to the diverse application potential of lantibiotics, and other lanthipeptides, it is 
inevitable that their clinical use will increase. 
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Chapter 3 
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Chapter Summary 
Lantibiotics are ribosomally synthesized and post-translationally modified antimicrobial 
peptides, with potential applications in the medical industry. They have been isolated from a 
variety of bacteria from diverse environments. Bacillus clausii AD1 and Bacillus 
amyloliquefaciens AD2 were isolated from the bacterially diverse soils of the Fynbos. Both 
bacteria produced potent antimicrobials active against Gram-positive bacteria. Purification of 
the antimicrobials by HPLC revealed a single active peak for the antimicrobial produced by B. 
clausii AD1. The antimicrobial produced by B. clausii AD1 was identified as clausin according 
to its mass and the presence of the flavoprotein ClausD. Only after combination of two HPLC 
purified peaks could activity be observed for the antimicrobial produced by B. 
amyloliquefaciens AD2. A complete lantibiotic operon could be identified in the genome of B. 
amyloliquefaciens AD2. Sequence comparison in the NCBI database revealed that the operon 
contains two putative genes encoding the individual precursor peptides of a two-component 
lantibiotic. The individual peptides have similarity to other two-component lantibiotics and 
was designated amyloliquecidin. In addition to the two-component lantibiotic genes, the 
operon also harboured all the required genes for biosynthesis, transport and amyloliquecidin 
immunity. Clausin and amyloliquecidin has activity against clinical Gram-positive isolates 
including methicillin-resistant Staphylococcus aureus. Amyloliquecidin has superior stability 
when stored at physiological pH compared to nisin and clausin. Amyloliquecidin is also heat 
stable at temperatures up to 100˚C. This is the first report of the two-component lantibiotic 
amyloliquecidin. The antimicrobial spectrum and stability suggests amyloliquecidins’ possible 
use in the treatment of Gram-positive infections. 
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Introduction 
Lantibiotics are post-translationally modified (PTM) peptides and require several enzymes to 
produce a mature active peptide. Their characteristic modification, the lanthionine bridges, are 
formed between dehydroalanine/dehydrobutyrine (Dha and Dhb, respectively) and cysteines 
(1, 2). Dehydratase enzymes are responsible for the dehydration of Ser to Dha and Thr to Dhb 
(1-3). Subsequent cyclization reactions between Dha/Dhb and cysteines, results in the 
formation of the lanthionine (Lan) and methyllanthionine (MeLan) rings, respectively (3). 
Class I lantibiotics utilize two separate enzymes for the dehydration and cyclization reactions, 
namely LanB (dehydratase) and LanC (cyclase). Class II on the other hand, have one bi-
functional enzyme, LanM, which has dehydratase and cyclase domains (1). In addition to these 
modifications, lantibiotics can have several other PTMs, including labionin residues formed by 
a second Michael addition with a second Dha, and oxidative decarboxylation of the lantibiotic 
C-terminus during aminovinylcysteine formation (4–6). The genes required for lantibiotic 
production are found in gene clusters. Genes required for introduction of modifications, 
transport, regulation and lantibiotic immunity are usually found in the same cluster (1, 7). 
Lantibiotics can be used as antimicrobials and nisin, the prototypical lantibiotic, is widely used 
as a preservative in dairy products (8). Lantibiotics also have potential applications in the 
medical industry due to their activity against clinical pathogens, including antibiotic-resistant 
strains (9–14). 
Lantibiotics are a diverse group of peptides that are found in several genera, including 
Staphylococcus spp., Streptococcus spp., Lactobacillus spp., Lactococcus spp. and Bacillus 
spp. Numerous lantibiotics have been isolated from Bacillus spp. representing both class I and 
II lantibiotics, including the well-studied mersacidin (Table 1). Bacillus spp. are well-known 
producers of not only lantibiotics, but also hydrolytic enzymes, surfactants and a variety of 
non-ribosomally synthesised peptides (15–17). Phenotypic properties, such as the ability to 
survive on a variety of substrates, withstand harsh conditions (spore formation), and 
antimicrobial production, provide Bacillus spp. with unique advantages. It is therefore not 
surprising that Bacillus species are so ubiquitous in nature. 
Fynbos forms part of the South African Cape floral kingdom, which is considered one of the 
worlds’ diversity hotspots (18). Fynbos is characterized by a richness of plant species with a 
high proportion of the plants being endemic (18). Recently, a study examined the bacterial 
diversity in four soils across the western hemisphere and reported on an estimated 10 000-50 
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000 bacterial species per gram of soil (19). The bacterial community of the Fynbos soil is highly 
diverse, with the high plant diversity contributing to the diversity of the microbial communities 
(20, 21). Molecular techniques indicated that more than 80% of bacteria associated with the 
rhizosphere of plants (Proteaceae family) are novel genospecies (21). This diverse and complex 
relationship with the bacterial communities of soil and plants in the Fynbos biome provides an 
ideal setting to isolate bacteria that may produce novel antimicrobial compounds (20). 
Furthermore, Fynbos is a largely prestine unexploited niche that increases the probability of 
isolating novel antimicrobial-producing bacteria. 
The current study aimed to characterize novel antimicrobials produced by bacteria isolated 
from the highly diverse Fynbos soils of the Western Cape, South Africa. 
  
TABLE 1. Lantibiotics Produced by Bacillus spp. 
Lantibiotic Producer Strain 
Mersacidin 1Bacillus amyloliquefaciens HIL-Y85 
Subtilin 2Bacillus subtilus ATCC6633 
Entainin 3Bacillus subtilus DSM15029T 
EricinS and A 4Bacillus subtilus A1/3 
Clausin 5Bacillus clausii OC 
Haloduracin 6Bacillus halodurans C-125 
Lichenicidin 7Bacillus licheniformis DSM13/VK21  
Amylolysin 8Bacillus amyloliquefaciens GA1 
1(22);  2(23);  3(24);  4(25);  5(26)  6(27);  7(28, 29);  (30) 
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Materials and Methods 
Materials 
All bacterial growth media were from Biolab Diagnostics (South Africa), unless otherwise 
stated. Trifluoroacetic acid (TFA) and XAD-16 beads were from Sigma-Aldrich (Germany). 
Acetonitrile and isopropanol were from Merck-Millipore (USA). All reagents used in Southern 
hybridization, including restriction enzymes, were from Roche Life Sciences (Germany). 
PureYieldTM Miniprep kits used for plasmid DNA isolation were from Promega (USA) 
Nisaplin was from Danisco (Denmark). SepPak C18 columns were from Waters (USA). The 
bicinchoninic acid (BCA) protein assay was from Pierce Biotechnology (USA). 
Isolation and Identification of Antimicrobial Producing Bacteria from 
Fynbos Soil 
Soil and plant samples collected from the Jonkershoek nature reserve (Stellenbosch, South 
Africa) were suspended in sterile distilled water. Flower samples were homogenized using a 
blender, and incubated at 30˚C for 24 h. After incubation, samples were plated onto selected 
media such as brain heart infusion (BHI) agar, Luria (LB) agar, nutrient (NB) agar and de Man 
Rosa Sharp (MRS) agar. Bromocresol purple (0.025 g/l) was added to all growth media to 
observe changes in pH. Fungal growth was inhibited by adding cycloheximide (0.001%, 
wt/vol) to all media. Plates were incubated aerobically and anaerobically at 37˚C until visible 
colonies appeared (24-48 h). Colonies were overlaid with BHI soft agar (1% wt/vol agar) 
seeded with Staphylococcus aureus Xen 36 and incubated for a further 24 h at 37˚C. Colonies 
surrounded by a clear zone of inhibition were selected, inoculated into respective media and 
incubated at 37˚C. Pure cultures were obtained after streaking onto agar plates.  
DNA was isolated from pure cultures according to standard methods (31). Genes encoding 16s-
rDNA and gyraseA were amplified using primer sets listed in Table 2. Amplified partial-16s 
rDNA and -gyraseA fragments were cloned into pGEM-T (Promega) and transformed into 
Escherichia coli BL21.  Transformants were selected on LB agar supplemented with ampicillin 
(100 μg/ml).  Plasmid DNA was isolated from positive clones and the DNA was sequenced 
(central analytical facility, Stellenbosch University, South Africa). Sequences were used in 
BLASTn searches of NCBI databases (http://www.ncbi.nlm.nih.gov/blast.cgi) to identify 
strains. ClausD primers were designed to amplify lanD present in putative lantibiotic gene 
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clusters (Table 2). Amplified lanD was cloned into pJET (Thermo Scientific) and E. coli BL21, 
and transformants were selected on LB agar supplemented with ampicillin (100 μg/ml). 
Degenerative lanM primers were used to amplify a region of the lanM gene from the putative 
lantibiotic gene clusters (Table 2). Positive amplicons were cloned into pGEM-T, transformed 
into E. coli BL21 and transformants were selected on LB agar supplemented with ampicillin 
(100 μg/ml). Plasmid DNA was isolated from positive clones, sequenced and used in BLASTn 
searches of the NCBI databases to identify clausD and partial lanM sequences.  
Production and Purification of Lantibiotics 
Mueller Hinton broth (MH; Sigma-Aldrich) was clarified with activated-XAD-16 beads before 
autoclaving. XAD-16 beads were activated using 80% isopropanol containing 0.1% 
trifluoroacetic acid (Iso-TFA) (vol/vol/vol). Activated beads were collected and rinsed with 
distilled water. Mueller Hinton broth (10 g/l) was added to activated-beads and incubated at 
26˚C for 30 min. Beads were removed and MH broth was autoclaved as per manufacturer’s 
instructions. 
TABLE 2. Primers used in this study 
Primer 
Name 
Primer 
Target 
Primer Sequence (5’-3’) 
F8 16s rDNA CAGGCATCCAGACTTTGATYMTGGCTCAG 
R1512 16s rDNA GTGAAGCTTACGGYTAGCTTGTTACGACTT 
1pGyrAF gyraseA CAGTCAGGAAATGCGTACGTCCTT 
1pGyrAR gyraseA CAAGGTAATGCTCCAGGCATTGCT 
2LanMDegF lanM ATGCWAGWYWTGCWCATGG 
2LanMDegR lanM CCTAATGAACCRTRRYAYCA 
AmyA2F amyAβ  ATAATTTAGCGGCCGCTTAGCAGCTTGATGTACATTTGG 
LicR1R licR1 CAATTAATTGGGTTGGCAGATCCAT 
ClausDF lanD GATCAAGCTTTTAGCTTTTTTCTTCTACAGCC 
ClausDR lanD CTAGATGGATCCATGCCGGAAAAGGAAGAA 
1(31); 2(32) 
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A single colony of B. clausii AD1 was inoculated into 10 ml of sterile XAD-16-treated MH 
broth, placed on an orbital shaker (100 rpm) at 30˚C for 24 h. The culture was subsequently re-
inoculated (1% vol/vol) into 500 ml of the same MH broth and incubated on an orbital shaker 
(100 rpm) at 30˚C for 8-10 days (26). Cells were removed by centrifugation at 10,000 × g for 
25 min (4˚C). Cell-free supernatant (CFS) was added to activated-XAD-16 beads (10 g/500 
ml) and placed on an orbital shaker (50 rpm) at 4˚C for 2 h. Beads were collected and washed 
with 30% ethanol (vol/vol), followed by several double-distilled water wash steps. Peptide 
bound to beads was eluted using 80% Iso-TFA (vol/vol) and filtered through a 45 μM cellulose 
acetate filter. Isopropanol was removed using rotary evaporation (RotaVapor®, Buchi). 
To the cell-pellet 80% Iso-TFA (vol/vol) was added and vigorously shaken at 4˚C for 24 h to 
retrieve any peptide bound to the bacterial cells. Cells were separated by centrifugation at 
10,000 × g for 25 min (4˚C). The CFS was filtered and the Iso-TFA removed by rotary 
evaporation, as previously described. 
Samples from the cell-pellet and XAD-16 beads were combined and loaded onto a Sep-Pak 
C18 column. The column was washed with double-distilled water and manually eluted using a 
stepwise acetonitrile (containing 0.1% TFA (vol/vol/vol)) gradient (10-80%, 10% increments 
at 1 ml/min). Fractions were tested for activity using the agar-well diffusion assay. Briefly, 
BHI soft agar (1 % wt/vol) was seeded with a dense overnight (18 h) culture of S. aureus (1% 
vol/vol) (Table 3). Wells (5 mm in diameter) were made into the solidified agar and filled with 
50 μl aliquots of each fraction. Activity was observed as a clear zone of growth inhibition. 
Active fractions were frozen at -80˚C, freeze-dried and stored at -20˚C until further use. 
Media (BHI) were treated with XAD-16 beads as previously described. Bacillus 
amyloliquefaciens AD2 was streaked onto BHI agar and grown for 24 h at 37˚C. A single 
colony was used to inoculate 5 ml LB broth, placed on an orbital shaker (100 rpm) at 37˚C and 
incubated for 24 h. Luria broth containing B. amyloliquefaciens AD2 was mixed with sterile, 
activated XAD-16 beads (5 g/5 ml LB). This suspension was spread over BHI agar (2% wt/vol 
agar; Ø150 mm plates) and incubated for 96 h at 30˚C. XAD-16 beads were removed from agar 
using double-distilled water and incubated on an orbital shaker (50 rpm) for 2 h at 4˚C. The 
beads were washed with double-distilled water to remove bacteria. The peptide was eluted from 
the beads and Iso-TFA removed as previously described. Samples from XAD-16 beads were 
combined and loaded onto a Sep-Pak C18 column. Peptide was eluted from Sep-Pak C18 
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columns and antimicrobial activity was tested as previously described. Active fractions were 
frozen at -80˚C, freeze-dried and stored at -20˚C until further use. 
Nisaplin was dissolved in 25% acetonitrile containing 0.1% TFA (vol/vol/vol). Undissolved 
particles were removed by centrifugation. The supernatant was loaded onto a C18 Sep-Pak 
column and eluted as previously described. Active fractions were frozen at -80˚C, freeze-dried 
and stored at -20˚C until further use. 
Peptides were further purified to homogeneity using high-performance liquid chromatography 
(HPLC). Freeze-dried samples were dissolved in 10% acetonitrile containing 0.1% TFA 
(vol/vol/vol) and applied to a Discovery BIO Wide Pore C18 HPLC column (10 μm, 250 × 10 
mm; Sigma-Aldrich). Clausin and amyloliquecidin (AmyA) were eluted in an increasing 
gradient of 25% to 60% B over 28 min (A: MilliQ water containing 0.1% TFA (vol/vol) and 
B: acetonitrile containing 0.1% TFA (vol/vol)). Nisin was eluted in an acetonitrile gradient of 
10% to 60% B over 38 min. Sample peaks were detected by measuring the absorbance at 230 
and 254 nm. Peaks were collected and tested for activity against S. aureus using the agar-well 
diffusion assay as previously described. Fractions with active peaks were freeze-dried as well 
as analyzed by electrospray ionization-mass spectrometry (ESI-MS; central analytical facility, 
Stellenbosch, South Africa). 
Identification of the Bacillus amyloliquefaciens Lantibiotic Operon 
Southern- and colony-hybridization were performed according to standard methods (34). Total 
DNA from B. amyloliquefaciens AD2 was digested with SalI, EcoRI, SacI, NcoI, PstI as well 
as combinations of these restriction enzymes. By using degenerative lanM primers, a partial 
lanM sequenced could be amplified. The partial lanM sequence was used to prepare probes 
labeled with DIG-11-dUTP.  Random priming was performed according to the manufacturer’s 
instructions (DIG DNA labeling mix). Appropriate restriction enzyme combinations were 
chosen after Southern blotting and hybridization, in order to clone the region containing the 
desired operon. DNA fragments were digested with selected restriction enzymes and ligated 
into pRSFDeut-1 (Novagen) and transformed into E. coli BL21. Transformants were plated 
onto LB agar containing kanamycin (50 μg/ml). Colony hybridization was performed using the 
same lanM probe. Plasmid DNA isolated from positive clones was sent for sequencing analysis. 
Sequences were used in BLASTn searches of NCBI databases to identify genes related to the 
lantibiotic gene cluster. Primers were generated to amplify the regions not identified with 
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Southern hybridization and are indicated in Table 2 (AmyA2 and LicR1). Amplified fragments 
were cloned into pJET, and E. coli BL21 transformants were plated onto LB agar containing 
ampicillin (100 μg/ml). Plasmid DNA was isolated from positive clones, sequenced and used 
in BLASTn searches of NCBI databases to identify amplified sequences. This resulted in the 
elucidation of the sequence of one of the structural genes for the antimicrobial peptides from 
B. amyloliquefaciens AD2. 
DNA was sent for whole genome sequencing on the Ion Proton (central analytical facility, 
Stellenbosch, South Africa). Ion Proton DNA preparation and system settings were done 
according to manufacturer’s instructions (Life Technologies). Velvet de novo genome 
assembler (version 1.2.10), CLC genomics workbench (version 7.0.3; Qiagen) and MIRA 
(version 4.0) were used for de novo assembly of contigs (35, 36). The partially identified 
lantibiotic operon obtained from the Southern hybridization approach was used to identify 
contigs containing the putative lantibiotic operon. 
Antimicrobial Spectrum and Determination of MIC against S. aureus 
An agar-well diffusion assay was used to determine the antimicrobial spectrum of lantibiotics. 
Indicator strains were grown for 18 h in appropriate media and under optimal conditions (Table 
3). Peptide concentration was determined by using the BCA protein assay according to the 
manufacturer’s instructions. Peptides were made up to a concentration of 50 μM in sterile 
double-distilled water (containing 0.1% TFA (vol/vol)). In the case of AmyA, the alpha and 
beta peptides were combined in a 1:1 molar ratio. Peptides were dispensed in wells (25 μl) and 
plates were incubated for 24 h at the appropriate temperatures (Table 3). Antimicrobial activity 
was qualitatively determined by the presence or absence of growth inhibition.  
Microtiter plates were used to determine the minimal inhibitory concentration (MIC) of 
peptides against S. aureus Xen strains (Table 3). Bacteria were grown overnight (18 h), 
inoculated into fresh MH broth and incubated at 37˚C until an OD600 of 0.1 was reached. 
Peptide concentrations were determined and adjusted as previously described. Each well was 
composed of 150 μl bacteria and 50 μl peptide. Controls were as follows: 150 μl media with 
and without bacteria with 50 μl double-distilled water containing 0.1% TFA (vol/vol). The  
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initial OD600 reading was taken with another at 5 h and the end point reading at 18 h. The MIC 
was determined as the lowest peptide concentration where no bacterial growth was observed 
after 18 h. 
Stability Assays 
Protease Stability Assay 
Trypsin and proteinase K were dissolved in 10 mM Tris-HCl (10 mg/ml; pH 8.0) and pepsin 
was dissolved in double-distilled water (containing 0.1% TFA (vol/vol); 10 mg/ml). All 
proteases were added to peptides (final peptide concentration of 50 μM) to a final concentration 
of 1 mg/ml. Peptide-protease combinations were incubated at 37˚C for 4 h. The alpha and beta 
peptides were incubated separately. Untreated peptides were dissolved in 10 mM Tris-HCl or 
TABLE 3. Bacteria and Culture Conditions 
Bacteria Media Temp 
(˚C) 
Reference 
Bacillus clausii AD1 BHI/NB 30  This study 
Bacillus amyloliquefaciens AD2 BHI/NB/LB 30/37  This study 
Bacillus cereus LMG13569 NB  Lab culture collection 
Beta-hemolytic streptococci (3 strains)  TSB 37 This study* 
Enterococcus spp. (5 strains) BHI/MRS 37 This study* 
Lactococcus lactis QU2 MRS 30 Lab culture collection1 
Lactobacillus plantarum 423 MRS 30 Van Reenen et al., 19982 
Listeria spp. (2 strains) BHI 37  This study* 
Listeria monocytogenes EDGE BHI 37 Caliper Life sciences, 
Hopkinton, MA, USA 
Staphylococcus epidermidis  BHI/MH 37 This study* 
Staphylococcus aureus  Xen29, 30 
(MRSA), 31 (MRSA), 36   
BHI/MH 37 Caliper Life sciences, 
Hopkinton, MA, USA 
Staphylococcus aureus (5 strains) BHI/MH 37 This study* 
Streptococcus mutans BHI/MH 37 Lab culture collection 
Escherichia coli  BL21 LB 37  Lab culture collection 
BHI: Brain heart infusion; NB: Nutrient Broth; LB: Luria broth; MRS: Man de Rosa Sharp;  MH: Mueler Hinton; 
TSB: Tryptic Soy Broth. 1Gift from Prof. Sonomoto;  2(36). * Clinical isolates, Pathcare, South Africa.  
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double-distilled water (containing 0.1% TFA (vol/vol)). After incubation the proteases were 
inactivated by heating at 95˚C for 5 min. Protease treated peptides were added to their 
respective untreated partner (alpha or beta) peptides and used in agar-well diffusion assays by 
dispensing 20 μl combined peptide into prepared wells. Wells were created in MH soft agar by 
using a 48-well PCR plate, with S. aureus as indicator strain. Digital photos were taken of the 
plates after incubation and activity was quantitatively measured by measuring the zone areas 
using the software program ImageJ (version 1.48).  
Heat Stability Assay 
The alpha and beta peptides of AmyA were made up to a concentration of 70 μM in double-
distilled water containing 0.1% TFA (vol/vol). The peptides were subsequently combined and 
incubated at 100˚C for 30 min and 121˚C for 15 min (autoclaved). The respective AmyA 
peptides were also separately treated at 121˚C and added to the corresponding untreated peptide 
after incubation. After incubation, treated peptides were spotted directly onto MH soft agar (10 
μl spots) seeded with S. aureus and incubated for 18 h at 37˚C. Digital photos were taken of 
the plates after incubation and activity was quantitatively measured using the software program 
ImageJ as previously described. 
Storage Stability Assay 
To determine the stability of peptides after storage in a neutral buffer, a stability assay similar 
to that described by Oman and van der Donk (13) was used. Stock solutions of nisin, clausin, 
AmyAα and AmyAβ were dissolved in phosphate buffered saline (PBS; pH 7.4) with final 
peptide concentrations of 50 μM. The peptide stocks were aliquoted into glass HPLC vials, 
sealed and incubated at 26˚C. Aliquots were removed at selected time intervals and stored at -
80˚C until analysis. Peptide aliquots were analysed by HPLC. Each aliquot (20 μl) was applied 
to a Hypersil Gold C18 HPLC column (5 μm, 100 × 4.6 mm; Thermo Scientific) and separated 
by maintaining the mobile phase at 10% B for 2 min followed by an increase to 100% B in 9 
min at a flow rate of 1 ml/min. For each peptide the peak area corresponding to intact peptide 
was determined and plotted as a percentage relative to the peak area of intact peptide at day 0. 
Agar-well diffusion assays were used to determine the antimicrobial viability of the peptides. 
A total of 40 μl was dispensed into each well. Nisin and clausin were added as 20μl peptide 
combined with 20μl sterile PBS (pH 7.4). The alpha and beta peptides of AmyA were added 
as 20μl AmyAα (day n) combined with 20μl AmyAβ (day n). Digital photos were taken of the 
Stellenbosch University  https://scholar.sun.ac.za
  
83 
 
plates after incubation and activity was quantified using the software program ImageJ as 
described previously. 
Results 
Isolation and Identification of Bacillus amyloliquefaciens and Bacillus clausii 
from Fynbos Soil 
The overlay assay used to identify potential antimicrobial producing bacteria provided for high 
throughput screening of hundreds of colonies. Activity was only observed with bacteria 
obtained from soil samples. The colony morphology of bacteria with antimicrobial activity 
were different from other isolated colonies and were further investigated (Fig. 1). One strain of 
the antimicrobial producing bacteria could be identified by its partial 16s rDNA sequence and 
was identified as a B. clausii strain (designated B. clausii AD1). However, this was not 
sufficient to properly identify the second bacterial strain which could only be isolated to species 
level (i.e. Bacillus spp.). The sequence of the partial gyraseA identified the second bacterial 
strain as a novel B. amyloliquefaciens with only 91% nucleotide- and 99% amino acid-identity 
to the nearest B. amyloliquefaciens. This novel strain was designated as B. amyloliquefaciens 
AD2. The lanD gene in B. clausii AD1 could be amplified using the selected primers and had 
100% amino acid and nucleotide identity (100% sequence coverage) to clausD (BAD66090.1) 
in B. clausii KSM-K16 (AP006627.1). A partial lanM sequence could be amplified from B. 
FIG 1 Bacillus clausii AD1 (left) and Bacillus amyloliquefaciens AD2 (right) grown on BHI 
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amyloliquefaciens AD2 and had the closest homology to a putative lanM from B. licheniformis 
9945A (GenBank: CP005965.1). 
Production and Purification of Lantibiotics 
Bacillus clausii AD1 and B. amyloliquefaciens AD2 had activity on solid media. However, 
activity could not be observed in supernatants of cultures grown in liquid broth. In the case of 
B. clausii AD1, activity could be observed in supernatant after prolonged incubation of the 
culture. Even after prolonged incubation in liquid broth activity could not be observed in the 
supernatant of B. amyloliquefaciens AD2. Activity could only be observed in isopropanol 
extracts of B. amyloliquefaciens AD2 cells after being scraped off solid agar. Solid media was 
subsequently used to produce AmyA. The initial purification process was significantly 
enhanced by using autoclaved activated XAD-16 beads to capture peptide being released by 
bacteria growing on solid media. Additionally, no residual peptide remained on the surface of 
the bacteria when they were grown in the presence of XAD-16 beads. The treatment of media 
with XAD-16 beads before autoclaving also significantly reduced the background of crude 
samples when run on HPLC. 
Clausin could be separated easily from crude extract using HPLC, with the active fraction 
eluting at 25.6 min. It had a size of 2,108.79 Da, corresponding to the known size of clausin 
(Fig. 2D, E and 3C). Multiple peaks were observed for AmyA, none of which exhibited any 
antimicrobial activity on their own (Fig. 2A-C). By combining different peaks antimicrobial 
activity was achieved, specifically when the peaks eluting at 17 and 27 min were combined 
(Fig. 2A insert). Electrospray ionization-MS revealed that the sizes of the peaks were 3,027.27 
and 2,438.04 Da for AmyAα (17 min) and Amyβ (27 min), respectively (Fig. 3A and B).  
Identification of Bacillus amyloliquefaciens Lantibiotic Operon 
Genomic DNA was digested with EcoRI plus SalI and using the partial lanM sequence as a 
probe in Southern hybridization, a ~4 kb fragment of the lantibiotic operon could be identified. 
The partially identified operon included the sequence for amyAβ (Fig. 4B). Based on the 
homology to B. licheniformis 9945A, primers were designed to amplify the amyAα structural 
gene. Forward and reverse primers were designed to the sequences of amyAβ and licR1 (from 
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B. licheniformis 9945A), respectively (Table 2). Using PCR, the structural gene of amyAα was 
obtained (Fig. 4A). 
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FIG 2 HPLC chromatograms of purified lantibiotics. A: 
AmyA semi-preparative HPLC, green and blue arrows 
indicate peaks for alpha and beta peptides, respectively. 
Insert: Activity of alpha and beta peptides separately and 
combined against S. aureus as indicator strain. B and C: 
Analytical HPLC of collected fractions for alpha (B) and 
beta (C) peptides. D: Clausin semi-preparative HPLC, 
black arrow indicates clausin peak. E: Analytical HPLC 
of peak collected for clausin. 
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FIG 3 ESI-MS (direct injections) of purified lantibiotics, AmyAα (A), AmyAβ (B) and clausin (C). 
A 
B 
C 
Average Mass: 3,027.2703 Da 
Average Mass: 2,438.0427 Da 
Average Mass: 2,108.7861 Da 
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However, after this initial success further elucidation of the operon was unsuccessful. 
Therefore, the genome of B. amyloliquefaciens AD2 was sequenced. Using the partially 
identified lantibiotic operon in BLASTn searches of the assembled contigs, the entire 
lantibiotic operon of AmyA could be identified and annotated. The AmyA lantibiotic operon 
 
A 
AmyAα       -------------CA--WYDISCKLGNKGAWCTLTVECQSSCN 
HalAα       -------------CA--WYNISCRLGNKGAYCTLTVECMPSCN 
LicAα       -------TITLSTCA--I--LSKPLGNNGYLCTVTKECMPSCN 
 
LtnAα       -------------CSTNTFSLSDYWGNNGAWCTLTHECMAWCK 
PlwAα       --------K----CK--WWNISCDLGNNGHVCTLSHECQVSCN 
SacAα       -------------CSTNTFSLSDYWGNKGNWCTATHECMSWCK 
BhtA1       IGTTVVNST-----------FSIVLGNKGYICTVTVECMRNCQ 
SmbB        IGTTVVNST-----------FSIVLGNKGYICTVTVECMRNCSK 
 
AmyAα leader peptide: MKMSIIETWKNPALRMNSQVVNPAGDLMEELSDNEMEMLAGG 
 
B 
AmyAβ       ADVTPH ---TTPSSVPC---GV------F-VTAAF--CPSTKCTSSC 
HalAβ       GDVHAQ ------TTWPC---AT------VGVSVAL--CPTTKCTSQC 
LicAβ       NDVNPE TTPATTSSWTCITAGV------T-VSASL--CPTTKCTSRC 
 
LtnAβ              TTPATPAISIL---SA------Y-ISTNT--CPTTKCTRAC 
PlwAβ       GDPEAR ------SGIPC-TIGA------A-VAASIAVCPTTKCSKRCGKRKK 
SacAβ              ---GTPLALLG---GAATGVIGY-ISNQT--CPTTACTRAC 
BhtA2              ------STPAC-AIGV-VG-----ITVAVT-GISTACTSRC--INK 
SmbA               ------STPAC-AIGV-VG-----ITVAVT-GISTACTSRC--INK 
 
AmyAβ leader peptide: MSNREKAELYRNAGKRTELGFVNPVGEVSEDELRNLAGA 
FIG 4 Sequence alignment of selected two-component lantibiotics. A: Sequence alignment of AmyAα core peptide with core peptides 
of haloduracin (HalAα, WP_010896632), lichenicidin (LicAα, Q65DC4) lacticin 3147 (LtnAα, O87236), plantaricin W (PlwAα, 
AAG02567), staphylococcin C55 (SacAα, BAB78438), BHT (BhtA1, AAZ76603), Smb (SmbB, BAD72777). B: Sequence alignment 
of AmyAβ core peptide with core peptides of haloduracin (HalAβ, WP_010896631), lichenicidin (LicAβ, P86720), lacticin 3147 (LtnAβ, 
O87237), plantaricin W (PlwAβ, AAG02566), staphylococcin C55 (SacAβ, BAB78439), BHT (BhtA2, AAZ76602), Smb (SmbA, 
BAD72776). Lines above alignments indicate bridging pattern of haloduracin, solid lines: Lan/MeLan rings and dashed line: disulphide 
bridge. Red arrow indicates secondary cleavage of hexapeptide from beta peptides. Bold purple and green letters indicate Thr/Ser that 
are dehydrated. Underlined letters indicate Ser/Thr that escape dehydration. Green highlighted Ser/Thr in AmyAα and AmyAβ indicates 
residues that possibly escape dehydration. Yellow highlighted Ser are converted to D-Ala. Grey highlighted letters indicates GG/GA 
cleavage site in AmyA leader sequence. Grey highlighted Thr are converted to 2-oxobutyryl. 
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is located on both strands and covers approximately 18 kb and contains all the components 
necessary for the biosynthesis of AmyA (Fig. 5). 
Analysis of the lantibiotic operon revealed the presence of two putative LanM modification 
enzymes, AmyM1 (40% and 36% identity to HalM1 (BAB04174.1) and LicM1 
(AAU42941.1), respectively) and AmyM2 (34% and 34% identity to HalM2 (BAB04171.1) 
and LicM2 (AAU42939.1), respectively). The two peptides, corresponding to those found in 
initial experiments, were found following each of the lanM genes. The leader sequence of 
AmyAα and AmyAβ peptides had the characteristic GA (alpha) or GG (beta) cleavage sites 
also found in other two-component lantibiotics (Fig. 4). Using the molecular mass of purified 
peptides it was observed that AmyAα should undergo three dehydration reactions and AmyAβ 
eight dehydrations. There is an additional cleavage reaction to remove a hexapeptide 
(ADVTPH) after the GA cleavage site of AmyAβ (Fig. 4). When comparing AmyA to other 
two-component lantibiotics from Bacillus spp. it was hypothesized that the two C-terminal Ser 
residues of AmyAα possibly escape dehydration and that two Thr and/or Ser residues escape 
dehydration in AmyAβ (Fig. 4A and B).The two peptides with their leaders attached has a 
length of 70 and 71 amino acids for AmyAα and AmyAβ, respectively. After all cleavage 
reactions the mature peptides are composed of 28 and 26 amino acids for AmyAα and AmyAβ, 
respectively (Fig. 4A and B). The two precursor- and core-peptides have limited homology to 
each other with only 28% and 29% identity, respectively. The core-peptides of AmyA has high 
amino acid sequence identity with other two-component lantibiotics including haloduracin 
(HalA), lichenicidin (LicA) and lacticin 3147 (LtnA; Fig. 4). The identity of AmyAα to HalAα, 
LicAα and LtnAα was 82%, 63% and 71%, respectively. Similarly, AmyAβ also has high 
identity to these two-component lantibiotics, HalAβ (62%), LicAβ (50%) and LtnAβ (70%). 
Open reading frames were identified that have identity to genes found in other lantibiotic gene 
clusters, with putative roles in transport, regulation and processing (Fig. 5). AmyP is classified 
as a putative serine protease with high identity to the putative LicP (AGN34600.1) found in B. 
licheniformis 9945A (67%) and lower identity to LicP (AAU25563.1) in B. licheniformis 
DSM13 (29%). LanE’F’G’EFG were identified as putative membrane proteins, typically 
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associated with immunity. They also have low sequence identity to related proteins in B. 
licheniformis (9945A and DSM13) and B. halodurans C-125, as well as other putative 
transmembrane proteins in other Bacillus spp. AmyT was identified as a lantibiotic transporter 
B. amyloliquefaciens AD2
18667 bp
AmyA2 AmyA1AmyP AmyE'
AmyG'
AmyF'
AmyR
AmyE
AmyG
AmyF
AmyY
AmyT AmyM2 AmyM1 AmyR1AmyR2
B. amyloliquefaciens AD2 
Bacillus lichiniformis 9945A
18661 bp
LicA2-Like
LicA1-Like
LicR1 LicR2LicP LicE' LicG' LicF' LicR
LicE
LicG LicF LicY LicT LicM1 LicM2
B. licheniformis 994  
B licheniformis DSM13
15418 bp
LicA1
LicA2
LicI LicH LicE
LicY
LicR
LicX
LicP LicTLicF LicG LicM2 LicM1
B. licheniformis DSM13 
Bacillus halodurans C-125
14720 bp
LanM2 LanM1LanTHalEHalGHalF' HalG' HalE' HalF
HalA2
HalA1
B. halodurans C125 
FIG 5 Organization of gene clusters involved in the biosynthesis of Bacillus spp. two-component lantibiotics. Genes coding for transport 
proteins involved lantibiotic immunity are indicated in blue and those coding for proteins involved in regulation are indicated in black. 
Genes involved in maturation and transport of lantibiotics are indicated in purple and green, respectively. Genes coding for the precursor 
peptides are indicated in red. Genes with unknown or putative functions are indicated in white. 
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with identity to HalT (54%; BAB04170.1) and LicT (81% and 49% identity to 9945A 
(AGN34609.1) and DSM13 (AAU25564.1), respectively) and belongs to the ABC transporter 
superfamily with an integrated peptidase domain. AmyY has identity to LicY (30% and 71% 
identity for DSM13 (AAU25560.1) and 9945A (AGN34608.1), respectively) and may be 
important in biosynthesis of one or both peptides, with a possible role as a membrane protein 
(38). AmyR was identified as a putative lantibiotic transcriptional regulator with identity to 
LicR (85% and 52% identity to 9945A (AGN34604.1) and DSM13 (AAU25561.1), 
respectively). AmyR1 has identity to multiple histidine kinases with 65% identity to LicR1 
from 9945A (AGN34614.1) and 76% C-terminal identity to a signal transduction histidine 
kinase from B. sonorensis (WP_006640356.1). AmyR2 was identified as a putative accessory 
gene regulator with 54% and 55% identity to LicR2 (AGN34615) from 9945A and AgrB from 
B. sonorensis (WP_006640357.1), respectively. LicR1/R2 possibly acts as a two-component 
regulatory system. 
Antimicrobial Spectrum and Determination of MIC against S. aureus 
All peptides had activity against clinical isolates of S. aureus, beta-haemolytic streptococci and 
Listeria spp. with nisin and clausin showing activity against all enterococci tested (Table 4). 
MIC values were determined for lantibiotics against an additional four S. aureus Xen strains, 
including two methicillin-resistant S. aureus (MRSA) strains, Xen 30 and 31. Clausin had the 
lowest MIC against the respective strains, followed by nisin and AmyA (Table 5). 
TABLE 4. Inhibitory Spectra of Lantibiotics in Agar 
Well-Diffusion Assay 
Bacteria Nisin Amy Clausin 
S. aureus (5 strains) + + + 
Enterococcus  spp. (4 strains) + + + 
Enterococcus  spp. 5 + - + 
L. lactis + + + 
L. plantarum 423 + + + 
Listeria spp. (2 strains) + + + 
B. cereus + - + 
S. epidermidis + - + 
S. mutans - - - 
1BHS (3 strains) + + + 
1BHS: beta-haemolytic streptococci. + and –  indicates presence or 
absence of growth inhibition, respectively.  
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Stability Assays 
Protease Stability Assay 
Both AmyA peptides were degraded by proteinase K and both peptides were resistant to 
degradation by pepsin (Fig. 6). Only the alpha peptide was degraded by trypsin (Fig. 6).  
TABLE 5. MIC against S. aureus Xen strains 
Peptide MIC (μM) 
 Xen36 Xen31 Xen30 Xen29 
Nisin 5 7 5 5 
AmyA 5 10 10 7 
Clausin 5 5 5 5 
FIG 6 Stability of AmyA peptides after treatment with trypsin (Tryp), pepsin (Pep) or proteinase K 
(ProtK). Error bars indicate standard deviation from three replicates. 
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Heat Stability Assay 
Marked stability was observed for AmyA when heated at 100˚C for 30 min with more than half 
of the activity remaining (Fig. 7). However, a substantial loss in activity was observed when 
AmyA was treated at 121˚C (Fig. 7A). When AmyAα was treated separately at 121˚C no 
activity could be observed when added to untreated AmyAβ, however, when AmyAβ was 
treated separately at 121˚C and added to untreated AmyAα almost all antimicrobial activity 
was retained (Fig. 7B). 
Storage Stability Assay 
Stability of AmyAα and AmyAβ were observed throughout the 12 day period (at 26˚C) with 
the best stability observed for AmyAα (Fig. 8). The peak areas of AmyAα and AmyAβ on day 
12 was 85.1% and 71.5%, respectively. Nisin and clausin showed a steady decrease in peak 
area with clausin having a sharp decline after day 6. Nisin had a minimum peak area of 38.8% 
on day 12. Clausin had a peak area of 73.1% on day 6 which dropped to 17.1 and 10.4% on 
days 9 and 12, respectively. The activity results for AmyA and clausin resembled that recorded 
by HPLC, with almost all activity being retained up to day 12 for AmyA. Clausin activity 
decreased steadily up to day 6 with a substantial loos in activity observed on days 9 and 12. In 
contrast to the decrease in peak area recorded by HPLC results, nisin retained almost all of its 
activity up to day 12. 
FIG 7 Stability of AmyA peptides after heat treatment. A: AmyAα and AmyAβ combined and incubated B: AmyAα and AmyAβ incubated 
separately at 121˚C (AmyAα (121˚C) + AmyAβ (untreated) not shown). Error bars indicate standard deviation from three replicates. 
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FIG 8 Storage stability of nisin, clausin and AmyA in PBS (pH 7.4). Bars indicate the percentage area of the respective intact lantibiotic HPLC 
peaks at day n relative to day 0. Blue, green, grey and yellow bars represent nisin, clausin AmyAα and AmyAβ, respectively Lines indicate activity 
on day n represented as area of growth inhibition zone in mm2. Black squares, purple circles and red triangles represent nisin, clausin and AmyA, 
respectively. 
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Discussion 
Lantibiotics are ubiquitous in nature and have been isolated from a wide range of bacteria and 
environments. The microbial diversity in the Fynbos soil is very high, increasing the likelihood 
of finding bacteria (or fungi) that produce antimicrobial substances used for competing in this 
diverse environment (20, 21). The majority of bacteria associated with soil are Gram-positive 
bacteria, further increasing the probability of isolating a bacterium that produces antimicrobial 
substance against other Gram-positive bacteria (19, 20, 39). Soil was isolated near or under 
plants (mainly Protea repens), and these areas are known to be rich in bacterial diversity (20, 
21, 39). Therefore, it is not surprising that the two Bacillus spp. strains that were isolated both 
produced potent anti-Gram-positive peptides. These lantibiotic producing Bacillus spp. were 
isolated using traditional techniques that rely not only on the ability to culture the bacteria but 
also on the production of active antimicrobial compounds. It may be simpler to use genome 
mining to identify novel lantibiotics, and produce them heterologously (40). However, putative 
lantibiotics first have to be expressed before activity can be determined. Although heterologous 
expression for lantibiotics are becoming more efficient, their complex biosynthesis still pose 
challenges. Traditional techniques provide the advantage of quickly identifying bacteria that 
actually produce active antimicrobials. Genome mining is also limited by the availability of 
novel genomes. Therefore, unexploited areas, such as the Fynbos, may contain lantibiotic 
producing bacteria that have not been sequenced. 
Initially antimicrobial activity could be observed on solid media, however, production in liquid 
broth was either absent or delayed (B. amyloliquefaciens AD2 and Bacillus clausii AD1, 
respectively). This was not surprising as some lantibiotics (and other bacteriocins) are better 
produced on solid media (27, 41, 42). Streptin was also initially only observed on solid media, 
and only after use of a bi-phasic culture system could activity be observed in liquid broth (41). 
Using the bi-phasic system the bacteria were grown on solid media for 24 hours followed by 
addition of liquid broth and a further 24 hour incubation period. Streptin production still 
essentially relies on the production of streptin on solid media first even with the bi-phasic 
system (41). Other lantibiotics from streptococci are also only produced on solid- or semi-solid 
media (43–45). The two-component lantibiotic, haloduracin (HalA) produced by B. halodurans 
C-125 is also only produced on rich solid media (27). The production of lantibiotics, including 
AmyA, is therefore, most likely controlled by quorum sensing in a cell density dependent 
manner (46). The production of clausin by B. clausii is known to be delayed in liquid media 
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with a correlation between antimicrobial activity and percentage sporulation (26). Both AmyA 
and clausin could, however, be successfully produced and purified to homogeneity following 
consecutive solid-phase extraction methods (Fig. 2 and 3). The molecular masses of the 
purified peptides were compared against those of known bacteriocins. Peptides produced by B. 
amyloliquefaciens AD2 did not correspond to the molecular mass of any known two-
component lantibiotics. The peptide produced by B. clausii AD1 did correspond to the 
molecular mass of clausin, which is known to be produced by B. clausii (47). Unfortunately, 
there was little success in obtaining a partial lanM sequence for clausin. However, clausD could 
be amplified out of gDNA from B. clausii AD1. The clausD was identical to one found in B. 
clausii KSM-K16, in which the clausD occurs in a lantibiotic gene cluster with a structural 
gene for clausin (100% amino acid identity to known clausin). Claus D is the LanD putatively 
responsible for the oxidative decarboxylation reaction in clausin (48). From these results it is 
proposed that the antimicrobial produced by the B. clausii AD1 isolated in this study is indeed 
clausin. Using the degenerative lanM primers a partial lanM fragment could be identified in B. 
amyloliquefaciens AD2, which aided subsequent isolation of the complete lantibiotic gene 
cluster. Initial experiments using Southern- and colony-hybridization revealed a lantibiotic 
operon. However, further attempts to identify the complete operon using these methods were 
hampered by a lack of appropriate restriction enzyme sites that were required for successful 
cloning. Therefore, genome sequencing was utilized to further elucidate the lantibiotic operon. 
Using genome sequencing and the partial lantibiotic gene cluster as driver, an entire lantibiotic 
gene cluster could be identified in B. amyloliquefaciens AD2 (Fig. 5).  
Comparison of the putative AmyA operon with those of other two-component producing 
lantibiotics revealed that the AmyA operon had the most similarity to another putative operon 
found in B. licheniformis 9945A, also isolated from soil (Fig. 5). The organization of genes in 
both operons are the same, and along with the high similarity of the individual genes it suggests 
possible distribution of this gene cluster between these two species. Other lantibiotics, such as 
nisin, have been associated with transmissible elements such as transposons and conjugative 
plasmids (28, 49). 
The maturation of lantibiotics includes the dehydration of Ser and Thr followed by cyclization 
and removal of the N-terminal leader peptide. These reactions are mainly performed by three 
enzymes in two-component lantibiotics from Bacillus species (27, 38, 50). The dehydration 
and cyclization steps are performed by a bi-functional dehydratase/cyclase, LanM, with each 
peptide requiring its own LanM (29, 51). The LanM enzymes have an N-terminal dehydratase 
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and a C-terminal LanC-like cyclase domain. LanM phosphorylates Ser to Dha and Thr to Dhb 
followed by cyclization by the C-terminal cyclase, producing Lan/MeLan rings, respectively 
(1, 52, 53). The LanM proteins in B. licheniformis DSM13 and B. halodurans C-125 are 
responsible for the dehydration and cyclization of their respective peptides (27, 38, 50). 
Disruption of respective lanM genes in lichenicidin (LicA) results in loss of activity, further 
illustrating their essential role in biosynthesis (29). Furthermore, heterologously expressed 
HalM1 and HalM2 are able to successfully modify HalAα and HalAβ in vitro, respectively 
(50). The LanM enzymes of B. amyloliquefaciens AD2 show similarity to those in B. 
licheniformis C-125 and B. halodurans DSM13 and therefore are putatively involved in the 
dehydration and cyclization of the precursor peptides. Following dehydration the peptides are 
transported out of the cell by the membrane bound LanT which also has an integral protease 
domain responsible for the removal of the leader peptide (27, 38, 50). The AmyT found in the 
lantibiotic operon of B. amyloliquefaciens AD2 has amino acid identity to those found in B. 
licheniformis DSM13 and B. halodurans C-125.  
The beta peptides of some two-component lantibiotics such as haloduracin, lichenicidin, 
plantaricin W and staphylococcin C55 have an additional hexapeptide that needs to be removed 
after transport (Fig. 4B). The hexapeptide, ADVTPH, in AmyAβ also needs to be removed for 
the mature peptide to correspond to its observed molecular mass. The supernatant of B. 
halodurans C-125 contains an enzyme that is able to cleave this hexapeptide (50). A licΔP 
mutant in E. coli, expressing the entire lichenicidin gene cluster, did not have expression of 
active lichenicidin (38). Activity could be restored by processing LicAβ in situ with sterile 
supernatant from E. coli expressing only licP (38). Interestingly, a licΔT mutant still produced 
trace amounts of mature LicAβ suggesting that LicP is still able to process the peptide with the 
leader attached (38). Both AmyP and LicP also have identity to CylA (30%, 36% and 32% 
identity for AmyP, LicP DSM13 and 9945A, respectively). The CylA is an extracellular 
protease responsible for N-terminal trimming of the cytolysin peptides (54). The putative 
regulators, AmyR1/R2, only have similarity to putative LicR1/R2 in B. licheniformis 9945A. 
However, AmyR1 has identity to several signal transduction histidine kinases and AmyR2 to 
accessory gene regulators. Together these two may act as a two-component regulatory system 
similar to that found in other bacteriocins (46). The two-component regulatory system consists 
of the membrane anchored sensor kinase that recognises a peptide pheromone (potentially the 
produced lantibiotics) which then transfers the signal to a cytoplasmic response regulator that 
then regulates expression of either the peptides or other components of the gene cluster (46).  
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The molecular masses of AmyAα and Amyβ indicate post-translational dehydration of three 
and eight Ser/Thr, respectively (Fig. 3 and 4). The core-peptide sequence of AmyAα contains 
three Ser and two Thr that can possibly be dehydrated (Fig. 4A). In order to correspond to the 
observed molecular mass two of these dehydrations presumably do not take place. 
Haloduracin-α and LicAα each have a Ser (Ser26 and 30, respectively) that escapes 
dehydration (28, 38, 50). It is, therefore, proposed that Ser26 of AmyAα may similarly escape 
dehydration. Due to the identical positions of Cys, Thr and Ser (excluding Ser25) it is also 
proposed that the only possible Ser/Thr that can also escape dehydration is Ser25. Ten Ser/Thr 
can possibly be dehydrated in AmyAβ (Fig. 4B). For the molecular mass of mature AmyAβ to 
correspond to the observed mass two Ser/Thr presumably escapes dehydration. In HalAβ and 
LicAβ the N-terminal Ser/Thr are all dehydrated, with the exception of Thr10 in LicAβ (28, 
38, 50). By analogy it is, therefore, proposed that the two Ser and two Thr in the N-terminal of 
AmyAβ are dehydrated. The C-terminals of the beta peptides in two-component lantibiotics 
are highly similar, with exception of BhtA2 and SmbA (Fig. 4B). Relative to AmyAβ, the Ser 
at position 24 in HalAβ and LicAβ escape dehydration. The Thr at position 20 escapes 
dehydration in the rest of the compared two-component lantibiotics, with the exception of 
SmbA (Fig. 4B). Due to the high similarity to HalAβ and LicAβ it is proposed that Thr20 and 
Ser24 (as oppose to Ser25) in AmyAβ escapes dehydration.  
Both HalAα and LicAα have similar ring topologies, with the exception of a disulphide bridge 
in HalAα instead of a Lan ring (28, 38, 50). It is proposed that the ring structure of AmyAα is 
similar to that of haloduracin, with one Lan ring (Ser7-Cys17) and two MeLan rings (Thr18-
Cys23 and Thr20-Cys27) and possibly also a disulphide bridge between Cys1 and Cys8. As 
with other two-component lantibiotics. The mersacidin-lipid II binding motif (C-T-L/x-T/S-x-
E-C) is also present in AmyAα from position 17 to 23. The beta peptides of haloduracin and 
lichenicidin both have similar ring topologies (28, 38, 50). It is proposed that AmyAβ also has 
the same ring topology, with two Lan- (Ser4-Cys8 and Ser19-Cys22) and two MeLan-rings 
(Thr13-Cys17 and Thr23-Cys26).  
Identification and annotation of novel lantibiotic gene clusters provides further information on 
the biosynthesis of lantibiotics. Using this information lantibiotic production can be optimized, 
especially with regards to heterologous expression systems. Furthermore, utilizing optimized 
heterologous expression systems will provide the tools required for the large scale production 
of lantibiotics.  
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The two peptides of two-component lantibiotics have to act synergistically in order for them to 
have antimicrobial activity (28, 38, 50). The alpha peptide binds to lipid II which is followed 
by the binding of the beta peptide to the alpha peptide-lipid II complex. This interaction then 
results in pore formation (13, 55, 56). With single peptide lantibiotics, such as nisin, lipid II is 
also bound via a lipid II-binding motif. After this binding they induce pore formation and 
inhibit cell wall biosynthesis (57–61). Lantibiotics, including two-component lantibiotics, have 
activity against a range of Gram-positive bacteria including antibiotic-resistant strains such as 
MRSA and vancomycin-resistant enterococci (VRE) (13, 29, 62). Similar to other two-
component lantibiotics AmyA has activity against clinical isolates of S. aureus and enterococci. 
Activity was, however, not observed against some of the bacteria tested, including 
Staphylococcus epidermidis and one of the enterococci isolates (Table 4). The highest MIC 
values against S. aureus Xen strains were observed with AmyA, with a twofold higher MIC 
against MRSA strains compared to clausin and nisin which were similar (Table 5). Lacticin 
3147 also has higher MIC values against antibiotic-resistant S. aureus when compared to nisin, 
but has lower MIC values against Enterococcus faecium (62). Haloduracin on the other hand 
has mixed results with higher MIC values against some strains but with significantly lower 
MIC values against others, including VRE (13).  
The stability of antimicrobials under various conditions is important if they are to be applied 
in either the medical or food industry. Resistance to proteolytic cleavage is an important trait, 
and lantibiotics such as nisin and epidermin show limited stability compared to the more stable 
globular peptides such as mersacidin. The globular nature of AmyAα was thought to provide 
protection from proteolytic cleavage, but it is only resistant to pepsin treatment. Resistance 
against trypsin was at least observed for AmyAβ (Fig. 6). The trypsin cleavage site of AmyAα 
is in the middle of the first Lan ring which should provide protection from cleavage. 
Lichenicidin-α is resistant to trypsin cleavage although it has a trypsin cleavage site in-between 
rings C and D which should provide sufficient protection from cleavage (28, 29). The first Lan 
ring in AmyAα is, however, made up of nine amino acids, making it a large ring which may 
not provide sufficient shielding from proteolytic cleavage. This may also explain the resistance 
observed in AmyAβ, as its trypsin site is in its much smaller C ring. The stability of AmyAβ 
after 121˚C treatment is also interesting and may imply that the peptide could be fragmented 
(Fig. 7B). The C-terminal of the beta peptides of two-component lantibiotics are important for 
interaction with the alpha peptide (38, 50, 63). Therefore, it may be possible for a truncated 
beta peptide to still be able to bind to the AmyAα-lipid II complex, resulting in activity. 
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Furthermore, AmyAβ digested with pepsin still results in activity when combined with 
untreated AmyAα. Pepsin possibly cleaves AmyAβ at Phe11, which is not protected by a 
Lan/MeLan ring, resulting in a truncated C-terminal with rings B-D intact. 
Nisin, has shown promise for use in the medical field, however, its instability and low solubility 
at neutral pH may hamper its use. Nisin is more stable at lower pH with increasing pH also 
increasing instability (64). Haloduracin-α remains stable for 36 days with more than 90% intact 
peptide. The beta peptide is less stable with only slightly more than 30% intact peptide after 36 
days (13). Up to day 12 the stability of AmyAα and AmyAβ are consistent with previous 
reports for HalA (13). Similar to previous reports, a decrease in HPLC peak area corrosponding 
to intact peptide could also be observed for nisin in this study (Fig. 8) (13). Nisin and AmyA 
stored for 12 days did not undergo drastic activity loss. Similarly nisin was previously found 
to only start significantly losing activity after 18 days, with HalA being active for longer (13). 
There was a sudden drop in the peak area of clausin on days 9 and 12. This drop was also 
observed in the antimicrobial activity. Clausin is an epidermin-like lantibiotic with sequence 
similarities to nisin. The instability of nisin at neutral pH is believed to be as a result of the 
unstable nature of Dha5 (64–66). Clausin also has a Dha at position 5 which may explain its 
instability at neutral pH. Due to limited amount of peptide stability could only be recorded for 
up to 12 days without replicates. Therefore, further investigation regarding the stability of 
AmyA is required. 
In this study a novel two-component lantibiotic, amyloliquecidin, was characterized from a 
Bacillus amyloliquefaciens strain isolated from Fynbos soil. The operon putatively involved in 
the biosynthesis of amyloliquecidin was sequenced and found to have the necessary 
biosynthetic machinery to successfully produce and export the lantibiotic. Amyloliquecidin 
had similar properties to its other two-component counterparts, with anti-staphylococcal and -
enterococcal activity, including activity against MRSA. The heat stability and pepsin 
degradation of AmyAβ provided interesting results, leading to the hypothesis of a possible 
truncated beta peptide that is sufficient for synergistic activity. This hypothesis does require 
further investigation. Furthermore, stability of amyloliquecidin was found to be comparable to 
that of haloduracin and superior to nisin and clausin. This study provides enough evidence for 
the continued investigation into the clinical application of amyloliquecidin, especially in the 
treatment or prevention of S. aureus and enterococci infections. 
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Chapter 4 
 Evaluation of the in vivo Efficacy of 
Lantibiotics in the Treatment of S. 
aureus-induced Skin infections in 
Mice 
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Chapter Summary 
The majority of skin and soft tissue infections (SSTIs) are caused by Staphylococcus aureus. 
Lantibiotics are known to be active against S. aureus, including antibiotic-resistant strains. 
Three lantibiotics namely, nisin, clausin and amyloliquecidin, were evaluated for their 
effectiveness in treating skin infections caused by S. aureus in a murine skin infection model. 
Lantibiotic treatments significantly reduced S. aureus Xen 36 bioluminescence and viable 
bacterial cell numbers. Lantibiotics were just as effective as the commercially available SSTI 
treatment, Bactroban (mupirocin). Furthermore, lantibiotics did not have a negative influence 
on wound closure rates of infected and non-infected wounds, compared to Bactroban- and 
control-treated wounds. These results further illustrate the potential of lantibiotics as treatment 
for skin infections caused by S. aureus. 
Introduction 
Skin acts as a protective barrier to the host and is in constant contact with the outside 
environment. Injury to this critical barrier provides an ideal opportunity for microbial invasion, 
resulting in infection. Skin and soft tissue infections (SSTIs) are the most common types of 
infection and have increased dramatically over the past few years, along with increased use of 
antibiotics for treatment of SSTIs (1, 2). Antimicrobial treatment options are becoming limited 
and alternatives to traditional antibiotics are needed. Bactroban, which is the recommended 
treatment for SSTIs caused by S. aureus, is ineffective in the treatment of some SSTIs caused 
by methicillin-resistant S. aureus (MRSA) (3, 4). Resistance has also emerged for vancomycin 
which is considered the “drug of last resort” for some severe MRSA infections (5, 6). 
Lantibiotics act by binding to bacterial cell wall precursors (i.e. lipid II), resulting in cessation 
of cell wall biosynthesis and cellular leakage by pore formation (7, 8). Certain lantibiotics have 
activity against human pathogens, including antibiotic-resistant strains (9–12). Studies have 
reported on the effectiveness of lantibiotics in the treatment/prevention of infections caused by 
S. aureus in vivo (12–16). Lantibiotics can thus serve as feasible alternatives to antibiotics for 
the treatment of SSTIs, specifically those caused by S. aureus. 
Sufficient wound healing is important for successful recovery from infection. However, this is 
a complex process that requires the completion of highly programmed phases (17–19). These 
phases are regulated by the immune system, which can be negatively influenced by a variety 
of factors including stress, diabetes, obesity and nutrition (18). In addition to direct 
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antimicrobial treatment, antimicrobial peptides also play an important role in modulation of 
the host immune system (18, 20–23). A group of cationic antimicrobial peptides with immune 
modulating properties is penol soluble modulins (PSMs). Staphylococci found on the skin, as 
commensals or pathogens, are able to secrete several compounds that are capable of effecting 
the innate immune system, including PSMs (18, 22, 23). Secreted PSMs can either play a role 
in immune defence or pathogenesis, as demonstrated by the ability of pathogenic S. aureus 
PSMs to lure neutrophils and then induce lysis of the infiltrating neutrophils by a subsequently 
secreting a higher dose of PSMs (22). On the other hand, PSMs from commensal S. epidermidis 
do not induce lysis, but enhance neutrophil bacterial-killing capabilities (21). Lantibiotics are 
also able to modulate the innate immune system. Nisin has immunomodulatory properties 
similar to natural host defence peptides, and it is speculated that this trait is shared by all 
lantibiotics (20). Nisin is able to induce a potent enough immune response to protect against 
Gram-negative bacterial infections, against which it does not have direct antimicrobial activity 
(20). Nisin eluting nanofibers also accelerates wound healing (13). It is, therefore, 
hypothesized, based on preliminary data that lantibiotics may also aid in the wound healing 
process (13). 
Bioluminescent bacteria are used to monitor the real-time progression of infection in vivo (3, 
13, 14, 24). Bacteria need to express all the genes in the luxABCDE operon in order to emit a 
bioluminescent signal (25). Luciferase is encoded by luxAB and catalyses the oxidation reaction 
of its aldehyde substrate (encoded by luxCDE) and FMNH2 to generate a bioluminescent signal 
(25, 26). This oxidation reaction requires adenosine-5`-tri-phosphate and oxygen. Therefore 
efficient bioluminescence is only observed in metabolically active cells (27). Bioluminescent 
bacterial strains are monitored using an in vivo imaging system (IVIS) that detects the 
bioluminescence. The IVIS thus provides a non-invasive way of monitoring the progression of 
infection and reduces the amount of animals needed to make significant conclusions (3, 13, 14, 
24) 
The current study aimed to investigate the effectiveness of lantibiotics in the treatment of full 
thickness wound infections caused by S. aureus and also compare them to a commercial anti-
bacterial ointment (Bactroban). Progression of infection was monitored using the IVIS and the 
effect on wound closure rates was also investigated for infected and non-infected wounds.  
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Materials and Methods 
Materials 
All bacterial growth media were from Biolab Diagnostics (South Africa), unless otherwise 
stated. Poly vinyl alcohol (PVA, 87-89% hydrolysed, Mw 146000-186000), trifluoroacetic acid 
(TFA) and XAD-16 beads were from Sigma-Aldrich (Germany). Acetonitrile and isopropanol 
used for peptide purification were from Merck-Millipore (USA). SepPak C18 columns were 
from Waters (USA). Nisaplin was from Danisco (Denmark). The bicinchoninic acid (BCA) 
protein assay was from Pierce Biotechnology (USA). Gauze and micropore type from 
AlphaPharm (South Africa). Punch biopsies were supplied by Stellenbosch Medical Supplies 
(South Africa). Isoflurane was from Safe Saline Pharmaceuticals (Isofor; South Africa). 
Buprenorphine was from Scheiring-Plough Ltd. (Tamgesic; South Africa). 
Production and Preparation of Lantibiotics for Use in Mice 
Lantibiotics (amyloliquecidin (AmyA), nisin and clausin) were produced as described 
previously (chapter 3). Briefly, Bacillus clausii AD1 was cultured in Mueller Hinton (Sigma-
Aldrich) broth for 8-10 days at 30˚C. The cell-free supernatant was obtained by centrifugation 
(10,000 × g, 25 min at 4˚C) and combined with activated XAD-16 beads. Clausin was eluted 
from XAD-16 beads as previously described. Bacillus amyloliquefaciens AD2 cultured in 
Luria broth was mixed with sterile activated XAD-16 beads. This suspension was spread onto 
brain heart infusion (BHI) agar (2% wt/vol agar) and incubated at 37˚C for 96 h. Beads were 
removed from agar using double distilled water. Elution of AmyA from XAD-16 beads were 
performed as previously described. Clausin and AmyA XAD-16 purified crude extracts were 
loaded onto SepPak C18 columns and eluted using an acetonitrile gradient as previously 
described. Active fractions were frozen at -80˚C, freeze-dried and stored at -20˚C. Nisin was 
obtained from the commercial nisin preparation, nisaplin. Nisaplin was dissolved in 25% 
acetonitrile containing TFA (vol/vol/vol) and loaded onto a SepPak C18 column. Nisin was 
eluted using an acetonitrile gradient as previously described. Active fractions were frozen at -
80˚, freeze-dried and stored at -20˚C. Peptides were further purified to homogeneity using high-
performance liquid chromatography (HPLC) as previously described. Lantibiotic purity was 
confirmed by analytical HPLC and electrospray-ionization mass spectrometry. Activity was 
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confirmed by agar-well diffusion assays as previously described, using S. aureus Xen 36 as 
indicator strain. 
Purified lantibiotics were freeze-dried, reconstituted in phosphate buffered saline (PBS, pH 
7.4) and peptide concentrations were determined using the BCA protein assay as per 
manufacturer’s instructions. Lantibiotics were prepared to a final concentration of 250 μM in 
PBS (pH7.4) containing 2.5% PVA (wt/vol) and stored at 4˚C throughout each respective trial. 
In the case of AmyA the alpha and beta peptides were combined in a 1:1 molar ratio. 
Lantibiotics were freshly prepared for each trial. 
Animals Used 
Approval to conduct research on animals was granted by the ethics committee of Stellenbosch 
University (SU-ACUM14-00009). Adult female nude mice (weighing 20-30g) were used for 
infection studies and housed in separate cages under controlled environmental conditions (12 
hour light/dark cycles, 20-22˚C). Animals were fed sterile standard rodent feed and water. 
Wound closure was investigated in male nude mice housed under similar conditions. Wound 
infection studies were conducted in three independent trials and wound closure studies of non-
infected wounds were conducted in two independent trials.  
Full thickness Wound Generation and Infection with S. aureus Xen 36 
A full thickness wound model similar to the one described by Heunis et al. (13) was used in 
this study. Mice were anesthetized with 1.5-2% (vol/vol) isoflurane in O2, and full thickness 
excisional wounds were generated using a 6 mm biopsy punch on the dorsal surface of each 
mouse. Mice received buprenorphine (~0.03 mg/kg) subcutaneously as an analgesic, directly 
after wound generation and for the first 3 days post-wound generation. A single S. aureus Xen 
36 colony was used to inoculate BHI broth supplemented with kanamycin (200 μg/ml) and was 
incubated overnight at 37˚C. The overnight culture was sub-inoculated into fresh media and 
grown to an OD600 of 1.0-1.2 (~2 × 10
8 CFU/ml). Cell counts were verified by serial dilution 
and plating onto BHI agar supplemented with kanamycin (200 μg/ml). Bacteria were harvested 
(10,000 × g, 2 min) and washed twice with sterile PBS (pH 7.4) and resuspended in sterile PBS 
(pH 7.4) to the original OD600. Wounds were infected with 10 μl S. aureus Xen 36 (~2 × 106 
CFU/wound) directly after wound generation. Wounds were left for 5 min to dry after which 
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they were covered with parafilm and gauze. Dressings were kept in place by using micropore 
surgical tape. 
Treatment of and Evaluation of S. aureus Xen 36 Wound Infections 
Mice (n=9 in each group) were left for 3 h post-wound generation before treatment 
commenced. For treatment of wounds and bioluminescent imaging mice were anesthetized as 
previously described. Wounds were treated with 12.5 μl of a 250 μM lantibiotic solution. The 
lantibiotic solution was dispensed directly onto wounds using a pipette, and spread evenly over 
the wound surface. The same volume of Bactroban was also dispensed onto wounds. Control 
mice wounds were treated with 2.5% PVA in PBS (pH 7.4) (CPVA). Mice were left for 5 min 
after which bioluminescent images were recorded using an in vivo imaging system (IVIS 100; 
Caliper life sciences, Perkin-Elmer). The wounds were subsequently closed by covering with 
gauze which was held in place using micropore surgical tape. Infection trials were conducted 
for 7 days. Mice were treated on days 0, 2, 4 and 6, using the same procedure as described 
previously. Before bioluminescence was recorded wounds were wetted with 50 μl sterile PBS 
(pH7.4). Bioluminescent images were recorded daily under anaesthesia and images were 
analysed using the Living Image software (v3.0; Caliper life sciences, Perkin-Elmer). 
Bioluminescence was quantified by measuring the photons in a region of interest (ROI; 25 × 
25 pixels), and was expressed as the log10 of photons per second per cm
2 per steradian (ps-1cm-
2sr-1). On day 7, mice were euthanized by pentabarbitone overdose (Euthapent, Kyron 
Laboratories). Wounds were subsequently excised and homogenised in sterile PBS (pH7.4). 
The homogenate was serially diluted in sterile saline and plated onto BHI agar supplemented 
with kanamycin (200 μg/ml). Plates were incubated for 24 h at 37˚C and colonies were 
enumerated to determine CFU/wound.  
Digital images were taken of wounds (n=6 per group) to determine the effect of treatment on 
wound closure. Digital photographs were analysed using the software program ImageJ (version 
1.48). Wound size on day n was expressed as a percentage relative to the wound size on day 0 
(DN/D0 × 100; where DN is the wound size on day n, and D0 is the wound size on day 0).  
Effect of Lantibiotics on the Wound Closure of Non-Infected Wounds 
Full thickness wounds were made as described previously and mice (n=5 per group) were 
treated with either CPVA, nisin, clausin, AmyA or Bactroban as previously described. Digital 
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images of wounds were taken, and wound closure was determined as previously described. 
Mice were monitored for 7 days after which they were euthanized by pentabarbitone overdose. 
Statistical Analysis 
All data were analysed using GraphPad Prism (version 6.05) and statistical differences between 
groups were determined using two-way analysis of variance (ANOVA) and unpaired t-test. 
Statistical analysis used are indicated for each data set. A statistical difference was considered 
when p < 0.05. Error is calculated as standard error of mean (SEM). 
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Results 
Efficacy of Lantibiotics in the Treatment of S. aureus Xen 36 Wound 
Infections 
All antimicrobial treatments reduced the bioluminescence signal emitted from S. aureus Xen 
36 throughout the study period and served as an indication of a reduction in bacterial load (Fig. 
1 and 2). On day 0 Bactroban and nisin treatments significantly reduced bioluminescence 
compared to wounds treated with the PVA control (CPVA), clausin and AmyA. From day 1 
onwards all treatments reduced bioluminescence significantly compared to CPVA-treated 
wounds. Bactroban-treated wounds had significantly lower bioluminescence on days 1 and 4, 
compared to the lantibiotic treatments (Fig. 2). On days 2, 3 and 7, Bactroban-treated wounds 
only had significantly lower bioluminescence compared to clausin-treated wounds (Fig. 2). 
Stable bioluminescence was observed for CPVA-treated wounds up to day 6, with a slight 
decline on day 7. 
All of the antimicrobial treatments significantly reduced the viable bacterial cells that could be 
enumerated from excised wounds, compared to CPVA-treated wounds, with an average 3.1 (± 
0.2) log drop (Fig. 3). Clausin-, AmyA-, Bactroban- and nisin-treated wounds had individual 
log drops of 3.03, 3.33, 3.44 and 2.56, respectively, compared to CPVA-treated wounds. There 
were no significant differences in CFU/wound between wounds treated with lantibiotics or 
Bactroban. Highest cell counts were observed with CPVA-treated wounds with 5.1 × 107 
CFU/wound and a mean of 1.44 × 107 CFU/wound. Clausin and Bactroban treatment resulted 
in two wounds from which <20 CFU/wound could be detected, respectively. Nisin treatment 
resulted in one wound from which <10 CFU/wound could be detected. Less than 20 
CFU/wound could be detected from three wounds treated with AmyA. Highest cell counts for 
antimicrobial treatments were recorded for nisin- and clausin-treated wounds, with 6.6 × 105 
(mean 1.58 × 105) and 7 × 105 (mean 1.57 × 105) CFU/wound, respectively. 
Wound closure rates of infected wounds were minimally affected by all treatments, with a 
gradual decrease in wound size over the 7 day study period. There were, however, some 
differences recorded on selected days (Fig. 4). There were statistical differences between 
Bactroban-treated wounds (107.9 ±4.13%) and that of CPVA- (94.6 ±4.84%) and AmyA-
treated wounds (96 ±2.14%) on day 1. Bactroban-treated wounds were also significantly  
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FIG 1 Images to track bioluminescence, used as indication of bacterial load, were taken over a 7 day period using the IVIS and 
are represented on a colour scale overlaid on top of a greyscale image. A: CPVA-; B: Bactroban-; C: Nisin-; D: Clausin- and E: 
AmyA-treated groups. Scale bar represents photons (ps-1cm-2sr-1) for each day. 
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larger compared to clausin-treated wounds on day 5 (69.6 ±8.00% and 52.7 ±2.69%, 
respectively). Significant differences were observed between the CPVA-treated wounds (45.2 
±4.59%) and that of clausin- (33.3 ± 1.59%) and AmyA-treated wounds (30.7 ±0.71%) on day 
7. Bactroban-treated wounds (47.3 ±6.93) were found to be significantly larger compared to 
FIG 2 Efficacy of treatments were determined by monitoring bioluminescence of wounds infected with S. aureus 
Xen 36 over a 7 day period. Letters and lines above bars indicate which groups have statistical differences with each 
other. Statistical analysis was determined by two-way ANOVA. 
FIG 3 Efficacy of treatments to reduce viable S. aureus Xen 36 cells was determined by plating homogonized 
excised wounds onto BHI agar and determining CFU/wound. CFU/wound is represented on a log10 scale. Lines 
through and above data points represents the mean and statistical differences between groups, respectively. 
Statistical analysis was conducted using unpaired t-test. 
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clausin- and AmyA-treated wounds on day 7 (30.7 ±0.71% and 33.3 ± 1.59%, respectively). 
Although not significant, nisin-treated (36.1% ±4.74) wounds were smaller compared to 
CPVA- (45.2% ±4.59%) and Bactroban-treated (47.3% ±6.93%) wounds on day 7. 
Effect of Lantibiotic Treatment on Wound Closure of Non-Infected Wounds 
Wound size steadily decreased over the 7 day study period, with Bactroban-, AmyA- and nisin-
treated wounds initially slightly increasing in size (Fig. 5). On day 7 Bactroban-treated wounds 
(64.3 ±3.04%) were significantly larger than nisin- (44.8 ±3.01%), clausin- (39.9 ±2.20%), 
AmyA- (44.5 ±4.78%) and CPVA-treated wounds (51.3 ±3.53%). Clausin-treated wounds 
(39.9 ±2.20%) were significantly smaller than CPVA-treated wounds (51.3 ±3.53%) on day 7. 
Although not significant nisin- (44.8% ±3.01%) and AmyA-treated wounds (44.5 ±4.78%) 
were smaller that CPVA treated wounds on day 7 (51.3 ±3.53%). 
FIG 4 The wound sizes of wounds infected with S. aureus Xen 36 were measured for 7 days. Wound sizes on day n are expressed as 
a percentage relative to the wound size on day 0. Letters and lines above bars indicate which groups have statistical differences as 
determined by two-way ANOVA. The grey arrow indicates statistical difference between bactroban and AmyA-treated wounds, 
determined by unpaired t-test. The red arrow indicates statistical difference between CPVA- and clausin-treated wounds, determined 
by unpaired t-test. 
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FIG 5 The wound sizes of non-infected wounds were measured for 7 days. Wound sizes on day n are expressed as a percentage relative 
to the wound size on day 0. Letters and lines above bars indicate which groups have statistical differences as determined by two-way 
ANOVA. The grey arrow indicates statistical difference between Bactroban- and CPVA-treated wounds, determined by unpaired t-
test. The red arrow indicates statistical difference between CPVA- and clausin-treated wounds, determined by unpaired t-test. 
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Discussion 
Skin is the largest organ in the human body and protects the host from the outside environment, 
as well as from infections (28). The microbial community residing on the skin is in symbiosis 
with the host. However, the same commensal bacteria, along with other non-commensal 
bacteria, can cause severe skin infections (28). Disruption of the skin can result in dysbiosis 
and microbial invasion which in turn can lead to infection and delays in wound healing. 
Therefore, proper treatment and prevention of skin infections is important not only for 
resolution of infection but also to aid in the healing process. In this study three lantibiotics were 
evaluated for their effectiveness in the treatment of skin infections caused by S. aureus. Their 
effect on wound closure rates of infected and non-infected wounds was also evaluated. 
The mixture of lantibiotics with 2.5% PVA in PBS (pH 7.4) created a more viscous solution 
that could easily be applied to wounds. Delivery vehicles composed of PVA have been used as 
for several pharmaceutical drugs as well as in topical formulations (29). Nisin has also been 
actively released from PDLLA (poly D, L-lactide) and PVA nanofibers were used to control 
infections caused by S. aureus (30). 
Bioluminescence has been used in several studies to monitor in vivo infections in real-time (3, 
13, 14, 24). S. aureus Xen 36 bioluminescence was stable throughout the study, although 
bioluminescence is known to decreases over time. This decrease is most likely due to a decrease 
in the metabolic activity of the bacteria or loss of the luxABCDE operon if carried on a plasmid 
(3). Bioluminescent S. aureus has been successfully used in skin infection models with stable 
bioluminescence occurring for up to 7 days (3, 13). Four treatments, on days 0, 2, 4 and 6, with 
the respective antimicrobials were sufficient to control S. aureus spread, as determined by 
bioluminescence (Fig. 1 and 2). Nisin and Bactroban treatment had an immediate effect (within 
5 minutes) on bacterial bioluminescence (Fig. 2). Similar results were reported for nisin-eluting 
nanofibers (NEF), with bioluminescence reported to be significantly less on day zero (13). 
Nisin and the active ingredient in Bactroban, mupirocin, have two different modes of action. 
Nisin inhibits cell wall biosynthesis by binding to lipid II thereby disrupting peptidoglycan 
synthesis (31). Once bound to lipid II it is also able to form pores resulting in cellular leakage 
(31). Mupirocin inhibits the isoleucyl-tRNA synthetase and has bacteriostatic and bactericidal 
activity (32–34). Nisin results in rapid cell death while mupirocin has initial bacteriostatic 
effects followed by bactericidal effects over 24 hours (14, 32, 35). The rapid drop in 
bioluminescence observed with nisin could be due to the rapid bacteriolytic effect of nisin. The 
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bioluminescent signal emitted by S. aureus Xen 36 requires the bacteria to be metabolically 
active. The decrease observed with mupirocin treatment could, therefore, be due to 
bacteriostatic effects resulting in S. aureus Xen 36 not being able to efficiently produce 
bioluminescent signal. Mupirocin-resistant S. aureus do not have this initial drop in 
bioluminescence (3). Unlike Bactroban and nisin treatment, clausin and AmyA treatment did 
not show an initial drop in bioluminescence (Fig. 2). Clausin is an epidermin-like lantibiotic, 
which are relatively short compared to the nisin-like lantibiotics. Although both epidermin- 
and nisin-like lantibiotics bind to lipid II, pore formation by epidermin-like lantibiotics is 
affected by membrane thickness (35). Nisin also results in more rapid leakage than epidermin 
and gallidermin (epidermin-like lantibiotic) in sensitive strains (35). These observations may 
explain the delayed reduction in bioluminescence observed in clausin-treated groups. Two-
component lantibiotics require two peptides to act synergistically to induce cellular leakage. 
Pre-incubation of sensitive cells with Haloduracin-α (lipid II binding) followed by 
Haloduracin-β (responsible for pore formation) results in a more rapid efflux of potassium, 
compared to simultaneous addition of the two peptides (10). In an in vivo situation it can be 
expected that this reaction may be delayed and could, therefore, account for AmyA not being 
able to rapidly reduced bioluminescence. Bioluminescence for all the antimicrobial treatments 
remained significantly less than that of the control (CPVA-treated), with Bactroban having the 
lowest bioluminescence. This is expected, as Bactroban is a commercially available treatment 
specifically recommended for SSTIs caused by S. aureus (4). However, the lantibiotics 
compared well with Bactroban, still being able to significantly reduce bioluminescence 
compared to CPVA-treated wounds (Fig. 1 and 2). Successful treatment of skin and 
subcutaneous infections caused by S. aureus Xen 36 have been reported for NEF as well as 
nisin-loaded bone cement, respectively (13, 14). In these studies bioluminescence also declined 
immediately after treatment. Nisin was, however, ineffective in the treatment of S. aureus 
subcutaneous and peritoneal cavity infections (36, 37). The nisin used in these studies were 
crude samples which could have resulted in inefficient local concentrations of peptide. In the 
current study lantibiotics were purified to homogeneity and could be used at known 
concentrations. The results in the current study, therefore, illustrate the importance of using 
purified antimicrobials in order to accurately determine antimicrobial activity. 
Although there is a correlation between bioluminescence and bacterial burden it is important 
to verify that low bioluminescence is associated with a reduction in viable bacterial cells (3). 
Bactroban and lantibiotic treatment resulted in decreased viable cells on excised wounds, 
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confirming that reduced bioluminescence was associated with a reduction in viable bacteria 
(Fig. 3). Bactroban and lantibiotic treatments performed equally well with regards to reduction 
in viable bacteria, and are consistent with other reports for treatments of skin infections caused 
by S. aureus (13, 38–40). It is interesting to note that although AmyA has higher minimum 
inhibitory concetrations against S. aureus in vitro, compared to clausin and nisin, it is just as 
effective as the other lantibiotics in vivo. Increasing the contact time with the lantibiotics could 
increase their effectiveness. This was observed with NEF, which were able to reduce S. aureus 
to 4.3 × 102 CFU/wound compared to the control with 2.2 × 107 CFU/wound (13). The NEF 
are in constant contact with the wound releasing active peptide over time. In addition to contact 
time, the formulation used to deliver the lantibiotics can also play a role in their effectiveness. 
Mupirocin treatment of S. aureus and Streptococcus pyogenes was affected by the formulation 
used. A 2% mupirocin oil-water emulsion is more effective in reducing bacterial counts than a 
2% mupirocin poly ethylene glycol formulation (38). The importance of drug delivery vehicles 
on bacterial burden is also reported for ointment formulations of mupirocin and retapamulin 
(3).  
Decreasing the spread of infection should be accompanied by efficient wound healing. Topical 
treatments satisfying both these requirements would have significant clinical relevance (3). 
Wound closure rates of infected wounds were similar for all treatments including the control. 
The only differences were on days 1, 5 and 7 (Fig.4). Subcutaneous treatment with 
vancomycin, daptomycin and linezolid resulted in smaller lesions on day 7, and in the case of 
topical treatment, on days 5 and 7 (24). Retapamulin is also effective in wound closure when 
treating MRSA infections, with significantly smaller lesions occurring from day 1, compared 
to Bactroban and controls (3). From the results reported in this study it is evident that 
lantibiotics, in addition to controlling infection, do not negatively influence wound healing. 
Although Bactroban is able to treat infection it delays wound closure in infected and non-
infected wounds, compared to lantibiotic- and CPVA-treated wounds. Similar delayed closure 
rates following mupirocin treatments have been reported in other comparative studies (41, 42). 
Non-infected and infected wounds treated with CPVA had similar closure rates, suggesting 
that in the current model infection does not dramatically influence wound closure (Fig. 4 and 
5). Similar results were reported by Kim et al. (43) while studying the dynamics of neutrophil 
infiltration during wound healing. Mice were either intraperitoneally injected with granulocyte 
macrophage-colony stimulating factor (GM-CSF) /saline (wounds uninfected) or wounds were 
infected with S. aureus. Wound closure rates were similar for all groups, despite infection with 
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S. aureus and treatment with GM-CSF resulting in increased neutrophil recruitment, compared 
to the saline injected controls (43). Lantibiotic treatment of infected and non-infected wounds 
does, however, appear to aid in wound closure (Fig. 4 and 5). Similarly, when non-infected 
wounds were treated with either NEF or control nanofibers wound closure rates were 
significantly increased, compared to a gauze-covered (untreated) control wounds. There were, 
however, no differences in wound closure rates between the control- and NEF-treated wounds 
(13). Additionally, NEF treated wounds had signs of connective tissue formation, re-
epithelialisation, keratinization and no neutrophil infiltration after 7 days (13). Additionally, 
lantibiotics also affect chemokines involved in the wound healing process. Gallidermin and 
nisin affect human peripheral blood mononuclear cells, with nisin causing stronger induction 
of interleukin-8 (IL-8), growth related oncogene-α (Gro-α) and monocyte chemoattractant 
protein-1 (MCP1; 20). Amongst other roles, IL-8 mediates neutrophil recruitment and is 
expressed by macrophages and neutrophils, and Gro-α stimulates the movement of neutrophils. 
MCP-1 participates in different stages of mast cell, monocyte and lymphocyte attraction during 
wound healing, and can also contribute to epithelial cell movement during angiogenesis (19). 
Lantibiotics can, therefore, indirectly affect wound healing by stimulating these immune cells. 
Although there was a significant difference between clausin- and CPVA-treated non-infected 
wounds, there was no difference between clausin and the other lantibiotic treatments. This 
suggests that their possible differences in immune modulation do not affect their wound healing 
capabilities. 
There is a high incidence of MRSA associated infections, with emergence of other resistant 
bacteria also on the increase (44, 45). Furthermore, the ineffectiveness of recommended 
treatments such as Bactroban against these strains warrants the development of new treatments 
using alternative antimicrobials (3, 4). Lantibiotics are known for their activity against 
antibiotic-resistant bacteria, including those involved in skin infections (9, 11, 12, 16, 46). 
Additionally, using delivery systems such as nanofibers, it is possible to provide a solution to 
solubility concerns by controlling the release of lantibiotics (13). Therefore, lantibiotics have 
great potential as topical treatments for infections caused by S. aureus, with several lantibiotic 
treatments already under development for the treatment of infections by Gram-positive bacteria 
(Novacta Biosystems and Oragenics).  
In conclusion, the current study comparatively evaluated the efficacy of three lantibiotics to 
treat skin infections caused by S. aureus using a full-thickness wound model in mice. 
Lantibiotics are just as effective as Bactroban in reducing bacterial load, as monitored by 
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bioluminescence. A reduction in viable cells from excised wounds confirmed this. Despite 
having a higher minimum inhibitory concentration in vitro the two-component lantibiotic, 
AmyA, is just as effective as the other lantibiotics in vivo. All the tested lantibiotics are superior 
to Bactroban with respect to wound closure. This is the first comparative in vivo study 
investigating the efficacy of a two-component lantibiotic in the treatment of skin infections. 
Additionally, it is the first in vivo study testing the newly isolated AmyA. The anti-bacterial 
and wound healing properties of the lantibiotics used in this study further illustrate the potential 
of their use in treatment of skin infections. 
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Chapter 5 
 General Discussion and Conclusions 
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General Discussion 
Antibiotic resistance is currently one of the most important problems faced by the medical 
industry (1–8). The wide spread use of antibiotics in the medical and agricultural industries 
further exacerbates this problem (3, 9). Bacteria can become resistant to antibiotics in a number 
of ways, including horizontal gene transfer of resistance elements (4). Horizontal gene transfer 
of antibiotic resistance elements have not only been reported between species but also across 
genera (10). In contrast to the antibiotic resistance crisis, discovery and development of new 
antibiotics have decreased over the past few decades (4, 11). Investigation into novel 
antimicrobials effective against drug-resistant pathogens is therefore essential.  
Lantibiotics have long been seen as alternatives to traditional antibiotics and have been isolated 
from bacteria originating from diverse backgrounds including soil, marine life, food products 
and human pathogens (12–18). In this study the Fynbos in the Western Cape was chosen as a 
sampling site to screen for possible lantibiotic producing bacteria. The Fynbos niche was 
chosen due the diversity of soil bacteria, especially in the rhizosphere of plants. (19, 20). It is 
an unexploited niche and information regarding antimicrobial producing bacteria is scant. It 
was predicted that high bacterial diversity would increase the probability of isolating novel 
antimicrobial producing bacteria. Two antimicrobial producing bacteria, namely Bacillus 
clausii AD1 and Bacillus amyloliquefaciens AD2 were isolated from Fynbos soil in this study. 
Bacillus amyloliquefaciens AD2 was identified using its gyraseA sequence, coding for the 
DNA gyrase subunit A (21). The gyraseA sequence from B. amyloliquefaciens AD2 has 92% 
nucleotide- and 99% amino acid-identity to other B. amyloliquefaciens strains, and was 
characterized as a novel strain. Some lantibiotics, such as streptin and haloduracin, are known 
to only be produced on rich solid media (13, 15). Similar observations were made for B. 
amyloliquefaciens AD2. Antimicrobial activity could only be observed from the compound 
produced by B. amyloliquefaciens AD2 after purified peak fractions from HPLC were 
combined. The molecular masses of these peaks did not correspond to any of the known masses 
of the two-component lantibiotics, indicating that a novel two-component lantibiotic had been 
isolated. There are two lantibiotics currently known to be produced by B. amyloliquefaciens. 
The most well know is the class II lantibiotic mersacidin, which was only recently shown to be 
produced by this strain (22). The other is the recently characterized class II mersacidin-like 
lantibiotic, amylolysin, from B. amyloliquefaciens GA1 (23). In this study, a full lantibiotic 
operon was identified in B. amyloliquefaciens AD2 after sequencing the genome, and the 
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lantibiotic was designated amyloliquecidin (AmyA). Annotation of the operon revealed that, 
in addition to the two lantibiotic peptide-encoding genes, all the biosynthetic machinery to 
produce AmyA was present. The genes required for two-component lantibiotic biosynthesis, 
export and immunity are known to cluster together, consistent with the observations made for 
B. amyloliquefaciens AD2 (15, 24–26). Thus far, the only other two-component lantibiotics 
characterized from Bacillus spp. are lichenicidin (LicA) and haloduracin (HalA). The structural 
peptides of AmyA were found to be similar to that of LicA and HalA. The Ser, Thr and Cys of 
AmyAα are in similar positions as that in HalAα. The beta peptide of AmyA has high similarity 
to both LicAβ and HalAβ. These similarities suggest that the peptides of AmyA have similar 
ring topologies to the peptides of LicA and HalA. 
Bacillus clausii AD1 could be identified using its 16s rDNA sequence, and was designated B. 
clausii AD1. Clausin, produced by B. clausii, is known to only be produced after prolonged 
incubation in liquid media, and coincides with sporulation (27). Antimicrobial activity in the 
supernatant of B. clausii AD1 could also only be observed after prolonged incubation of the 
culture. The antimicrobial compound isolated from B. clausii AD1 has a molecular mass 
similar to clausin. The biosynthetic genes associated with lantibiotic production usually cluster 
together in the same operon (26). The biosynthetic enzyme, LanD, is involved in the oxidative 
decarboxylation of the C-terminal in epidermin-like lantibiotics (28). Therefore, although the 
clausin structural gene was not elucidated, the presence of clausD, along with the similar 
molecular mass, was sufficient evidence to assume that the peptide produced was similar to, or 
a variant of, the epidermin-like lantibiotic, clausin (29). 
Two-component lantibiotics have activity against a wide range of Gram-positive bacteria 
including S. aureus (30–32). The alpha peptides are classified as class II mersacidin-like 
lantibiotics and have the mersacidin lipid II-binding motif (C-T-L/x-T/S-x-E-C) (33–35). Two-
component lantibiotics act synergistically, with the alpha peptide binding to lipid II to form an 
alpha peptide-lipid II complex (30, 35). This is followed by binding of the beta peptide to the 
alpha peptide-lipid II complex resulting in subsequent pore formation (30, 36). The alpha 
peptide of AmyA also has the mersacidin like-lipid II binding motif, and when combined with 
the beta has activity against a several Gram-positive bacteria. Activity was observed against 
clinical isolates of S. aureus, enterococci, and methicillin-resistant S. aureus (MRSA). Lacticin 
3147 is known to be more active against enterococci compared to its activity against S. aureus 
(37). This is consistent with the higher minimum inhibitory concentrations reported for AmyA 
against S. aureus. 
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After incubation with pepsin AmyAβ combined with undigested AmyAα still results in 
activity. There is, however, a pepsin cleavage site in AmyAβ just before the B-ring and 
cleavage at this site would result in a C-terminal truncated peptide. The C-terminal rings in 
beta peptides of two-component lantibiotics have been proposed to be important for interaction 
with the alpha peptide-lipid II complex (38). In lacticin 3147-β, HalAβ, LicAβ destruction of 
any of the C-terminal rings results in loss of activity (38–40). However, none of the Ala 
substitutions in the N-terminal region of lacticin 3147β and LicAβ results in activity loss (38, 
40). Destruction of ring A in HalAβ also does not result in activity loss (39). Gardiner et al. 
(41) reported on a C-terminal truncated lacticin 3147-β after digestion with α-chymotrypsin, 
with lacticin 3147-α being more susceptible to cleavage. Digestion did not result in complete 
loss of activity, but a significant reduction was observed. It should be noted that the activity 
assay was performed by combining peptides that were both digested with α-chymotrypsin. 
These results suggest that it may be possible for a truncated C-terminal beta peptide to still 
interact with the alpha peptide-lipid II complex and result in activity. The activity would most 
likely be as a result of disruption in cell wall biosynthesis as appose to pore formation. Under 
physiological storage conditions AmyA remained remarkably stable, particularly AmyAα, 
which is consistent with results for haloduracin (30). The stability of the alpha peptides is 
proposed to be due to their globular nature and low number of residues that can undergo 
oxidation (30). The beta peptide is more susceptible to oxidation, similar to nisin, and this is 
proposed to be due to the high number of thioether bridges (30). 
The in vitro characterization of AmyA as well as the identifaction and annotation of its operon 
contributes to the knowledgebase of lantibiotic research. However, from the results in the in 
vitro section of the current study it is evident that there are several areas where future research 
should focus on: 
1. The AmyA operon should be functionally characterized, in order to confirm the putative 
annotations of genes. Heterologous expression systems have proven useful in assigning 
function to lantibiotic biosynthetic genes (40, 42–45).  
2. The dehydration of Ser and Thr residues must be confirmed in the alpha and beta 
peptides. Methods have been developed that use mass spectrometry based analysis to 
elucidate which Ser and Thr are dehydrated and can also be used to determine ring 
topology (46–48). 
3. The hypothesis that a truncated beta peptide could still act synergistically with the alpha 
peptide, to exert antimicrobial activity, must also be investigated. This can be achieved 
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by proteolytic cleavage or heterologous expression systems to produce C-terminal 
truncated beta peptides (49, 50).  
In vitro activity of clausin and AmyA against S. aureus suggests possible application in the 
treatment of S. aureus-induced skin infections. The lantibiotic treatments compared well with 
Bactroban in preventing the spread of S. aureus, as determined by bioluminescence. 
Lantibiotics and Bactroban were equally effective in reducing viable bacterial cells, isolated 
from excised wounds, compared to control polyvinyl alcohol-treated wounds (CPVA; 
lantibiotic carrier vehicle). Treatment of S. aureus wound infections using topical lantibiotic 
treatment has been reported with nisin nanofibers (NEF) (51). Treatment with NEF resulted in 
a 5 log drop in viable bacterial cells compared to the control nanofiber group. In the current 
study the best lantibiotic treatment only resulted in a 3.3 log drop (AmyA). It could be that the 
NEF provides prolonged contact time between the area of infection and the lantibiotic. These 
results illustrate how a delivery system could improve effectiveness. Subcutaneous treatment 
of wounds with lantibiotics has, however, proven to be ineffective (52). However, these results 
could be due to insufficient peptide concentrations (52). Other studies have reported on the 
successful treatment of infections caused by of S. aureus, where lantibiotic administration 
routes includes intranasal, subcutaneous, intraperitoneal and intravenous (53–58). However, 
none of these studies, with the exception of NEF, evaluated the topical efficacy of lantibiotics.  
Lantibiotics did not negatively influence wound healing when used to treat infected and non-
infected wounds. Delayed wound closure rates were, however, observed for Bactroban-treated 
wounds. In previous studies Bactroban also resulted in delayed wound closure (59, 60). Non-
infected and infected wounds treated with CPVA had similar closure rates. These results 
suggests that in the current model infection does not significantly influence wound closure 
rates. These observations are consistent with reports of wounds in mice infected with S. aureus 
or left uninfected (with intraperitoneal granulocyte macrophage colony-stimulating 
factor/saline injections) having similar closure rates (61). Lantibiotic treatment of non-infected 
wounds does, however, result in smaller wounds after 7 days, compared to CPVA- and 
Bactroban-treated wounds. It is possible that the increased wound closure rates reported for 
lantibiotics can be due to stimulation of innate immune cells. Lantibiotics and other peptides 
are known to stimulate the immune system (62–65). The cationic peptide IDR-1018 (innate 
defense regulator), increases wound healing in a porcine S. aureus wound model, independent 
of antimicrobial activity (66). When treated with the pheromone plantaricin A, keratinocytes 
show increased migration and proliferation as well as differential gene expression of several 
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growth factors. Furthermore, plantaricin A also induces interleukin-8 expression, which is 
known to be involved in wound healing (67, 68). 
The in vivo evaluation of lantibiotics as a topical treatment for infections caused by Gram-
positive bacteria have not been extensively investigated. The current study, therefore, adds 
valuable information regarding the use of lantibiotics as topical treatments. The results of the 
in vivo section, especially regarding wound healing, raises several questions that should be 
addressed in future research: 
1. The immunomodulatory properties of clausin and AmyA should be investigated, along 
with possible cytotoxicity against human cells. Using ELISA assays the secretion of 
chemokines from immune cells can be monitored (62). Furthermore, gene expression 
of cytokines/chemokines can be investigated using real-time PCR/microarrays (69). 
2. The effects lantibiotics have on human keratinocytes should be investigated, by making 
use of ex vivo tissue culturing techniques. The effects of lantibiotics on the migration 
and proliferation of human keratinocytes should be investigated (66, 68, 70). The effect 
lantibiotics have on the gene expression of growth factors and cytokines/chemokines 
involved in wound healing can be investigated using real-time PCR/microarrays (68, 
69, 71). Furthermore, the secretion profiles of lantibiotic treated keratinocytes can be 
investigated using ELISA (70). 
3. Additional in vivo studies should focus on the efficacy of lantibiotics in the treatments 
of skin infections caused by multiple drug-resistant Gram-positive pathogens. 
Furthermore, effective delivery systems must be evaluated, such as the polymeric 
nanofibers already reported for nisin. 
Final Conclusion 
We have isolated and purified a novel two-component lantibiotic, amyloliquecidin, from B. 
amyloliquefaciens AD2. The entire operon was annotated and contains all the genes required 
for amyloliquecidin biosynthesis. The novel lantibiotic was active against Gram-positive 
clinical isolates and MRSA. Amyloliquecidin has remarkable stability at physiological pH, 
superior to that of nisin and clausin. Lantibiotics are just as effective in controlling the spread 
of S. aureus, as recorded by bioluminescence. Treatment of wounds with lantibiotics and 
Bactroban are equally effective in reducing viable bacterial cell counts. Furthermore, 
lantibiotics do not have a negative influence on wound closure in infected and non-infected 
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wounds. Bactroban, however, results in delayed wound closure. This study adds to the 
scientific knowledge base with the isolation and characterization of a novel two-component 
lantibiotic. Additionally, valuable information is gained on the in vivo efficacy of lantibiotics 
from different classes in the treatment of topical S. aureus-induced infections.  
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